Skizzle: a Novel Streptococcus agalactiae-secreted Cofactor of Human Plasminogen Activation by Wiles, Karen Godfrey
SKIZZLE: A NOVEL STREPTOCOCCUS AGALACTIAE-SECRETED COFACTOR OF 
HUMAN PLASMINOGEN ACTIVATION 
 
By 
 
Karen G. Wiles 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Pathology 
December, 2010 
Nashville, Tennessee 
 
Approved: 
Richard L. Hoover, Ph.D. 
Ingrid Verhamme, Ph.D. 
David Gailani, M.D. 
Andrzej Krezel, Ph.D. 
Eric P. Skaar, Ph.D, M.P.H. 
                                                                                               
 
 
 
 
 
 
 
 
 
 
Copyright © 2010 by Karen G. Wiles 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
For the men in my life: my father, my husband and my son.
iii 
 
ACKNOWLEDGEMENTS 
 
I would first and foremost like to thank my advisor Paul E. Bock, Ph.D. for his 
patience, perseverance and support. His wisdom and guidance helped to find and nurture 
the scientist in me. His support on this long and non-traditional journey will never be 
forgotten. I am also grateful to the members of my thesis committee, Richard L. Hoover, 
Ph.D., Ingrid Verhamme, Ph.D., David Gailani, M.D., Andrzej Krezel, Ph.D., and Eric P. 
Skaar, Ph.D, M.P.H. for their professional and personal guidance.  I would like to thank 
past and present members of the lab—including Malabika Laha, Miranda Nolan, Heather 
K. Kroh, Ph.D., Jonathan Creamer, Ph.D., and Peter Panizzi, Ph.D.—for their 
unconditional support and assistance. While not a member of the academic community, 
particular thanks must be paid to Cordozar Calvin Broadus (aka. Snoop Dogg), from 
whose vernacular my beloved protein earned its name – fo’shizzle.  Finally, I am grateful 
for financial support from the American Heart Association, Greater Southeast Affiliate 
through Predoctoral Fellowship 0715393B.  
 Personal thanks must go to my parents, Barbara and Larry Godfrey, for giving me 
their unconditional love and support―and for teaching me that no dream was out of 
reach. I am indebted to my husband, Paul Wiles, for his unwavering strength and love 
and for never letting me give up. To Patrick, whose smile is the light in my day.  I am 
also grateful for Roger and Cathy Wiles, the parents who love me as one of their own. 
This journey has been far from solitary and I am forever grateful for the support and 
encouragement of my entire family, especially Maureen McMichael, Michael Godfrey, 
James and Claudia Godfrey, Jean Godfrey and Margaret Weiss.  
iv 
 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
LIST OF TABLES ............................................................................................................ vii 
LIST OF FIGURES ......................................................................................................... viii 
Chapter 
I.      INTRODUCTION .......................................................................................................1 
        Fibrinogen, Fibrin, and Thrombus Formation .............................................................2 
        Plasminogen and Plasmin ............................................................................................4 
        Plasminogen Activation ...............................................................................................8 
        Inhibitors of Plasmin and Plasminogen Activation ...................................................13 
        Thrombosis and Fibrinolysis in Bacterial Infection ...................................................14 
        Bacterial Plasminogen Activators ..............................................................................16 
        Streptococcus agalactiae Pathogenesis ......................................................................18 
        References ..................................................................................................................19 
   
II.     SKIZZLE IS A NOVEL PLASMINOGEN- AND PLASMIN-BINDING  
         PROTEIN FROM STREPTOCOCCUS AGALACTIAE THAT TARGETS  
         PROTEINS OF HUMAN FIBRINOLYSIS TO PROMOTE PLASMIN  
        GENERATION ..........................................................................................................26 
 
        Abstract ......................................................................................................................27 
        Introduction ................................................................................................................28 
        Experimental Procedures ...........................................................................................32 
               Protein Purification and Characterization ...........................................................32 
               S. agalactiae Protein Expression ........................................................................34 
               Fluorescence Equilibrium Binding .....................................................................34 
               Chromogenic Substrate Hydrolysis ....................................................................36 
               Plasminogen Activation Kinetics ........................................................................37 
               Plasma Clot Lysis ...............................................................................................37 
        Results ........................................................................................................................38 
               Structural Characterization of SkzL ....................................................................38 
               Secretion of SkzL by S. agalactiae .....................................................................41 
               Binding of Pg and FFR-Pm to [5F]-SkzL ...........................................................42 
               LBS-mediated Binding of SkzL to Active Site-labeled Fluorescent  
               Pg/Pm Analogs....................................................................................................46 
               LBS-mediated Binding of SkzL to Active Pm ...................................................49 
v 
 
               Effect of SkzL on Plasminogen Activation by uPA ...........................................50 
               Effect of SkzL on Plasminogen Activation by sctPA .........................................53 
               SkzL Enhances uPA- and sctPA-mediated Plasma Clot Lysis ...........................54 
        Discussion ..................................................................................................................55 
        References ..................................................................................................................65 
        Appendix A (Published Supplemental Data) .............................................................71 
        Appendix B (Unpublished Results) ...........................................................................76 
         
III.    SKIZZLE IS AN EFFECTOR OF TISSUE-TYPE PLASMINOGEN                           
ACTIVATOR-MEDIATED PLASMINOGEN ACTIVATION ..............................85 
 
        Abstract ......................................................................................................................85 
        Introduction ................................................................................................................86 
        Experimental Procedures ...........................................................................................89 
               Protein Purification and Characterization ...........................................................89 
               Thiol-Specific Labeling of sctPA .......................................................................89 
               Fluorescence Equilibrium Binding .....................................................................90 
               Plasminogen Activation Kinetics ........................................................................90 
        Results ........................................................................................................................94 
               Effect of SkzL on Plasminogen Activation by nctPA and tctPA ........................94 
               LBS-mediated Binding of SkzL to an Active Site-labeled Fluorescent  
               sctPA Analog ......................................................................................................96 
               Effect of SkzL Lys415 on [Lys]Pg Activation by nctPA and tctPA ..................98 
               Effect of Chloride-regulated Pg Conformation on the SkzL-mediated  
               Enhancement of Pg Activation by tPA ...............................................................99 
               Effect of wtSkzL on [Lys]Pg Activation by tPA as a Function of Pg and  
               SkzL Concentrations .........................................................................................104 
        Discussion ................................................................................................................112 
        References ................................................................................................................119 
 
IV.    SIGNIFICANCE AND FUTURE DIRECTIONS .................................................122 
 
       Identification of Skizzle as a Plasminogen and Plasmin Binding Protein ................122 
       Significance of Skizzle Enhancement of Pg Activation ...........................................123 
       Proposed Skizzle ternary complex formation ...........................................................125 
       Hijacking the Fibrinolytic System to Evade Fibrinolytic Regulation .......................127 
       Role of Skizzle in Streptococcus agalactiae Pathogenesis .......................................128 
       References .................................................................................................................133 
 
 
 
 
 
vi 
 
LIST OF TABLES 
 
Table              Page 
2-1.    Parameters for binding of [Glu]Pg, [Lys]Pg, and FFR-Pm to [5F]-SkzL and  
          competitive binding of wtSkzL or SkzLΔK415 ......................................................44   
 
2-2.    Parameters for wtSkzL and SkzLΔK415 binding to active site  
          fluorescein-labeled Pg/Pm analogs.. ........................................................................48   
 
2-3.    Parameters for the effect of SkzL on pyro-EPR-pNA hydrolysis by Pm. ...............49   
 
2-4.    Parameters for the effect of SkzL on Pg activation by uPA ....................................52   
 
2-A1. Quantification of SkzL Cys Residues ......................................................................73   
 
2-A1.  Secreted protein profile for Streptococcus agalactiae ............................................75   
 
3-1.    Parameters for the effect of SkzL on Pg activation by tPA .....................................96 
3-2.    Parameters for role of Pg conformation on the effect of wtSkzL on Pg activation  
          by nctPA and tctPA ................................................................................................103 
3-3.    Parameters for the effect of [Lys]Pg and wtSkzL concentration-dependences  
          on [Lys]Pg activation by nctPA and tctPA ............................................................108 
3-4.    Parameters obtained from bimodal data analysis for the effect of wtSkzL  
          concentration on the [Lys]Pg concentration-dependence of [Lys]Pg  
          activation by nctPA and tctPA ...............................................................................109 
 
3-4.    Parameters for the effect of quaternary complex formation on [Lys]Pg 
          activation by nctPA and tctPA ...............................................................................112 
 
4-1.    Michaelis-Menten kinetic parameters for effect of fibrin on [Glu]Pg  
          activation by tPA ....................................................................................................124 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
Figure              Page 
1-1.   Schematic of haemostatic response following vessel injury. .....................................2 
1-2.   Human fibrinogen .......................................................................................................3                         
1-3.   Cartoon of fibrin generation and fibrin protofibril formation ....................................4 
1-4.   Schematic of Pg conformations ..................................................................................8 
 
1-5.   Cartoons of the semi-conserved domain structure of native Pg, tPA and uPA ..........9 
 
1-6.   Illustration of fibrin-bound tPA-mediated Pg activation and fibrin degradation .....12 
 
1-7.   Crystal structure of bacterial Pg activators with human Pm catalytic domain .........17 
 
2-1.   Sequence alignment and secondary structure prediction for SkzL and SK ..............40 
 
2-2.   Secretion of SkzL by Streptococcus agalactiae .......................................................41 
 
2-3.   Fluorescence titrations of [5F]-SkzL with [Glu]Pg, [Lys]Pg, and FFR-Pm ............43 
 
2-4:   Competitive binding of wtSkzL and SkzL∆K415 to Pg/Pm ....................................45 
 
2-5.   Binding of wtSkzL and SkzL∆K415 to [5F]FFR-[Glu]Pg, [5F]FFR-[Lys]Pg,  
         and [5F]FFR-Pm .......................................................................................................47 
 
2-6.   Effect of SkzL on pyro-EPR-pNA hydrolysis by Pm...............................................50 
 
2-7.   Effect of SkzL on Pg activation by uPA...................................................................51 
 
2-8.   Effect of SkzL on Pg activation by sctPA ................................................................54 
 
2-9.   Effect of SkzL on uPA- and sctPA-mediated plasma clot lysis ...............................55 
 
2-10. Diagram of the proposed mechanism of SkzL-mediated [Glu]Pg activation  
         by uPA, and postulated LBS-dependent complexes formed with [Lys]Pg  
         and Pm mediated by two sites on SkzL ....................................................................62 
 
2-B1. Fluorescence labeling following conformational activation of Pg ..........................79 
 
2-B2. Measurement of VLK-pNA hydrolysis to detect Pg activation by SkzL ................80 
viii 
 
ix 
 
 
2-B3. Analytical Ultracentrifugation of purified recombinant SkzL .................................81 
 
2-B4. SkzL stability as a function of Pm concentration ....................................................83 
 
3-1.   Effect of SkzL on Pg activation by nctPA and tctPA ...............................................95 
 
3-2.   Fluorescence titrations of [TMR]FFR-sctPA with wtSkzL and SkzL∆K415 ..........97 
 
3-3.   Effect of SkzL Lys415 on Pg activation by nctPA and tctPA ..................................99 
 
3-4.   Role of Pg conformation in SkzL-mediated enhancement of Pg activation by  
         nctPA and tctPA ......................................................................................................101 
 
3-5.   Pg and wtSkzL concentration-dependences on [Lys]Pg activation by  
         nctPA and tctPA ......................................................................................................105 
 
3-6.   Mechanism of Pg activation by tPA in the absence and presence of SkzL ............106 
 
3-7.   Mechanism of Pg activation by tPA in the absence and presence of SkzL, 
         including quaternary complex formation ................................................................110 
 
3-8.   Evidence for productive quaternary complex formation in SkzL  
         enhancement of [Lys]Pg activation by tPA ............................................................111 
 
3-9.   Proposed mechanism for SkzL-catalyzed enhanced Pg activation by tPA ............118 
 
4-1.   Comparison of SK- and SkzL-enhanced Pg activation ..........................................126 
 
4-2.   Comparison of surface-bound Pg receptor-mediated and secreted SkzL- 
         mediated enhanced Pg activation ............................................................................ 132 
 
CHAPTER I 
 
INTRODUCTION 
 
 Blood coagulation helps to restore the structural integrity of the vasculature 
following blood vessel injury by sealing ruptures in the vessel wall. The systems of 
hemostasis and fibrinolysis are responsible for maintenance of the balance between 
vessel repair and normal blood fluidity. Upon vessel injury, a clot mainly composed of 
activated platelets and fibrin is formed to minimize blood loss and maintain the closed, 
high pressure nature of the circulatory system (Fig. 1) (1-3). The rapid process of blood 
coagulation can be initiated through either the extrinsic or intrinsic pathways (2,4,5). 
Traditionally, the initial phase of coagulation is triggered by the extrinsic pathway 
consisting of the membrane receptor, tissue factor (TF), and FVII/FVIIa. The 
amplification phase of coagulation is traditionally thought to be regulated by the intrinsic 
pathway consisting of several plasma proteins including FXI, FIX, and FVIII (4,5). 
Following clot formation, the gradual processes of wound healing and clot dissolution 
begin. The dissolution of the clot occurs through degradation of the fibrin network, which 
acts as a structural framework providing integrity to the clot. Upon fibrinolytic 
dissolution of the clot, the slower processes of collagen deposition, formation of fibrous 
tissue, and wound healing occur. The rapid process of clot formation protects against 
blood loss during the elaborate wound healing process (1,2).  
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 Figure 1. Schematic of hemostatic response following vessel injury adapted from 
Mackman et al (5). A. inactive platelets (dark purple) circulating in the lumen of a 
vessel. B. upon vessel injury platelets bind collagen exposed upon endothelial rupture, 
FVIIa (green) and TF (red) trigger extrinsic pathway initiation and thrombin activation. 
C. aggregation of activated platelets (light purple) and amplification of the coagulation 
cascade culminating in fibrinogen to fibrin proteolysis. D. platelet aggregation and fibrin 
deposition to restore vessel integrity. 
 
Fibrinogen, Fibrin, and Thrombus Formation 
 The process of hemostasis, the normal regulation and formation of thrombi, 
involves a complex cascade of zymogen precursors whose proteolytic activation is 
required for cascade advancement, culminating in thrombus formation. This process is 
highly regulated by the succession of proteolytic activation reactions and by proteinase 
inhibitors. The cascade culminates in activation of prothrombin to thrombin by the 
prothrombinase complex, which includes factor Xa, factor Va, Ca2+, and phospholipid 
membranes (6-8). Thrombin proteolytically cleaves soluble fibrinogen to insoluble fibrin. 
Fibrinogen is found at high concentrations (2-4 mg/ml) in plasma (9). Each half of the 
340 kDa dimer is composed of three distinct polypeptide chains (Aα, Bβ and γ), which 
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form a 45 nm elongated coiled-coil tertiary structure with three distinct structural regions 
(Fig. 2) (9-11). The central E region, previously referred to as the E domain, is a dimer of 
the NH2-terminal portion of all three polypeptide chains. This central domain structure 
contains NH2-terminal fibrinopeptides A and B, the sequential removal of which by 
thrombin results in fibrin generation. The two terminal D regions include the COOH-
terminal portions the Bβ and γ chains and part of the Aα chain. The αC region is 
comprised of the compact COOH-terminal portion of the Aα chain, connected to the 
linear D-E-D structure through the flexible αC-connector region (9-13).  
 
 
Figure 2. Human fibrinogen. Crystal structure of human fibrinogen highlighting the α 
chains (blue), β chains (pink), and γ chains (green), generated using PDB Protein 
Workshop 3.7 (PDB file 3GHG) (14,15).  
 
 Conversion of fibrinogen to insoluble fibrin involves proteolytic cleavage by 
thrombin resulting in removal of fibrinopeptides A and B from the Aα and Bβ chains. 
Cleavage of the fibrinopeptides exposes polymerization sites (“knobs”) in the E region, 
which interact with complimentary sites (“holes”) in the D region of adjacent fibrin 
molecules (Fig. 3) (14). Following removal of the fibrinopeptides, the two intramolecular 
αC domains disassociate and reassociate in an intermolecular arrangement to promote 
protofibril formation. In addition to triggering fibrinogen proteolysis, thrombin also 
activates factor XIII, which cross-links fibrin to reinforce its structural integrity. In 
addition to cross-linked connections between the polymerization sites (knobs) in the E 
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region and complimentary sites (holes) in the D region of adjacent fibrin molecules, 
cross-linking occurs between the COOH-terminal ends of the γ-chains in the D regions of 
neighboring molecules (γ-γ) and between intermolecular αC domain-interactions (9-14).   
 
 
Figure 3. Cartoon of fibrin generation and fibrin protofibril formation adapted 
from Weisel (11). Fibrinopeptides (pink) are released following proteolysis by thrombin. 
Knobs (green) located on the central E region (blue) pair with holes (white) located on 
the terminal D region (purple) to promote fibrin protofibril formation. 
 
Plasminogen and Plasmin 
 The human fibrinolytic system is responsible for degradation of these cross-linked 
fibrin networks and the resulting dissolution of thrombi in the vasculature. Plasminogen 
(Pg) is a 791 amino acid, 92 kDa protein synthesized in the liver and found at plasma 
concentrations of ~1.6-2.1 µM (1,16,17). Zymogen Pg consists of an NH2-terminal PAN 
(Pg/apple/nematode) module, five homologous kringle domains, each stabilized by a 
series of disulfide bonds, and a COOH-terminal serine proteinase catalytic domain (18-
25). Two main post-translationally modified forms of Pg are found in plasma, with a 
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different number of carbohydrate modifications. Pg I contains both N-linked (Asn288) and 
O-linked (Thr345) polysaccharides and Pg II contains only the O-linked (Thr345) 
polysaccharide post-translational modification (26,27). Zymogen Pg is converted through 
proteolysis to the active serine proteinase, plasmin (Pm). The native form of Pg, [Glu]Pg, 
is characterized by its NH2-terminal glutamic acid residue. Following cleavage by Pm, 
the NH2-terminal 77-residue PAN module is removed to form [Lys]Pg (84 kDa), 
characterized by an NH2-terminal lysine residue (21).  
 The fibrinolytic system utilizes two plasminogen activators, urokinase (uPA) and 
tissue-type plasminogen activator (tPA) to convert Pg to Pm. Proteolytic Pg activation by 
these proteinases occurs through cleavage of the Arg561-Val562 peptide bond in the Pg 
catalytic domain to form Pm.  This cleavage results in a conformational change in which 
the new Pg NH2-terminus inserts into the NH2-terminal binding cleft in the catalytic 
domain. The result is formation of an active site within the Pm catalytic domain 
containing the catalytic triad (Asp645, His602, Ser740), with the NH2-terminal heavy-chain 
and COOH-terminal light-chain of Pm connected through two or more disulfide bonds 
(24,26). As a serine proteinase, Pm degrades cross-linked fibrin networks within thrombi, 
resulting in blood clot dissolution, which will be discussed in more detail below. When 
generated in the extracellular milieu, Pm can degrade fibronectin and other extracellular 
matrix proteins allowing for higher permeability between cell layers (27). 
 Much of the functional interaction between Pg/Pm and fibrin occurs through the 
Pg/Pm kringle domains. The kringle domains (~10 kDa each) have highly conserved 
sequence homology and homology with similar domains found in prothrombin, tissue-
type plasminogen activator, urokinase, and factor XII (27). Three of the Pg kringle 
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domains (kringles 1, 4, and 5) contain lysine binding sites (LBS) with moderate to low 
affinity for L-lysine and higher affinity for the lysine analogs, 6-aminohexanoic acid (6-
AHA), and trans-4(aminomethyl)-cyclohexane carboxylic acid (19-23,26,27).  
 Early studies of the interaction between 6-AHA and Pg/Pm indicate that 6-AHA 
inhibits Pm activity with a KI of ~0.32 M and inhibits Pg activation by streptokinase with 
a KI of 0.96 mM (28,29). While there is some variation in the determined parameters 
among different studies, results of a representative study of 6-AHA binding to [Glu]Pg 
reveal one tight interaction (n = 0.93, KD = 9 µM) and five weak interactions (n = 4.93, 
KD = 5 mM) (20,27,30-32). [Glu]Pg and [Lys]Pg are held in separate structural 
conformations due to interaction of Lys50 and/or Lys62 in the NH2-terminal PAN module 
of [Glu]Pg with the LBS of kringle 5 (33). As a result of the NH2-terminal PAN module 
interaction with kringle 5, [Glu]Pg is held in a compact structural conformation. Early 
studies on the effect of 6-AHA binding on the physical properties of [Glu]Pg reveal a 
conformational change occurring as a function of 6-AHA concentration with a KD of ~ 
0.45 mM (19).  
 As it lacks the NH2-terminal PAN module and resulting LBS interaction with 
kringle 5, [Lys]Pg adopts a partially extended conformation (16,34).  A study on potential 
conformational changes in [Glu]Pg and [Lys]Pg suggested the existence of two 
conformational states. The T-state represented the compact conformation of [Glu]Pg and 
the R-state represented the expanded form of either [Lys]Pg or [Glu]Pg saturated with 6-
AHA. Binding of 6-AHA was thought to have no effect on the conformation of [Lys]Pg 
(35).  
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 A concurrent, landmark study revealed the presence of three distinct Pg 
conformations. This study employed three experimental methods (size exclusion high 
performance liquid chromatography (FPLC), small-angle x-ray scattering, and dynamic 
laser light scattering) to determine parameters (molecular elution time, radius of gyration, 
and stokes radius, respectively) for the effect of 6-AHA on [Glu]Pg and [Lys]Pg 
conformation (36). The authors used benzamidine, which selectively binds kringle 5, to 
disrupt the kringle 5-PAN interaction and isolate its effect on overall [Glu]Pg 
conformation (36). The results supported the presence of three distinct conformations 
summarized as follows: (1) the compact α-conformation is [Glu]Pg in the absence of 
ligand, (2) the partially extended β-conformation of [Lys]Pg/[Lys]Pm in the absence of 
ligand or [Glu]Pg in the presence of 50 mM benzamidine, and (3) the fully extended γ-
conformation of [Lys]Pg/[Lys]Pm in the presence of 6-AHA or [Glu]Pg in the presence 
of 6-AHA ± benzamidine (Fig. 4) (36).  
 Physiological chloride ion stabilizes [Glu]Pg in the α-conformation, in which the 
LBS of kringle 4 is masked (34,37-40).  The α-conformation of [Glu]Pg, however, is in 
an equilibrium with a low concentration (~25-40%) of a partially extended, β-
conformation [Glu]Pg (20,32,34,41,42).  Binding of a kringle 4-specific monoclonal 
antibody has been shown to enhance uPA activation of [Glu]Pg, indicating a shift from 
the kringle 4-accesible β-conformation to the γ-conformation (43,44). The extended β- 
and γ-conformations offer more accessibility of the LBS for protein interaction, and 
therefore, [Lys]Pg and ligand-bound [Glu]Pg are better substrates for activation than 
[Glu]Pg in the α-conformation (16,34-36,45). As chloride ion stabilizes [Glu]Pg in the α-
conformation, chloride is classified as an inhibitor of [Glu]Pg activation (34,45,46). 
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 Figure 4. Schematic of Pg conformations. Native [Glu]Pg-α with the PAN-module 
(red) occupying the LBS of kringle 5 (yellow) and unoccupied kringle 1 and 4 LBS 
(white), with transition to [Glu]Pg-β and [Glu]Pg-γ upon LBS occupation by 
benzamidine (blue) and 6-AHA (pink), respectively. [Lys]Pg, and [Lys]Pm (active site in 
green) β- and γ-conformations illustrated with kringle LBS in the absence of ligand 
(white) and in the presence 6-AHA (pink), respectively. 
 
Plasminogen Activation 
 Endogenous Pg activation occurs through proteolysis by one of two activators, 
urokinase and tissue-type plasminogen activator (tPA). The native form of urokinase, 
high molecular weight single-chain urokinase (uPA), is a 54 kDa protein which contains 
a serine proteinase catalytic domain (catalytic triad: Asp255, His204, Ser356) in its COOH-
terminal region, an epidermal growth factor domain, a finger-like domain, and one 
kringle domain in the NH2-terminal region (Fig. 5) (47,48). The kringle domain of uPA 
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does not contain an LBS and therefore uPA lacks the fibrin-binding properties observed 
for tPA (27). The epidermal growth factor domain and kringle domain are removed 
following cleavage of the Glu143-Leu144 peptide bond by metalloprotease, pump-1 to form 
low molecular weight urokinase (33 kDa) (47,49). Both uPA and low molecular weight 
urokinase are cleaved by Pm or kallikrein at the Lys158-Ile159 peptide bond, to the more 
enzymatically active two-chain urokinase (47,48,50-52).  
 
 
Figure 5. Cartoons of the semi-conserved domain structure of native Pg, tPA and 
uPA. Serine proteinase (SP), kringles (1-5), epidermal growth factor (EGF) and finger-
like (F) domains with LBS illustrated as white circles (18,27). 
 
 Several studies have shown that activation of [Glu]Pg by uPA is enhanced by 6-
AHA. This enhancement is due to the 6-AHA-induced α- to β/γ-conformational transition 
to a more rapidly activated [Glu]Pg molecule (34,45). The same enhancement occurs 
upon L-lysine binding of [Glu]Pg (53). 
 The low activity zymogen-like form of tPA, single-chain tPA (sctPA), is a 70 kDa 
protein (27). One structural difference from uPA is the presence of a second kringle 
domain within sctPA (tPA-kringle 2) which contains an LBS with high affinity for 
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lysine-sepharose, 6-AHA (KD ~70 µM, (54)), intact fibrin (KD ~1.4-3.3 nM (27,55)), and 
fibrin fragments (KD ~1.2 nM (55)). The more active two-chain form of tPA (tctPA) is 
formed following cleavage of the Arg275-Ile276 peptide bond by Pm (46). The activity of 
tPA toward Pg is greatly enhanced in the presence of effectors such as fibrin, cyanogen 
bromide fragments of fibrinogen, and 6-AHA. In steady-state kinetic studies of [Glu]Pg 
and [Lys]Pg activation by uPA and tPA, binding of 6-AHA results in a decrease in Km 
with no appreciable effect on kcat seen for uPA and varying degrees of kcat enhancement 
seen for tPA (12,41,45,53,56-59). 
 Chloride is an inhibitor of uPA- and tPA-mediated [Glu]Pg activation as it 
stabilizes [Glu]Pg in the compact α-conformation, which is only very slowly activated by 
uPA and tPA. The KI for chloride ion-mediated inhibition of [Glu]Pg activation by uPA 
and tPA is ~ 9 mM for each enzyme (34,46). One study of uPA-mediated [Glu]Pg 
activation determined the order of inhibitory level of several ions with the following 
ranked from highest level of inhibition to lowest: I->SCN->Cl->IO3->HCOO->F->OAc- 
(45). As a result, acetate (OAc-) is commonly used in place of chloride to study [Glu]Pg 
in the extended β/γ-conformations independent of changes in ionic strength. The effector 
molecules bind through the Pg LBS to extend the conformation of [Glu]Pg to the β/γ-
conformations, thereby reversing the chloride-mediated inhibition and enhancing 
activation by uPA and tPA (34,45,46,55).   
 While lysine and 6-AHA serve as excellent tools for in vitro study of Pg kringle 
domain interactions, it is the study of fibrin-Pg interactions that is most physiologically 
relevant. Early studies suggested that Pg bound the central E region of fibrin, however it 
is now accepted that Pg kringle 5 binds within the D region of fibrin (Fig. 6) (12,33,60). 
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It is also through the D region that interaction with tPA-kringle 2, but not uPA, occurs 
(12,61). As an example of the highly regulated nature of thrombosis and fibrinolysis, it is 
the culmination of the coagulation cascade at fibrinogen to fibrin proteolysis that exposes 
cryptic tPA and Pg binding sites in the D region of fibrin, triggering initiation of 
fibrinolysis (12). Binding of fibrin to Pg kringle 5 results in the α- to β- conformational 
transition in [Glu]Pg which enhances binding and subsequent Pm generation. A ternary 
complex is formed upon binding of tPA and Pg to fibrin resulting in Pg activation. The 
Pm generated cleaves fibrin between the D and E regions. The limited fibrin proteolysis 
results in new COOH-terminal Lys residues which have been shown to bind the 
remaining LBS on Pg, promoting the β- to γ-conformational transition and accelerating 
Pm activation, fibrin proteolysis, and clot dissolution (12,33,55).  
 The process of Pg activation stimulation by fibrin is inhibited by the glycoprotein 
metallocarboxypeptidase, thrombin-activatable fibrinolysis inhibitor (TAFI). The 
mechanism of inhibition by TAFI will be described in more detail to follow. Briefly, 
TAFI hydrolyzes lysine and arginine residues, resulting in removal of the carboxy-
terminal lysine residues of fibrin generated upon limited proteolysis by Pm that are 
responsible for enhanced Pg binding and activation to Pm. The removal of these residues 
impedes the cofactor function of fibrin in tPA-mediated Pg activation (62).  
 In contrast to easily isolated and controlled solution studies, studies of tPA-
mediated activation of Pg in plasma are inherently complicated to interpret. Single-chain 
tPA (sctPA) is cleaved to the more enzymatically active two-chain form (tctPA) in clot 
lysis assays performed with 125I-sctPA (63). Clot lysis assays have also shown that prior 
to total clot lysis, ~ 20 % of [Glu]Pg is proteolytically converted to [Lys]Pg (64). These 
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 Figure 6. Illustration of fibrin-bound tPA-mediated Pg activation and fibrin 
degradation (12). Pg kringle 5 and tPA-kringle 2 bind fibrin in the D region (purple) 
forming a ternary complex, followed by proteolysis in the catalytic domain of Pg to Pm. 
Pm cleaves fibrin between the D (purple) and E (blue) regions represented by orange 
arrows resulting in FXIIIa-cross-linked (pink) fibrin degradation products (E3, D-D and 
D-D:E1). Limited proteolysis results in exposure of novel COOH-terminal fibrin Lys 
residues which bind Pg kringle 1 and kringle 4 to enhance binding and in turn enhance 
Pm generation and fibrin proteolysis. The fibrin degradation product D-D:E1 is the 
smallest unit shown to stimulate Pg activation by tPA (12).  
 
two proteolytic cleavage events, from less active/less activated precursors to more 
active/more readily activated species, cause clot lysis assays to be inherently complicated 
to interpret. For this reason, clot lysis assays will be used in this thesis for mainly 
qualitative purposes.   
 Administration of purified plasminogen activators is currently a main therapeutic 
approach to treatment of myocardial infarction. In addition to some bacterial plasminogen 
activators to be discussed later, several recombinant forms of uPA and tPA are currently 
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used as drug treatments with varying degrees of efficacy (65,66). Effective thrombolytic 
therapy must balance efficient reversal of vessel occlusion with the risk for intracranial 
hemorrhage (65,66). As the use of bacterial-derived therapeutic agents comes with the 
potential for immune or allergic response, genetic optimization of recombinant tPA and 
uPA remains the focus of the majority of research in the field (65,66).  
 
Inhibitors of Plasmin and Plasminogen Activation 
 Inhibition of the fibrinolytic system is critical to maintaining the balance between 
proper vascular repair to prevent bleeding and aberrant thrombus formation. The balance 
of this system is partly regulated by inhibition of the main enzymes involved: Pm, uPA 
and tPA. The majority of plasma proteases are regulated by a class of inhibitors called 
serine protease inhibitors or serpins, which have a highly conserved fold structure 
consisting of a bundle of nine α-helices, and a β-sandwich of three β-sheets (67). The 
mechanism of serpin inhibition is well studied and complex. Briefly, serpins form an 
encounter complex (or Michaelis complex) with the serine protease, where the reactive 
center loop of the serpin is recognized by the protease as a substrate (bait). This is 
followed by cleavage of the reactive center loop and dragging of the acyl-enzyme to the 
opposite pole of the serpin by insertion of the reactive center loop into β-sheet A. The 
result is formation of a terminal covalent complex where the protease is trapped in an 
inactive state (67).  
 The main inhibitor of circulating Pm is the serpin α2-antiplasmin (α2-AP), a 63 
kDa glycoprotein which circulates at ~ 70 µg/ml and has a half-life of ~ 2.6 days 
(12,27,67,68). Pm bound to fibrin is protected from inactivation by α2-AP, allowing for 
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efficient fibrin proteolysis. The main inhibitor of uPA and tPA is the serpin, plasminogen 
activator inhibitor-1 (PAI-1), a 50 kDa glycoprotein that has a half-life of ~1.2 hours 
(67,69). This serpin is the main physiological inhibitor of plasminogen activation (67). 
As with α2-AP and Pm, fibrin-bound tPA is protected from inactivation by PAI-1 (67-69). 
The major non-serpin inhibitor of fibrinolysis is TAFI, which circulates as a zymogen 
and is activated proteolytically by thrombin, trypsin, or plasmin (62,68).  Activated TAFI 
is a metallocarboxypeptidase that cleaves the Pm-generated COOH-terminal Lys residues 
from fibrin, preventing further Pg/Pm binding and inhibiting further fibrin proteolysis 
(62,68). The presence of inhibitors in the fibrinolytic cascade ensures that thrombus 
formation is restricted to sites of vessel injury and ensures thrombus dissolution only 
following vessel repair.  
 
Thrombosis and Fibrinolysis in Bacterial Infection 
 Many bacterial species target the human haemostatic and fibrinolytic systems in 
their mechanisms of pathogenesis. These processes are manipulated by many bacterial 
types; however, for these purposes only mechanisms employed by the gram-positive 
staphylococci and streptococci will be discussed. Staphylococcus aureus causes skin 
infections such as impetigo and serious invasive diseases like endocarditis, septic 
arthritis, and sepsis (70). Acute bacterial endocarditis (ABE) is a disease of high (~ 40 %) 
mortality with risk factors including intravenous drug use, and heart valve replacement 
(71). The streptococci are composed of heterogeneous groups of pathogens which differ 
in their disease states. Group A, C, and G streptococci cause pharyngitis (strep throat), 
scarlet fever, and skin infections like impetigo, as well as severe invasive infections like 
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toxic shock-like syndrome, endocarditis, and necrotizing fasciitis (70). Group B 
streptococci (GBS) cause severe diseases including sepsis, meningitis, arthritis, and 
endocarditis in neonates, pregnant women, and immune-compromised patients (72,73).  
Streptococcus agalactiae (GBS) serotype V is emerging as an invasive GBS pathogen 
with particular morbidity and mortality in neonates (74-76). 
 The blood coagulation system is targeted by two main proteins secreted by S. 
aureus. Staphylocoagulase (SC) and von Willebrand factor-binding protein (VWBP) are 
members of a recently established family of structural homologs known as zymogen 
activator and adhesion proteins (ZAAPs) (77). Although the specific mechanism of action 
differs, both SC and VWBP circumvent the blood coagulation system to cause 
unregulated, non-proteolytic prothrombin activation, resulting in fibrinogen to fibrin 
proteolysis (77-80). This mechanism is involved in the pathogenesis of ABE, which 
involves formation of bacteria-containing thrombotic vegetations on heart valves (81). 
The efficient, unregulated deposition of fibrin by these secreted S. aureus proteins is 
thought to contribute to the high mortality of this disease (77,78,80).  
 In addition, the initial host-defense response to bacterial infection is tissue-factor 
initiated blood clotting to form a protective fibrin wall of defense against invasion. 
Activation of the fibrinolytic system is a mechanism of bacterial pathogenesis employed 
by staphylococci and streptococci through expression of cell-surface Pg binding proteins 
and the secretion of Pg activators to escape the fibrin barriers. In this mechanism, the 
bacteria can hijack the host fibrinolytic system to cause increased Pm generation, which 
can degrade the fibrin barrier and extracellular matrix proteins to disseminate spread of 
the bacteria through soft tissue (27). Activation of Pg localized on the cell surface 
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through Pg binding proteins such as Pg-binding Group A M-like protein (PAM, Group A, 
C, G streptococci), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Group A, B, C 
streptococci), and α-enolase (Group A, B streptococci) can result in coating of the cell 
surface with Pg or active Pm (18,82-86). Pg activating proteins secreted by the bacteria, 
such as streptokinase and staphylokinase, are not enzymes themselves but form 
complexes with Pg or Pm to facilitate Pg activation. This proteolysis can occur localized 
to bacterial cell surfaces through Pg-binding proteins or systemically by secreted Pg 
activators in the vascular system. 
 
Bacterial Plasminogen Activators 
 Streptokinase (SK), a 47 kDa protein secreted from Group A, C and G 
streptococci, is a well studied bacterial Pg activator (18). SK consists of three β-grasp 
domains (α, β, and γ) joined by flexible linker segments (Fig. 7) (87,88). It activates Pg 
through a non-proteolytic mechanism of conformational activation known as the 
molecular sexuality mechanism (89). Briefly, when SK binds Pg, an immediate 
conformational change occurs and SK inserts its own NH2-terminus into the Pg NH2-
terminal binding pocket. This results in another conformational change within the 
catalytic domain of Pg generating the oxyanion hole and primary substrate binding site 
(S1site) required for proteolytic activity. This conformationally active SK•Pg* complex 
then binds a second Pg molecule in the substrate mode which is proteolytically converted 
to Pm (90-98). Binding of Pg as a substrate occurs through an LBS interaction between 
kringle 5 and residues Arg253, Lys256, and Lys257 in the 250-loop of SK (99). The Pm 
generated binds more tightly to SK than Pg, forming a SK•Pm catalytic complex that 
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propagates Pg activation (98).  Similar to fibrin-bound Pm, Pm bound by SK is protected 
from inhibition by α2-AP (100).  
 
 
Figure 7. Crystal structure of bacterial Pg activators with human Pm catalytic 
domain. Complexes of SK (purple) and SAK (green) with the human Pm catalytic 
domain, µPm (blue) illustrating structural similarity between the SK-α domain and SAK, 
generated using PDB Protein Workshop 3.7 with PDB files 1BML (SK) and 1BUI (SAK) 
(15,87,101). 
  
 Staphylokinase (SAK) is a 16 kDa protein homologous to the α-domain of SK 
that is secreted by Staphylococcus aureus (Fig. 7) (101). Proteolytic Pg activation by 
SAK occurs in the presence of catalytic concentrations of Pm. Pg activation occurs when 
SAK binds Pm, altering its substrate specificity into a protease capable of activating Pg 
(102-104). In contrast to SK, SAK-bound Pm is susceptible to inhibition by α2-AP and 
therefore requires a fibrin cofactor in vivo (100). PauB and its homolog from S. uberis, 
PauA appear to follow a mechanism similar to SK, including formation of a non-
proteolytically activated Pg complex, followed by proteolysis of a substrate molecule of 
Pg, but are specific for activation of bovine Pg (105-109). 
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Streptococcus agalactiae Pathogenesis 
 Streptococcus agalactiae (Group B streptococci) interacts with the fibrinolytic 
system through surface expression of two known Pg binding proteins, α-enolase and 
GAPDH (82-84,100,110). While complete proteomic studies have not been performed, 
there are no known Streptococcus agalactiae-secreted proteins with human fibrinolytic 
activity. Group B streptococci is the only species of streptococci that does not express 
SK. Genomic sequencing of a Streptococcus agalactiae serotype V clinical isolate (2603 
V/R) revealed 2,175 predicted genes (74-76,111,112). The gene of interest in this work, 
NP_688136.1, corresponds to a novel protein subsequently named skizzle (SkzL), with 
unknown function. A sequence homology search revealed that SkzL contains 22% 
identity to SK from S. equisimilis and S. pyogenes, 33% identity to SAK from S. aureus, 
and 24% identity to PauB from S. uberis. As a result, it was hypothesized that SkzL 
would bind Pg and activate Pg to Pm. Initial studies, however, revealed that SkzL does 
not directly activate Pg to Pm.  
 As the work in Chapters 2 and 3 of this thesis shows, SkzL binds tightly to 
[Lys]Pg and Pm and weakly to [Glu]Pg in an LBS-dependent manner facilitated by the 
SkzL COOH-terminal Lys415 residue. As SkzL enhances [Glu]Pg activation by uPA to 
levels seen with 6-AHA, it is hypothesized that SkzL-binding induces the [Glu]Pg α- to 
γ-conformational transition. While the exact mechanism is still unclear, SkzL enhances 
activation of [Glu]Pg and [Lys]Pg activation by tPA, likely through formation of a 
ternary complex. SkzL enhances plasma clot lysis by both tPA and uPA, providing the 
rationale for a physiological role for the interaction of SkzL with Pg in the context of S. 
agalactiae pathogenesis.  
18 
 
References 
1. Colman, R. W. C., Alexander W.; Goldhaber, Samuel Z.; Marder, Victor J.; 
George, James N. (ed) (2006) Hemostasis and Thrombosis: Basic Principles and 
Clinical Practice, Lippincott Williams and Wilkins 
2. Furie, B., and Furie, B. C. (1988) Cell 53, 505-518 
3. Schenone, M., Furie, B. C., and Furie, B. (2004) Curr Opin Hematol 11, 272-277 
4. Gailani, D., and Renne, T. (2007) Arterioscler Thromb Vasc Biol 27, 2507-2513 
5. Mackman, N., Tilley, R. E., and Key, N. S. (2007) Arterioscler Thromb Vasc Biol 
27, 1687-1693 
6. Bock, P. E., Panizzi, P., and Verhamme, I. M. (2007) J Thromb Haemost 5 Suppl 
1, 81-94 
7. Bianchini, E. P., Orcutt, S. J., Panizzi, P., Bock, P. E., and Krishnaswamy, S. 
(2005) Proc. Natl. Acad. Sci. U S A 102, 10099-10104 
8. Hacisalihoglu, A., Panizzi, P., Bock, P. E., Camire, R. M., and Krishnaswamy, S. 
(2007) J. Biol. Chem. 282, 32974-32982 
9. Wolberg, A. S. (2007) Blood Rev 21, 131-142 
10. Mosesson, M. W. (2005) J Thromb Haemost 3, 1894-1904 
11. Weisel, J. W. (2005) Adv Protein Chem 70, 247-299 
12. Medved, L., and Nieuwenhuizen, W. (2003) Thromb. Haemost. 89, 409-419 
13. Mosesson, M. W. (1998) Semin Thromb Hemost 24, 169-174 
14. Kollman, J. M., Pandi, L., Sawaya, M. R., Riley, M., and Doolittle, R. F. (2009) 
Biochemistry 48, 3877-3886 
15. Moreland, J. L., Gramada, A., Buzko, O. V., Zhang, Q., and Bourne, P. E. (2005) 
BMC Bioinformatics 6, 21 
16. Ponting, C. P., Marshall, J. M., and Cederholm-Williams, S. A. (1992) Blood 
Coagul Fibrinolysis 3, 605-614 
17. Sottrup-Jensen. (1978) Progress in chemical fibrinolysis and thrombolysis, Raven 
Press, New York 
18. Lahteenmaki, K., Kuusela, P., and Korhonen, T. K. (2001) FEMS Microbiol. Rev. 
25, 531-552 
19 
 
19. Brockway, W. J., and Castellino, F. J. (1972) Arch Biochem Biophys 151, 194-
199 
20. Markus, G., DePasquale, J. L., and Wissler, F. C. (1978) J. Biol. Chem. 253, 727-
732 
21. Robbins, K. C., Boreisha, I. G., Arzadon, L., and Summaria, L. (1975) J. Biol. 
Chem. 250, 4044-4047 
22. Sjoholm, I. (1973) Eur. J. Biochem. 39, 471-479 
23. Violand, B. N., Byrne, R., and Castellino, F. J. (1978) J. Biol. Chem. 253, 5395-
5401 
24. Robbins, K. C., Summaria, L., Hsieh, B., and Shah, R. J. (1967) J. Biol. Chem. 
242, 2333-2342 
25. Summaria, L., Hsieh, B., and Robbins, K. C. (1967) J. Biol. Chem. 242, 4279-
4283 
26. Castellino, F. J., and Powell, J. R. (1981) Methods Enzymol. 80 Pt C, 365-378 
27. Henkin, J., Marcotte, P., and Yang, H. C. (1991) Prog. Cardiovasc. Dis. 34, 135-
164 
28. Abiko, Y., Iwamoto, M., and Tomikawa, M. (1969) Biochim Biophys Acta 185, 
424-431 
29. Brockway, W. J., and Castellino, F. J. (1971) J. Biol. Chem. 246, 4641-4647 
30. Lerch, P. G., Rickli, E. E., Lergier, W., and Gillessen, D. (1980) Eur. J. Biochem. 
107, 7-13 
31. Lin, L. F., Houng, A., and Reed, G. L. (2000) Biochemistry 39, 4740-4745 
32. Markus, G., Priore, R. L., and Wissler, F. C. (1979) J. Biol. Chem. 254, 1211-
1216 
33. Cockell, C. S., Marshall, J. M., Dawson, K. M., Cederholm-Williams, S. A., and 
Ponting, C. P. (1998) Biochem J 333 ( Pt 1), 99-105 
34. Urano, T., Chibber, B. A., and Castellino, F. J. (1987) Proc. Natl. Acad. Sci. U S 
A 84, 4031-4034 
35. McCance, S. G., and Castellino, F. J. (1995) Biochemistry 34, 9581-9586 
36. Marshall, J. M., Brown, A. J., and Ponting, C. P. (1994) Biochemistry 33, 3599-
3606 
20 
 
37. Castellino, F. J., Brockway, W. J., Thomas, J. K., Liano, H. T., and Rawitch, A. 
B. (1973) Biochemistry 12, 2787-2791 
38. Hochschwender, S. M., and Laursen, R. A. (1981) J. Biol. Chem. 256, 11172-
11176 
39. Plow, E. F., and Collen, D. (1981) J. Biol. Chem. 256, 10864-10869 
40. Vali, Z., and Patthy, L. (1982) J. Biol. Chem. 257, 2104-2110 
41. Markus, G. (1996) Fibrinolysis 10, 75-85 
42. Weisel J. W., N. C., Korsholm B., Petersen L. C., Suenson E. (1984) J. Mol. Biol. 
235, 1117-1135 
43. Cummings, H. S., and Castellino, F. J. (1985) Arch Biochem Biophys 236, 612-
618 
44. Ploplis, V. A., Cummings, H. S., and Castellino, F. J. (1982) Biochemistry 21, 
5891-5897 
45. Urano, T., Sator de Serrano, V., Chibber, B. A., and Castellino, F. J. (1987) J. 
Biol. Chem. 262, 15959-15964 
46. Urano, T., Sator de Serrano, V., Gaffney, P. J., and Castellino, F. J. (1988) 
Biochemistry 27, 6522-6528 
47. de Munk, G. A., Groeneveld, E., and Rijken, D. C. (1993) Thromb. Haemost. 70, 
481-485 
48. Lijnen, H. R., De Cock, F., and Collen, D. (1994) Eur. J. Biochem. 224, 567-574 
49. Novokhatny, V., Medved, L., Lijnen, H. R., and Ingham, K. (1995) J. Biol. Chem. 
270, 8680-8685 
50. Lijnen, H. R., Nelles, L., Van Hoef, B., Demarsin, E., and Collen, D. (1988) Eur. 
J. Biochem. 177, 575-582 
51. Lijnen, H. R., Van Hoef, B., Nelles, L., and Collen, D. (1990) J. Biol. Chem. 265, 
5232-5236 
52. Nelles, L., Lijnen, H. R., Collen, D., and Holmes, W. E. (1987) J. Biol. Chem. 
262, 5682-5689 
53. Peltz, S. W., Hardt, T. A., and Mangel, W. F. (1982) Biochemistry 21, 2798-2804 
54. de Munk, G. A., Caspers, M. P., Chang, G. T., Pouwels, P. H., Enger-Valk, B. E., 
and Verheijen, J. H. (1989) Biochemistry 28, 7318-7325 
21 
 
55. Fleury, V., Loyau, S., Lijnen, H. R., Nieuwenhuizen, W., and Angles-Cano, E. 
(1993) Eur. J. Biochem. 216, 549-556 
56. Hoylaerts, M., Rijken, D. C., Lijnen, H. R., and Collen, D. (1982) J. Biol. Chem. 
257, 2912-2919 
57. Zamarron, C., Lijnen, H. R., and Collen, D. (1984) J. Biol. Chem. 259, 2080-2083 
58. Ranby, M. (1982) Biochim Biophys Acta 704, 461-469 
59. Silverstein, R. L., Nachman, R. L., Leung, L. L., and Harpel, P. C. (1985) J. Biol. 
Chem. 260, 10346-10352 
60. Lucas, M. A., Fretto, L. J., and McKee, P. A. (1983) J. Biol. Chem. 258, 4249-
4256 
61. Horrevoets, A. J., Smilde, A., de Vries, C., and Pannekoek, H. (1994) J. Biol. 
Chem. 269, 12639-12644 
62. Bouma, B. N., and Mosnier, L. O. (2003) Pathophysiol Haemost Thromb 33, 375-
381 
63. Rijken, D. C., Hoylaerts, M., and Collen, D. (1982) J. Biol. Chem. 257, 2920-
2925 
64. Fredenburgh, J. C., and Nesheim, M. E. (1992) J. Biol. Chem. 267, 26150-26156 
65. Armstrong, P. W., and Collen, D. (2001) Circulation 103, 2862-2866 
66. Collen, D., and Lijnen, H. R. (1991) Blood 78, 3114-3124 
67. Rau, J. C., Beaulieu, L. M., Huntington, J. A., and Church, F. C. (2007) J Thromb 
Haemost 5 Suppl 1, 102-115 
68. Fay, W. P., Garg, N., and Sunkar, M. (2007) Arterioscler Thromb Vasc Biol 27, 
1231-1237 
69. Kvassman, J. O., Verhamme, I., and Shore, J. D. (1998) Biochemistry 37, 15491-
15502 
70. Nitsche-Schmitz, D. P., Rohde, M., and Chhatwal, G. S. (2007) Thromb. 
Haemost. 98, 488-496 
71. Rivera, J., Vannakambadi, G., Hook, M., and Speziale, P. (2007) Thromb. 
Haemost. 98, 503-511 
72. Schuchat, A. (1999) Lancet 353, 51-56 
22 
 
73. Pietrocola, G., Schubert, A., Visai, L., Torti, M., Fitzgerald, J. R., Foster, T. J., 
Reinscheid, D. J., and Speziale, P. (2005) Blood 105, 1052-1059 
74. Blumberg, H. M., Stephens, D. S., Modansky, M., Erwin, M., Elliot, J., Facklam, 
R. R., Schuchat, A., Baughman, W., and Farley, M. M. (1996) J. Infect. Dis. 173, 
365-373 
75. Brochet, M., Couve, E., Zouine, M., Vallaeys, T., Rusniok, C., Lamy, M. C., 
Buchrieser, C., Trieu-Cuot, P., Kunst, F., Poyart, C., and Glaser, P. (2006) 
Microbes Infect.  
76. Fluegge, K., Schweier, O., Schiltz, E., Batsford, S., and Berner, R. (2004) Eur. J. 
Clin. Microbiol. Infect. Dis. 23, 818-824 
77. Panizzi, P., Friedrich, R., Fuentes-Prior, P., Bode, W., and Bock, P. E. (2004) Cell 
Mol. Life Sci. 61, 2793-2798 
78. Kroh, H. K., Panizzi, P., and Bock, P. E. (2009) Proc. Natl. Acad. Sci. U S A 106, 
7786-7791 
79. Panizzi, P., Friedrich, R., Fuentes-Prior, P., Kroh, H. K., Briggs, J., Tans, G., 
Bode, W., and Bock, P. E. (2006) J. Biol. Chem. 281, 1169-1178 
80. Panizzi, P., Friedrich, R., Fuentes-Prior, P., Richter, K., Bock, P. E., and Bode, 
W. (2006) J. Biol. Chem. 281, 1179-1187 
81. Korzeniowski OM, K. D. (1992) Infective Endocarditis, W.B. Saunders, 
Philadelphia 
82. Bergmann, S., Wild, D., Diekmann, O., Frank, R., Bracht, D., Chhatwal, G. S., 
and Hammerschmidt, S. (2003) Mol. Microbiol. 49, 411-423 
83. Magalhaes, V., Veiga-Malta, I., Almeida, M. R., Baptista, M., Ribeiro, A., Trieu-
Cuot, P., and Ferreira, P. (2007) Microbes Infect. 9, 1276-1284 
84. Whiting, G. C., Evans, J. T., Patel, S., and Gillespie, S. H. (2002) J. Med. 
Microbiol. 51, 837-843 
85. Boyle, M. D., and Lottenberg, R. (1997) Thromb. Haemost. 77, 1-10 
86. Cork, A. J., Jergic, S., Hammerschmidt, S., Kobe, B., Pancholi, V., Benesch, J. L., 
Robinson, C. V., Dixon, N. E., Aquilina, J. A., and Walker, M. J. (2009) J. Biol. 
Chem. 284, 17129-17137 
87. Wang, X., Lin, X., Loy, J. A., Tang, J., and Zhang, X. C. (1998) Science 281, 
1662-1665 
88. Wang, X., Tang, J., Hunter, B., and Zhang, X. C. (1999) FEBS Lett. 459, 85-89 
23 
 
89. Bode, W., and Huber, R. (1976) FEBS Lett. 68, 231-236 
90. Boxrud, P. D., and Bock, P. E. (2000) Biochemistry 39, 13974-13981 
91. Boxrud, P. D., and Bock, P. E. (2004) J. Biol. Chem. 279, 36642-36649 
92. Boxrud, P. D., Verhamme, I. M., and Bock, P. E. (2004) J. Biol. Chem. 279, 
36633-36641 
93. Boxrud, P. D., Verhamme, I. M., Fay, W. P., and Bock, P. E. (2001) J. Biol. 
Chem. 276, 26084-26089 
94. Gladysheva, I. P., Sazonova, I. Y., Houng, A., Hedstrom, L., and Reed, G. L. 
(2007) Biochemistry 46, 8879-8887 
95. Wang, S., Reed, G. L., and Hedstrom, L. (1999) Biochemistry 38, 5232-5240 
96. Wang, S., Reed, G. L., and Hedstrom, L. (2000) Eur. J. Biochem. 267, 3994-4001 
97. Bean, R. R., Verhamme, I. M., and Bock, P. E. (2005) J. Biol. Chem. 280, 7504-
7510 
98. Boxrud, P. D., Fay, W. P., and Bock, P. E. (2000) J. Biol. Chem. 275, 14579-
14589 
99. Tharp, A. C., Laha, M., Panizzi, P., Thompson, M. W., Fuentes-Prior, P., and 
Bock, P. E. (2009) J. Biol. Chem. 284, 19511-19521 
100. Bergmann, S., and Hammerschmidt, S. (2007) Thromb. Haemost. 98, 512-520 
101. Parry, M. A., Fernandez-Catalan, C., Bergner, A., Huber, R., Hopfner, K. P., 
Schlott, B., Guhrs, K. H., and Bode, W. (1998) Nat. Struct. Biol. 5, 917-923 
102. Esmon, C. T., and Mather, T. (1998) Nat. Struct. Biol. 5, 933-937 
103. Grella, D. K., and Castellino, F. J. (1997) Blood 89, 1585-1589 
104. Jespers, L., Vanwetswinkel, S., Lijnen, H. R., Van Herzeele, N., Van Hoef, B., 
Demarsin, E., Collen, D., and De Maeyer, M. (1999) Thromb. Haemost. 81, 479-
485 
105. Ward, P. N., Field, T. R., Rosey, E. L., Abu-Median, A. B., Lincoln, R. A., and 
Leigh, J. A. (2004) J. Mol. Biol. 342, 1101-1114 
106. Johnsen, L. B., Rasmussen, L. K., Petersen, T. E., Etzerodt, M., and Fedosov, S. 
N. (2000) Biochemistry 39, 6440-6448 
107. Sazonova, I. Y., Houng, A. K., Chowdhry, S. A., Robinson, B. R., Hedstrom, L., 
and Reed, G. L. (2001) J. Biol. Chem. 276, 12609-12613 
24 
 
25 
 
108. Ward, P. N., and Leigh, J. A. (2002) J Bacteriol 184, 119-125 
109. Ward, P. N., and Leigh, J. A. (2004) Indian J. Med. Res. 119 Suppl, 136-140 
110. Hughes, M. J., Moore, J. C., Lane, J. D., Wilson, R., Pribul, P. K., Younes, Z. N., 
Dobson, R. J., Everest, P., Reason, A. J., Redfern, J. M., Greer, F. M., Paxton, T., 
Panico, M., Morris, H. R., Feldman, R. G., and Santangelo, J. D. (2002) Infect. 
Immun. 70, 1254-1259 
111. Fluegge, K., Supper, S., Siedler, A., and Berner, R. (2004) Antimicrob Agents 
Chemother 48, 4444-4446 
112. Tettelin, H., Masignani, V., Cieslewicz, M. J., Eisen, J. A., Peterson, S., Wessels, 
M. R., Paulsen, I. T., Nelson, K. E., Margarit, I., Read, T. D., Madoff, L. C., 
Wolf, A. M., Beanan, M. J., Brinkac, L. M., Daugherty, S. C., DeBoy, R. T., 
Durkin, A. S., Kolonay, J. F., Madupu, R., Lewis, M. R., Radune, D., Fedorova, 
N. B., Scanlan, D., Khouri, H., Mulligan, S., Carty, H. A., Cline, R. T., Van Aken, 
S. E., Gill, J., Scarselli, M., Mora, M., Iacobini, E. T., Brettoni, C., Galli, G., 
Mariani, M., Vegni, F., Maione, D., Rinaudo, D., Rappuoli, R., Telford, J. L., 
Kasper, D. L., Grandi, G., and Fraser, C. M. (2002) Proc. Natl. Acad. Sci. U S A 
99, 12391-12396 
 
CHAPTER II 
 
SKIZZLE IS A NOVEL PLASMINOGEN- AND PLASMIN-BINDING PROTEIN 
FROM STREPTOCOCCUS AGALACTIAE THAT TARGETS PROTEINS OF HUMAN 
FIBRINOLYSIS TO PROMOTE PLASMIN GENERATION 
 
Karen G. Wiles*, Peter Panizzi§, Heather K. Kroh*, and Paul E. Bock* 
 
*Department of Pathology, Vanderbilt University, Nashville, TN 37232 
§Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114 
 
(This research was originally published in the Journal of Biological Chemistry. Karen G. 
Wiles, Peter Panizzi, Heather K. Kroh, and Paul E. Bock. Skizzle is a novel plasminogen- 
and plasmin-binding protein from Streptococcus agalactiae that targets proteins of 
human fibrinolysis to promote plasmin generation. 2010; 285(27): 21153-21164.  
© the American Society for Biochemistry and Molecular Biology.) 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Abstract 
 Skizzle (SkzL), secreted by Streptococcus agalactiae, has moderate sequence 
identity to streptokinase and staphylokinase, bacterial activators of human plasminogen 
(Pg).  SkzL binds [Glu]Pg with low affinity (KD 3-16 µM), and [Lys]Pg and plasmin 
(Pm) with indistinguishable high affinity (KD 80 nM and 50 nM, respectively).  Binding 
of SkzL to Pg and Pm is completely lysine-binding site-dependent, as shown by the effect 
of the lysine analog, 6-aminohexanoic acid.  Deletion of the COOH-terminal SkzL Lys415 
residue reduces affinity for [Lys]Pg and active site-blocked Pm 30-fold, implicating 
Lys415 in a lysine-binding site interaction with a Pg/Pm kringle.  SkzL binding to active 
site fluorescein-labeled Pg/Pm analogs demonstrates distinct high and low affinity 
interactions.  High affinity binding is mediated by Lys415, whereas the source of low 
affinity binding is unknown.  SkzL enhances the activation of [Glu]Pg by urokinase 
(uPA) ~20-fold, to a maximum rate indistinguishable from that for [Lys]Pg and [Glu]Pg 
activation in the presence of 6-aminohexanoic acid.  SkzL binds preferentially to the 
partially extended, β-conformation of [Glu]Pg, which is in unfavorable equilibrium with 
the compact, α-conformation, thereby converting [Glu]Pg to the fully extended, γ-
conformation and accelerating the rate of its activation by uPA.  SkzL enhances [Lys]Pg 
and [Glu]Pg activation by single-chain tissue-type Pg activator, ~42-fold and ~650-fold, 
respectively.  SkzL increases the rate of plasma clot lysis by uPA and single-chain tissue-
type Pg activator ~2-fold, confirming its cofactor activity in a physiological model 
system.  The results suggest a role for SkzL in S. agalactiae pathogenesis through 
fibrinolytic enhancement. 
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Introduction 
 Group B streptococci (GBS)1 cause severe diseases including sepsis, meningitis, 
arthritis, and endocarditis in neonates and immune-compromised patients (1,2).  
Streptococcus agalactiae serotype V is emerging as an invasive GBS pathogen with 
particular morbidity and mortality in neonates (3-5), but the mechanism of GBS 
pathogenesis is not fully understood.  Unlike group A, C, and G streptococci, GBS does 
not express streptokinase (SK), a pathogenicity factor in group A streptococcal infection 
(6).  Activation of the fibrinolytic system is a mechanism of bacterial pathogenesis 
employed by many bacteria through expression of cell-surface plasminogen (Pg)-binding 
proteins and the secretion of Pg activators.  In this mechanism, aberrant upregulation of 
the fibrinolytic system increases plasmin (Pm) generation, which degrades fibrin and 
extracellular matrix to disseminate the bacteria through soft tissue (7).  Activation of Pg 
on the cell-surface through Pg-binding proteins, such as Pg-binding group A 
streptococcal M-like protein (PAM; group A, C, and G streptococci), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; group A, B, and C streptococci), and α-enolase 
(group A and B streptococci) results in coating of the cell surface with Pg or active Pm 
(8-12).  A recent study indicated that Pg activation on the surface of S. agalactiae occurs 
through the GAPDH-bound Pg complex, facilitating GBS virulence and promoting 
bacterial dissemination in a murine model (10).  Secreted Pg-activating proteins, such as 
SK and staphylokinase (SAK), are not enzymes themselves but form complexes with Pg 
or Pm to enable proteolytic Pm generation.  This proteolysis can occur locally on 
bacterial cell surfaces through Pg-binding proteins or systemically by the free, secreted 
Pg-activators in the vascular system.  Although complete proteomic functional studies 
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have not been performed, to date there are no known S. agalactiae secreted proteins with 
established human fibrinolytic activity. 
 Genomic sequencing of an S. agalactiae serotype V clinical isolate (2603 V/R) 
revealed 2,175 predicted genes (13), including NP_688136.1, which corresponds to a 
novel protein of unknown function, subsequently named skizzle (SkzL).  SkzL has 22% 
sequence identity to SK from Streptococcus equisimilis and pyogenes, 33% to SAK from 
Staphylococcus aureus and 24% to PauB, a bovine Pg activator from Streptococcus 
uberis (14).  In studies of genomic sequence diversity, SkzL (protein unnamed, gene 
name sk1A2) had weak similarity to SAK and SK (4).  SAK, SK, and PauB facilitate the 
conversion of Pg into Pm, albeit through different mechanisms. 
 Native [Glu]Pg, the form circulating in blood, consists of an NH2-terminal PAN 
(Pg/apple/nematode) module, 5 kringle domains, and a serine proteinase catalytic 
domain.  Kringles 1, 4, and 5 contain lysine-binding sites (LBS) with moderate to low 
affinity for L-lysine and higher affinity for the lysine analog, 6-aminohexanoic acid (6-
AHA) (15-20).  Following cleavage by Pm, the NH2-terminal 77-residue PAN module of 
[Glu]Pg is released to yield [Lys]Pg (18).  As a result of the NH2-terminal PAN module 
interaction with kringle 5, [Glu]Pg is stabilized in the compact α-conformation by 
physiological concentrations of chloride ion (21,22).  The α-conformation of [Glu]Pg, 
however, is in equilibrium with a low concentration of a partially extended, β-
conformation governed by the chloride ion concentration (17,22-25).  Lacking the PAN 
module, [Lys]Pg adopts the β-conformation in the absence or presence of chloride ion 
(22,26).  Upon low affinity binding of lysine analogs, such as 6-AHA to kringles 4 and 5, 
both [Glu]Pg and [Lys]Pg assume the fully extended γ-conformation (22,23,26-32). 
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 Proteolytic Pg activation occurs through cleavage of the Arg561-Val562 peptide 
bond in the catalytic domain to form Pm.  SK activates Pg through a conformational, 
nonproteolytic molecular sexuality mechanism (33-38).  The SK NH2-terminus inserts 
into the NH2-terminal binding cleft in the Pg catalytic domain, inducing a conformational 
change to form a functional active site capable of proteolytically activating substrate Pg 
molecules (34-41).  Binding of Pg as a substrate occurs through LBS interaction between 
kringle 5 and residues Arg253, Lys256, and Lys257 in the 250-loop of SK (42).  SAK 
facilitates activation of Pg in the presence of catalytic concentrations of Pm.  Binding of 
SAK to Pm changes the substrate specificity of Pm, allowing activation of Pg (43-45).  
PauB and its homolog, PauA appear to follow a mechanism similar to SK, including 
formation of a nonproteolytically activated Pg complex, followed by proteolysis of 
substrate molecules of Pg, but are specific for activation of bovine Pg (46-50).   
 Human Pg is proteolytically activated endogenously by either of two activators, 
urokinase and tissue-type plasminogen activator (tPA).  High molecular weight single-
chain urokinase (uPA) contains a catalytic domain in the COOH-terminal region and an 
epidermal growth factor domain and one kringle domain in the NH2-terminal region 
(51,52).  The epidermal growth factor and kringle domains are liberated by cleavage at 
Glu143-Leu144 by the metalloproteinase, pump-1 to form low molecular weight urokinase 
(52).  Single-chain urokinase is converted to the more enzymatically active form, two-
chain urokinase, through cleavage of Lys158-Ile159 in the catalytic domain by Pm or 
kallikrein (51-55).  The low activity zymogen-like form of tPA, single-chain tPA (sctPA), 
is a 70-kDa protein that is cleaved by Pm at Arg275-Ile276 to form the more active two-
chain tPA (56).  One structural difference between tPA and uPA is the presence of a 
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second kringle domain in tPA containing an LBS with high affinity for lysine, 6-AHA, 
and fibrin fragments (57,58). 
 The modest sequence identity between SkzL and SK includes conservation of the 
NH2-terminal (Ile1-Ala2-Gly3) residues and the COOH-terminal Lys415 residue (Lys414 for 
SK) required for SK-induced Pg activation (36-39,59).  Despite the presence of these 
residues and predicted secondary structure similarity to SK, SkzL could not be shown to 
activate Pg to Pm, conformationally or proteolytically, in the absence or presence of 
catalytic concentrations of Pm.  The conservation of the COOH-terminal Lys residue 
suggested a potential binding interaction of SkzL with the LBS of a Pg and Pm kringle.  
The present studies were undertaken to characterize the binding interactions of SkzL with 
Pg and Pm and to elucidate its function as a potential fibrinolytic cofactor of uPA- and 
sctPA-catalyzed Pg activation.  The studies show that SkzL is secreted from S. agalactiae 
serotype V and binds both Pg and Pm in a LBS-dependent manner, primarily through 
Lys415.  SkzL enhances uPA-catalyzed activation of [Glu]Pg by facilitating its conversion 
from the compact α-conformation to the fully extended γ-conformation, and enhances 
uPA-mediated plasma clot lysis.  SkzL also enhances [Glu]Pg and [Lys]Pg activation by 
sctPA and plasma clot lysis by sctPA.  To our knowledge, SkzL is the first secreted 
protein from S. agalactiae to be identified that usurps the human fibrinolytic system, 
presumably to enable dissemination of infection. 
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Experimental Procedures 
 
Protein Purification and Characterization 
 [Glu]Pg, [Lys]Pg, and Pm (all carbohydrate form 2) were prepared as previously 
described (41,60,61).  [5F]FFR-[Lys]Pg, [5F]FFR-[Glu]Pg, and [5F]FFR-Pm were 
generated by a thiol-specific reaction with 5-(iodoacetamido)fluorescein following 
inactivation of the SK-induced active site in [Lys]Pg and [Glu]Pg with Nα-
[(acetylthio)acetyl]-ᴅ-Phe-Phe-Arg-CH2Cl essentially as previously described (39-41,62).  
Native Pm activity was calculated based on known parameters for  ᴅ-Val-Leu-Lys-р-
nitroanalide (VLK-pNA) hydrolysis (41).  Human high molecular weight uPA 
(Calbiochem) was reconstituted in ultra-pure water (yielding a solution containing 150 
mM Cl- contributed by NaCl and Tris-Cl).  Protein concentration of uPA and sctPA were 
determined by bicinchoninic acid protein assay (Pierce).  sctPA (Molecular Innovations) 
was stored in 0.5 M HEPES, 0.5 M NaCl, pH 7.4 buffer to ensure solubility and was 
limited to one freeze-thaw cycle to maintain stable activity.  
The gene for SkzL (NP_688136.1) was cloned from S. agalactiae 2603 V/R 
genomic DNA (ATCC) into a modified Pet30b vector (59) containing a tobacco etch 
virus (TEV) protease-cleavable NH2-terminal His6 tag.  SkzL was expressed by 
Rosetta2(DE3)plysS Escherichia coli (Novagen) in 0.1 mg/ml kanamycin following 0.5 
mM isopropyl β-D-thiogalactopyranoside induction for 4 h at 30 °C.  Following bacterial 
lysis by sonication, protein in the clarified supernatant was purified by Ni2+- 
iminodiacetic acid-Sepharose (5 ml) chromatography in 50 mM HEPES, 325 mM NaCl, 
20 mM imidazole, pH 7.4, eluted with a 50 ml gradient of 20-500 mM imidizole in the 
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equilibration buffer.  Trace protein contaminants, including dimeric SkzL, were removed 
by anion exchange chromatography on Q-Sepharose (Amersham Biosciences) 
equilibrated with 50 mM HEPES, 50 mM NaCl, 1 mM EDTA, pH 7.4, eluted with a 
gradient of 50-500 mM NaCl over 30 column volumes.  A 1:10 molar equivalent of 
recombinant tobacco etch virus protease was added to SkzL and the mixture was 
incubated for 12 h to liberate the His6 tag, followed by repeated Ni2+-iminodiacetic acid-
Sepharose chromatography to separate noncleaved protein and free His6 tag from cleaved 
protein (59).  To preserve disulfide bond integrity, cleavage was performed in the 
absence of dithiothreitol.  Tobacco etch virus protease cleavage resulted in the proper 
SkzL NH2-terminal sequence as confirmed by NH2-terminal sequencing (Ile1-Ala2-Gly3-
Pro4-Ser5).  Cysteine-to-serine substitution mutants and the COOH-terminal lysine 
deletion mutant (SkzL∆K415) were generated by Quikchange site-directed mutagenesis 
(Stratagene) and purified as described.  [5F]-SkzL was generated by reaction of free thiol 
groups with 5-(iodoacetamido)fluorescein followed by chromatography on Sephadex G-
25 and dialysis to remove excess probe.  Probe incorporation was determined to be 1.0 
mol probe/mol SkzL by absorbance measurements at 280 and 498 nm with an absorption 
coefficient of 84,000 M-1 cm-1 for fluorescein and an A280/A498 nm ratio of 0.19 in 6 M 
guanidine, 100 mM Tris-HCl, 1 mM EDTA, pH 8.5 buffer (63). 
All proteins were snap-frozen and stored in 50 mM HEPES, 125 mM NaCl, pH 
7.4 at -80 °C.  Protein concentrations were determined from the 280 nm-absorbance using 
the following absorption coefficients ((mg/ml)-1cm-1) and molecular masses (Da): 
[Glu]Pg, 1.69 and 92,000; [Lys]Pg and Pm, 1.69 and 84,000 (60,64).  The SkzL 
absorption coefficient at 280 nm of 1.23 was calculated from the amino acid sequence 
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and confirmed by absorbance measurements (65).  The molecular mass of 47,400 Da for 
SkzL was determined in excellent agreement with that calculated from the amino acid 
sequence by mass spectrometry using a Waters Acquity Ultraperformance LC/Thermo 
Finnigan LTQ with a lysozyme standard for optimization and calibration.  
 
S. agalactiae Protein Expression 
 S. agalactiae serotype V was cultured in Todd-Hewitt yeast broth at 37 °C.  
Bacterial supernatant was obtained at various time points by centrifugation at 39,000 x g 
for 15 min.  Secreted proteins were obtained by precipitation with trichloroacetic acid 
(7.5%) and washed with acetone for use in western blotting.  A polyclonal rabbit anti-
SkzL antibody was generated and purified by affinity chromatography on SkzL-coupled 
CNBr-activated Sepharose 4B (ProSci Inc.).  Proteins were subjected to SDS-PAGE on 
4-15% gradient gels, transferred onto polyvinylidine fluoride membranes, and developed 
with a BM Chemiluminescence Western Blotting Kit (Roche).  
 
Fluorescence Equilibrium Binding  
 Titrations of 50 nM [5F]FFR-[Lys]Pg, [5F]FFR-[Glu]Pg, and [5F]FFR-Pm with 
wtSkzL and SkzL∆K415 were performed in 50 mM HEPES, 125 mM NaCl, 1 mM 
EDTA, 1 mg/ml PEG 8,000, 10 µM FFR-CH2Cl, and 1 mg/ml bovine serum albumin, pH 
7.4 at 25 °C using PEG 20,000-coated acyclic cuvettes.  Titrations of active site-blocked 
fluorescent Pg/Pm analogs with wtSkzL and SkzL∆K415 performed without the use of 
polarizers revealed a high affinity decrease in fluorescence intensity, and a low affinity 
decrease in fluorescence anisotropy.  Consequently, identical titrations were performed 
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with vertical excitation and emission at the magic angle to eliminate anisotropy effects.  
Excitation was at 500 nm and emission was measured at 516 nm with 4-nm band-passes. 
Fluorescence titrations of native [Glu]Pg, [Lys]Pg, and FFR-Pm binding to 100 
nM  and 500 nM [5F]-SkzL were performed using identical buffer conditions.  
Fluorescence was measured with excitation at 492 nm and emission at 510 nm with 8-nm 
band-passes without the use of fluorescence polarization.  Competitive binding 
experiments with 100 nM [5F]-SkzL in the absence and presence of fixed concentrations 
of wtSkzL or SkzL∆K415 to [Lys]Pg and FFR-Pm were performed under identical 
conditions.  In these titrations, mixtures of [5F]-SkzL and either wtSkzL or SkzL∆K415 
were pre-incubated for 10 min at 25 °C prior to titration with [Lys]Pg or FFR-Pm.  
Following correction for buffer blank and probe dilution (≤ 10%), data were expressed as 
the fractional change in the initial fluorescence, (Fobs-Fo)/Fo = ∆F/Fo.  Titrations were 
analyzed by nonlinear least-squares fitting of the quadratic binding Equation 1,  
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where ΔFmax/Fo is the maximum fluorescence change; KD is the dissociation constant; n is 
the stoichiometric factor; [P]o is the total concentration of probe-labeled protein, and [L]o 
is the total ligand concentration (39-41,62).  Competitive titrations were analyzed by 
nonlinear least-squares fitting of the cubic competitive binding equation for tight binding 
interactions to give dissociation constants for both ligand and competitor, with the 
stoichiometry fixed at 1 for the competitors (66). 
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Direct titrations of wtSkzL binding to [5F]FFR-[Lys]Pg and [5F]FFR-Pm 
performed without polarizers revealed an apparent anisotropy decrease, representing a 
second distinct binding interaction.  These data were analyzed by nonlinear least-squares 
fitting of the sum of the solution to the quadratic equation (Equation 1) as ΔF1/Fo, with 
n=1 for the high affinity interaction, and a hyperbola for the weak interaction with the 
assumption that [L]free ≈ [L]o for this interaction,  
 
 
          Eqn. 2 
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where KD1 obtained from the quadratic equation and KD2 are the dissociation constants for 
the high and low affinity interactions, respectively, ΔFmax 1/Fo from the quadratic equation 
and ΔFmax 2/Fo are the corresponding maximum fluorescence changes, and [L]o is the total 
ligand concentration.  Experimental error in the fitted parameters represents ± 2 S.D. 
 
Chromogenic Substrate Hydrolysis  
 The initial rates of hydrolysis of 200 µM pyro-Glu-Pro-Arg-pNA (pyro-EPR-
pNA) by 10 nM Pm in PEG 20,000-coated microtiter plates was measured continuously 
at 405 nm as a function of SkzL concentration.  kcat and Km were determined by fitting of 
the substrate dependence in the absence and presence of SkzL by the Michaelis-Menten 
equation.  Rates of substrate hydrolysis were normalized to a 1-cm path length by a 
correction factor of 1.66 for reaction volumes of 300 µl.  Titrations as a function of SkzL 
were normalized to the rate of pyro-EPR-pNA hydrolysis in the absence of SkzL and 
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analyzed by Equation 2 (wtSkzL) or Equation 1 (SkzL∆K415) to determine dissociation 
constants. 
 
Plasminogen Activation Kinetics 
 The kinetics of activation of 100 nM [Glu]Pg or 100 nM [Lys]Pg by uPA (0.32 or 
0.11 nM, respectively) or sctPA (3 nM) as a function of SkzL concentration were 
performed by continuous measurement of hydrolysis of 200 µM VLK-pNA at 405 nm 
and 25 °C, as previously described (35,42).  Assays were performed in chloride 
containing buffer (100 mM HEPES, 100 mM NaCl, 1 mM EDTA, 1 mg/ml PEG 8,000, 
pH 7.4) or no chloride buffer (100 mM HEPES, 100 mM sodium acetate, 1 mM EDTA, 1 
mg/ml PEG 8,000, pH 7.4) using PEG 20,000-coated polystyrene cuvettes.  In assays 
containing SkzL, uPA or sctPA and SkzL diluted in buffer were preincubated in the 
cuvette at 25 °C for 10 min prior to addition of Pg and substrate.  Progress curves at 
varying SkzL concentrations were fit by the parabolic rate equation and truncated to 
include only data linear when plotted as absorbance against time2 and less than 10% 
substrate consumption.  
 
Plasma Clot Lysis 
 Plasma clot lysis was measured by incubation of 160 µL normal human plasma at 
37 °C with final concentrations of 6 nM thrombin, 10 mM CaCl2, and 7 nM uPA or 1.5 
nM sctPA, in a final volume of 200 µL.  All proteins were diluted in 50 mM HEPES, 125 
mM NaCl, pH 7.4 prior to addition.  Increasing concentrations of SkzL were 
preincubated for 10 min at 37 °C with 10 mM CaCl2 and either uPA or sctPA in the 
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above buffer prior to addition of thrombin and plasma to initiate the assay.  Turbidity was 
measured at 650 nm in a microtiter plate reader.  Results are reported as time to half-clot 
lysis as a function of SkzL concentration, and analyzed by Equation 1, where [P]o was 1.6 
µM, representing the dilution-corrected plasma Pg concentration of 2.0 µM (67). 
 
Results 
 
Structural Characterization of SkzL 
 SkzL was cloned, expressed, and purified as a 47,400-Da monomer.  The 
molecular mass was determined by mass spectrometry in excellent agreement with the 
molecular mass calculated from the amino acid sequence.  SkzL exhibits 22% sequence 
identity to SK including conservation of the NH2-terminal and COOH-terminal residues 
of SK required for Pg activation.  Primary sequence alignment and secondary structure 
prediction shows the relatively weak structural similarity of SkzL to SK (Fig. 1) (68-70).   
 One distinguishing primary structural feature of SkzL that is absent in SK is the 
presence of three Cys residues: Cys120, Cys393, and Cys401.  During the expression and 
purification of monomeric SkzL, trace amounts of a disulfide-bonded dimeric form was 
generated.  Dimeric and monomeric SkzL were separated by anion exchange 
chromatography as described in “Experimental Procedures” to yield pure monomeric 
SkzL and a 1:1 mixture of monomeric and dimeric SkzL (Fig. 2A, lanes 2, 3, 6, and 7).  
Results of cysteine-to-serine mutagenesis studies indicated that Cys120 was buried within 
the protein and that Cys393 and Cys401 occurred partially as free thiols and partially as an 
internal disulfide bond (Appendix Table A1).  The results also indicated that trace levels 
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of disulfide-mediated dimeric SkzL may occur through Cys393 or Cys401.  These results 
were confirmed by mass spectrometry analysis of a thiol-specific 5-fluorescein-labeled 
analog of SkzL monomer (Fig. 2A, lanes 1 and 5). ).  Labeled and unmodified SkzL were 
subjected to chymotrypsin cleavage followed by liquid chromatography-tandem mass 
spectrometry.  A mass shift of 387 Da, corresponding to the probe modification, was 
found in peptides containing either Cys393 or Cys401 (389PQAACYP395 and 
399FACENTDSKYN409), indicating modification of both Cys residues under non-
denaturing conditions.  Peptides with unmodified Cys393 and Cys401 residues were also 
found.  No modification was seen for Cys120 (117PVTCT121), supporting the results of the 
thiol quantification assays. 
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 Figure 1. Sequence alignment and secondary structure prediction for SkzL and SK. 
Sequence alignment of SkzL and SK from S. equisimilis was performed using the Clustal 
2.0.10 multiple sequence alignment algorithm (69). Identical residue pairs are highlighted 
in blue with conserved residues in yellow. Secondary structure prediction was performed 
by PSIPRED for SkzL in green and SK in violet (68). SkzL Cys120, Cys 393, and Cys401 
are highlighted in red. The pairs of Lys and Glu residues representing part (Lys256 and 
Lys 257) of the SK motif involved in kringle 5-mediated Pg substrate recognition, and the 
pairs of Lys and Glu residues in SkzL that may be involved in the low affinity LBS-
dependent interaction of SkzL with Pg are also highlighted in red (70). 
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 Figure 2. Secretion of SkzL by Streptococcus agalactiae. A, Protein-stained (top) and 
fluorescence (bottom) SDS-PAGE of non-reduced (lanes 1-3) and reduced (lanes 5-7) 
recombinant SkzL. [5F]-SkzL monomer (lanes 1, 5), purified SkzL monomer (lanes 2, 
6), a 1:1 mixture of SkzL monomer and SkzL dimer (lanes 3, 7), with the migration 
positions of molecular mass markers indicated (kDa). B, Western blotting of a mixture of 
recombinant SkzL monomer and dimer (lane 1) and proteins secreted from the lag, mid-
logarithmic, late-logarithmic, early stationary, and late stationary growth phases (lanes 2-
6), with molecular mass markers (kDa) from the corresponding Ponceau S-stained 
membrane. SDS-PAGE and blotting were performed, and membranes were probed with a 
polyclonal anti-SkzL antibody as described under “Experimental Procedures”. 
 
 
Secretion of SkzL by S. agalactiae 
 As shown by western blotting with a polyclonal anti-SkzL antibody, SkzL was 
secreted in monomeric form by S. agalactiae serotype V in all growth phases (Fig. 2B).  
The subsequent studies were restricted to monomeric SkzL as this was the secreted and 
putative physiological form of the protein.  Mass spectrometry of triplicate bacterial 
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supernatant samples confirmed that SkzL was present in both the mid-logarithmic and 
stationary phases of S. agalactiae growth (Appendix Table A2).  Nineteen proteins were 
consistently observed in the S. agalactiae secretome during at least one growth phase, 
including the Pg-binding proteins, α-enolase and GAPDH.  All peptides identified 
distinct proteins with no cross-identifications. NP_687847.1, a putative 
staphylocoagulase homolog, was also identified in the proteomic analysis (71). 
 
Binding of Pg and FFR-Pm to [5F]-SkzL 
 Fluorescence equilibrium binding studies were performed to quantitate binding of 
native [Glu]Pg, [Lys]Pg, and active site-blocked, FFR-Pm to SkzL labeled at Cys393 and 
Cys401 with 5-(iodoacetamido)fluorescein ([5F]-SkzL).  Titrations were performed in the 
absence and presence of 6-AHA to disrupt potential LBS interactions mediated by the 
kringle domains of Pg/Pm (Fig. 3).  Binding of [Glu]Pg to [5F]-SkzL was weak, with a 
dissociation constant of ~3 µM (Fig. 3A; Table 1).  Titrations of [Lys]Pg and FFR-Pm 
were performed at two [5F]-SkzL concentrations to determine stoichiometry (Fig. 3B and 
C).  Binding of [Lys]Pg and FFR-Pm to [5F]-SkzL was characterized by similar 
dissociation constants of 15 ± 2 nM and 23 ± 8 nM, respectively, and unit stoichiometries 
(Table 1).  Binding of all three proteins was eliminated by 10 mM 6-AHA, indicating 
completely LBS-dependent interactions. 
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 Figure 3. Fluorescence titrations of [5F]-SkzL with [Glu]Pg, [Lys]Pg, and FFR-Pm. 
A, Titrations of the fractional change in fluorescence (ΔF/Fo) of 100 nM [5F]-SkzL as a 
function of total  [Glu]Pg concentration ([[Glu]Pg]o) in the absence (●) and presence (○) 
of 10 mM 6-AHA.  B, titrations of 100 nM (●) and 500 nM (Δ) [5F]-SkzL as a function 
of total [Lys]Pg ([[Lys]Pg]o) concentration in the absence of 6-AHA, and titration of 100 
nM [5F]-SkzL with [Lys]Pg in the presence (○) of 10 mM 6-AHA.  C, titrations as in B 
of 100 nM (●) and 500 nM (Δ) [5F]-SkzL, as a function of total FFR-Pm concentration 
([FFR-Pm]o) in the absence of 6-AHA, and titration as in B of 100 nM [5F]-SkzL with 
FFR-Pm in the presence (○) of 10 mM 6-AHA.  Solid lines represent the least-squares fits 
of the data by the quadratic binding equation (Equation 1) with the parameters listed in 
Table 1.  Experiments were performed and the data analyzed as described under 
“Experimental Procedures”. 
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 To determine the affinity of wtSkzL for native [Lys]Pg and Pm, competitive 
binding studies were performed by titration of [5F]-SkzL with [Lys]Pg and FFR-Pm in 
the absence and presence of two fixed concentrations of unlabeled wtSkzL (Fig. 4A and 
C).  Analysis of the competitive titrations for wtSkzL binding to [Lys]Pg and FFR-Pm 
gave KD values of 82 ± 13 nM and 49 ± 23 nM, respectively, 2-5 fold weaker than 
binding to [5F]-SkzL (Table 1).  These KD values, unlike those for [5F]-SkzL, are 
independent of perturbations of the affinity due to the presence of the fluorescence probe, 
which accounts for the higher affinity of labeled SkzL for all of the proteins.  It was not 
possible to carry out competitive binding experiments for [Glu]Pg because of the 
prohibitively high concentrations that would be required. 
 
Table 1. Parameters for binding of [Glu]Pg, [Lys]Pg, and FFR-Pm to [5F]-SkzL and 
competitive binding of wtSkzL or SkzLΔK415. Dissociation constants (KD ligand), 
maximum fluorescence changes (ΔFmax/Fo), and stoichiometric factors (n) are listed from 
direct titrations of [5F]-SkzL with the indicated Pg/Pm ligands. Results of competitive 
binding studies for the indicated ligand and competitor were analyzed by simultaneous 
fitting of the titration in the absence and presence of one or two fixed concentrations of 
competitor to obtain the dissociation constant for the ligand (KD ligand) and competitor 
(KD competitor), with the stoichiometric factor for the ligand interaction fixed at its 
determined value, and fixed at 1 for the competitors. For analysis of the [Glu]Pg 
titrations, n was fixed at 1. ND represents not determined. Experimental error in 
parameters represents ± 2 S.D. Binding studies were performed and the data analyzed as 
described under “Experimental Procedures”. 
Probe Ligand Competitor KD ligand n KD competitor  ∆Fmax/Fo 
   (nM) (mol/mol) (nM) (%) 
[5F]- [Glu]Pg wtSkzL 3000 ±  ND - 20 ± 3 
[5F]- [Lys]Pg wtSkzL 15 ± 2 0.92 ± 0.03 82 ± 13 - 35 ± 1 
[5F]- [Lys]Pg SkzL∆K415 14 ± 7  2500 ± 1200 - 34 ± 1 
[5F]- FFR-Pm wtSkzL 23 ± 8 0.97 ± 0.05 49 ± 23 - 30 ± 1 
[5F]- FFR-Pm SkzL∆K415 9 ± 3  1500 ± 600 - 34 ± 1 
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 To elucidate the potential role of the COOH-terminal Lys415 residue in mediating 
LBS interactions, experiments were also performed with a SkzL mutant lacking this 
residue (SkzL∆K415).  Competitive binding studies in the absence and presence of 
SkzL∆K415 (Fig. 4, B and D) gave probe-independent KD values for SkzL∆K415 binding 
to native [Lys]Pg and FFR-Pm of 2.5 ± 1.2 µM and 1.5 ± 0.6 µM, respectively (Table 1).  
Deletion of Lys415 resulted in a 30-fold decreased affinity for native [Lys]Pg and FFR-Pm 
compared to wtSkzL, indicating a major role of Lys415 in mediating the interactions. 
 
 
Figure 4. Competitive binding of wtSkzL and SkzL∆K415 to Pg/Pm.  A, Titrations of 
the fractional change in fluorescence (ΔF/Fo) of 100 nM [5F]-SkzL as a function of total 
[Lys]Pg concentration ([[Lys]Pg]o) in the absence (●) and presence of 2000 (○) and 5000 
nM (▲) wtSkzL.  B, Titrations as in A of 100 nM [5F]-SkzL with [Lys]Pg in the absence 
(●) and presence of 20 µM (○) SkzL∆K415.  C, Titrations as in A of 100 nM [5F]-SkzL 
as a function of total FFR-Pm concentration ([FFR-Pm]o) in the absence (●) and 
presence of 760 (○) and 2000 nM (▲) of wtSkzL.  D, Titrations as in A of 100 nM [5F]-
SkzL with FFR-Pm in the absence (●) and presence of 20 µM (○) SkzL∆K415.  Solid 
lines represent least-squares fits of the data by the cubic competitive binding equation 
with the parameters listed in Table 1.  Experiments were performed and the data analyzed 
as described under “Experimental Procedures”. 
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LBS-mediated Binding of SkzL to Active Site-labeled Fluorescent Pg/Pm Analogs 
  
To examine the interactions from a different perspective, equilibrium binding 
studies were performed using active site fluorescein-labeled analogs of [Glu]Pg, [Lys]Pg, 
and FFR-Pm in the absence and presence of 6-AHA (Fig. 5). Binding to [5F]FFR-
[Glu]Pg was very weak (KD ~10 µM), 3-fold weaker than observed with [5F]-SkzL, and 
was abolished by 10 mM 6-AHA (Fig. 5,A and B; Table 2).  The source of the weaker KD 
values obtained for [5F]FFR-[Glu]Pg, -[Lys]Pg, and -Pm is explained by 2-3-fold 
decreases in affinity due to active-site labeling of the proteins.  Titrations of [5F]FFR-
[Glu]Pg with SkzL∆K415 demonstrated no apparent fluorescence change, suggesting the 
absence of binding or an interaction occurring more weakly than could be detected under 
the experimental conditions used.  Titrations of [5F]FFR-[Lys]Pg and [5F]FFR-Pm with 
wtSkzL revealed bimodal behavior, suggestive of  two binding interactions.  The high 
affinity interactions occurred with equivalent dissociation constants of 160-170 nM (Fig. 
5,C and E; Table 2).  The low affinity interactions were not well determined, with 
dissociation constants of ~18 and ~20 µM, respectively, and appeared to be due to a 
decrease in anisotropy.  When vertically polarized light was used for excitation and 
emission polarizers were set to the magic angle to eliminate anisotropy, only the high 
affinity SkzL interaction was observed, with KD values for labeled [Glu]Pg, [Lys]Pg and 
Pm indistinguishable from those obtained for the bimodal titrations (Fig. 5, D and F; 
Table 2).  The values for the high affinity interactions were 2-3-fold weaker than the KD 
values from the competitive binding experiments (Table 1), due to fluorescence probe 
labeling of the active site. 
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 Figure 5. Binding of wtSkzL and SkzL∆K415 to [5F]FFR-[Glu]Pg, [5F]FFR-
[Lys]Pg, and [5F]FFR-Pm.  A and B, Titrations of the fractional change in fluorescence 
(ΔF/Fo) of 50 nM [5F]FFR-[Glu]Pg as a function of total wtSkzL concentration ([SkzL]o) 
in the absence (●) and presence (○) of 10 mM 6-AHA, and as a function of total 
SkzL∆K415 concentration ([SkzLΔK415]o) in the absence (▲) and presence (Δ) of 10 
mM 6-AHA.  C and D, Titrations as in A and B of 50 nM [5F]FFR-[Lys]Pg as a function 
of total wtSkzL concentration in the absence (●) and presence (○) of 10 mM 6-AHA, and 
as a function of total  SkzL∆K415 concentration in the absence (▲) and presence (Δ) of 
10 mM 6-AHA.  E and F, Titrations as in A and B of 50 nM [5F]FFR-Pm as a function of 
total wtSkzL concentration in the absence (●) and presence (○) of 10 mM 6-AHA, and as 
a function of total SkzL∆K415 concentration in the absence (▲) and presence (Δ) of 10 
mM 6-AHA.  Solid lines represent the least-squares fits of the data by Equation 1 (A, B, 
D, and F) or Equation 2 (C, and E) with the parameters listed in Table 2.  The dashed line 
represents zero.  Titrations were performed without polarizers (A, C, E), or with vertically 
polarized excitation and emission at the magic angle (B, D, F).  Titrations were 
performed and analyzed as described under “Experimental Procedures”. 
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 Titrations of [5F]FFR-[Lys]Pg, and [5F]FFR-Pm with SkzL∆K415 under non-
magic angle (Fig. 5, C and E) and magic angle (Fig. 5, D and F) conditions gave weak KD 
values of 3-12 µM (Table 2).  The low affinity binding of SkzLΔK415 was eliminated in 
the presence of 6-AHA, consistent with more than one LBS-dependent interaction 
between SkzL and Pg/Pm. 
 
 
Table 2. Parameters for wtSkzL and SkzLΔK415 binding to active site fluorescein-
labeled Pg/Pm analogs. Dissociation constants for the high affinity (KD1) and low 
affinity (KD2) interactions and corresponding maximum fluorescence changes (∆Fmax 
1/Fo) and (∆Fmax 2/Fo) from titrations of [5F]FFR-[Glu]Pg, [5F]FFR-[Lys]Pg, and 
[5F]FFR-Pm (Probe-labeled protein) with wtSkzL or SkzL∆K415 (Ligand) as indicated.  
Titrations were performed without polarizers or with vertically polarized excitation and 
emission at the magic angle (magic angle) to eliminate anisotropy.  Experimental error in 
the parameters represents ± 2 S.D.  Experiments were performed and the results analyzed 
as described under “Experimental Procedures”. 
Probe-labeled 
protein Ligand 
magic 
angle KD1 KD2 ∆Fmax 1 /Fo ∆Fmax 2 /Fo 
   (nM) (nM) (%) (%)
[5F]FFR-[Glu]Pg wtSkzL no 10000 ± 3200  - 18 ± 2  
[5F]FFR-[Glu]Pg wtSkzL yes 16000 ± 9000  - 14 ± 4  
[5F]FFR-[Glu]Pg SkzL∆K415 no no binding  no binding  
[5F]FFR-[Glu]Pg SkzL∆K415 yes no binding  no binding  
[5F]FFR-[Lys]Pg wtSkzL no 170 ± 90 ~18000 - 10 ± 2 - 22 ± 10 
[5F]FFR-[Lys]Pg wtSkzL yes 150 ± 40  - 9 ± 1  
[5F]FFR-[Lys]Pg SkzL∆K415 no 12000 ± 8000  - 15 ± 5  
[5F]FFR-[Lys]Pg SkzL∆K415 yes 2800 ± 1300  - 8 ± 1  
[5F]FFR-Pm wtSkzL no 160 ± 80 ~20000 - 11 ± 2 -18 ± 12 
[5F]FFR-Pm wtSkzL yes 140 ± 14  - 14 ± 2  
[5F]FFR-Pm SkzL∆K415 no 8000 ± 3000  - 18 ± 3  
[5F]FFR-Pm SkzL∆K415 yes 4400 ± 1600  - 16 ± 3  
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LBS-mediated Binding of SkzL to Active Pm 
 To detect any changes in Pm chromogenic substrate kinetics on binding to SkzL, 
assays were performed by continuous measurement of the initial rates of pyro-EPR-pNA 
hydrolysis by Pm as a function of SkzL concentration.  Comparison of the Michaelis-
Menten kinetic parameters in the absence and presence of 1 or 5 µM SkzL, showed a 1.7-
fold decrease in kcat compared to free Pm, no significant change in Km, and a 2-fold 
decrease in kcat/Km (Table 3). 
   
Table 3. Parameters for the effect of SkzL on pyro-EPR-pNA hydrolysis by Pm. 
Kinetic parameters (kcat, Km, kcat/Km) obtained from Michaelis-Menten analysis of the 
substrate dependence. Experiments were performed in the absence and presence of 1 µM 
and 5 µM total SkzL concentration ([SkzL]o). Experimental error in the parameters 
represents ± 2 S.D.  Experiments were performed and the results analyzed as described 
under “Experimental Procedures”. 
 
[SkzL]o kcat Km kcat/Km 
(µM) (s-1) (µM) (s-1µM-1) 
0 78 ± 2 130 ± 2 0.60 
1 46 ± 1 140 ± 11 0.33 
5 47 ± 1 160 ± 22 0.30 
 
 SkzL had no effect on the rate of hydrolysis of chromogenic substrates with Lys 
at the P12 position (ᴅ-VLK-pNA, pyro-Glu-Phe-Lys-pNA, and ᴅ-Val-Phe-Lys-pNA).  
However, similar effects on kcat were seen with other substrates with Arg at the P1 
position (ᴅ-Ile-Pro-Arg-pNA and ᴅ-Val-Leu-Arg-pNA) (results not shown).  Titration 
with SkzL at 200 µM pyro-EPR-pNA showed two distinct LBS-dependent binding 
interactions between SkzL and native Pm, with apparent dissociation constants of 170 ± 
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140 nM and ~9 µM, where the latter value was poorly determined (Fig. 6).  Titration with 
SkzL∆K415 demonstrated a loss of the high affinity interaction and an LBS-dependent 
low affinity interaction with a KD of 3.8 ± 1.2 µM (Fig. 6). 
 
 
Figure 6. Effect of SkzL on pyro-EPR-pNA hydrolysis by Pm.  Titrations of the 
fractional change in initial velocity (Δv/vo) of 10 nM Pm as a function of total wtSkzL 
concentration ([SkzL]o) in the absence (●) and presence (○) of 10 mM 6-AHA, and as a 
function of total SkzL∆K415 concentration ([SkzLΔK415]o) in the absence (▲) and 
presence (Δ) of 10 mM 6-AHA.  Solid lines represent the least-squares fits of the data by 
Equation 1 (▲) or Equation 2 (●), with the parameters given under “Results”.  The 
dashed line represents zero.  Titrations were performed and analyzed as described under 
“Experimental Procedures”. 
  
 
Effect of SkzL on Plasminogen Activation by uPA 
 Chromogenic substrate kinetic assays of Pm formation were performed to 
determine the effect of SkzL on activation of [Glu]Pg and [Lys]Pg by uPA.  To 
investigate the possible effects of SkzL on Pg conformation, assays were done in the 
absence and presence of 10 mM 6-AHA and in low chloride ion buffer, with the uPA 
preparation as the only source of Cl- (0.45 mM in the reactions) and in buffer containing 
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100 mM Cl-.  In the presence of 100 mM Cl-, saturating SkzL concentrations resulted in a 
~2-fold decreased rate of [Lys]Pg activation with minimum rates of Pm generation 
equivalent to those in the presence of 10 mM 6-AHA (Fig. 7A).   
 
 
Figure 7. Effect of SkzL on Pg activation by uPA.  Assays were performed in buffer 
containing 100 mM chloride (A) or 0.45 mM chloride (B).  Initial rates of Pm generation 
((nM Pm/s)/(nM uPA)) for activation of 100 nM [Lys]Pg by 0.11 nM uPA in the absence 
(●) and presence (○) of 10 mM 6-AHA as a function of total SkzL concentration 
([SkzL]o).  Initial rates of Pm generation ((nM Pm/s)/(nM uPA)) for activation of 100 nM 
[Glu]Pg by 0.32 nM uPA in the absence (▲) and presence (Δ) of 10 mM 6-AHA as a 
function of total SkzL concentration ([SkzL]o).  Solid lines represent the least-squares fits 
of the data by the quadratic binding equation with the parameters listed in Table 4.  
Experiments were performed and the data analyzed as described under “Experimental 
Procedures”. 
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 Fitting of the SkzL-dependence in the absence of 6-AHA yielded an apparent KD 
value for SkzL-[Lys]Pg binding of 300 ± 120 nM (Fig. 7A; Table 4), which was ~4-fold 
weaker than the KD value of 80 nM obtained for SkzL binding to [Lys]Pg in competitive 
binding studies.  An identical phenomenon was seen at low Cl- concentration, with an 
indistinguishable apparent KD of 340 ± 150 nM (Fig. 7B; Table 4), consistent with the 
lack of effect of Cl- on the [Lys]Pg β- to γ- conformational change. 
 
 
Table 4. Parameters for the effect of SkzL on Pg activation by uPA. Dissociation 
constants (KD) for the SkzL-dependent change in the rate of Pm generation for activation 
of 100 nM [Glu]Pg or [Lys]Pg by 0.11 nM uPA. Experiments were performed in the 
presence of low and high total chloride ion concentration ([chloride ion]o). Experimental 
error in the parameters represents ± 2 S.D.  Experiments were performed and the results 
analyzed as described under “Experimental Procedures”. 
 
Substrate [chloride ion]o KD 
 (mM) (nM) 
[Lys]Pg 100 300 ± 120 
[Lys]Pg 0.45 340 ± 150 
[Glu]Pg 100 13000 ± 12000
[Glu]Pg 0.45 1900 ± 900 
 
 The rate of Pm generation from [Glu]Pg by uPA in the presence of chloride ion 
was greatly enhanced, ~20-fold to a rate indistinguishable from that for [Lys]Pg at 
saturating concentrations of SkzL or 6-AHA (Fig. 7A; Table 4).  Fitting of the SkzL 
dependence gave an apparent KD value for SkzL-[Glu]Pg binding of 13 ± 12 µM, in good 
agreement with the estimates of 10-16 µM for SkzL binding to [5F]FFR-[Glu]Pg (Table 
2).  The rate of [Glu]Pg activation by uPA in the presence of 10 mM 6-AHA was 
essentially the same as the rate in the presence of saturating concentrations of SkzL.  This 
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indicated that, similar to the effect of 6-AHA, the α-conformation of [Glu]Pg was being 
extended by SkzL to resemble the γ-conformation of [Lys]Pg.  The basal rate of [Glu]Pg 
activation by uPA was enhanced ~11-fold at low Cl- concentration compared with high 
Cl- concentration (Fig. 7B; Table 4).  Saturating SkzL concentrations resulted in a slight, 
~2-fold further enhancement of [Glu]Pg activation.  This small enhancement resulted in 
rates of Pm generation equivalent to those in the presence of 10 mM 6-AHA (Fig. 7B; 
Table 4).  
 
Effect of SkzL on Plasminogen Activation by sctPA 
 Chromogenic substrate kinetic assays of Pm formation were performed to 
determine the effect of SkzL on activation of [Lys]Pg and [Glu]Pg by sctPA.  The rate of 
Pm generation from [Lys]Pg and [Glu]Pg by sctPA was greatly enhanced ~42-fold and 
~650-fold, respectively, in a totally LBS-dependent manner (Fig. 8), although the 
maximum rate at saturating SkzL was 3.4-fold higher for [Lys]Pg compared to [Glu]Pg.  
Fitting of the SkzL dependence gave KD values for [Lys]Pg and [Glu]Pg of 12 ± 7 µM 
and 14 ± 13 µM, respectively.  While the apparent KD of SkzL for [Glu]Pg was consistent 
with those obtained in the binding studies, the KD value for [Lys]Pg was ~60-140-fold 
weaker than the affinity determined in the binding studies for the high affinity interaction 
(Table 2).  This very large difference suggested that a different mechanism was involved 
for sctPA. 
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 Figure 8. Effect of SkzL on Pg activation by sctPA.  Initial rates of Pm generation 
((nM Pm/s)/(nM sctPA)) for activation of 100 nM [Lys]Pg by 3 nM sctPA in the absence 
(●) and presence (○) of 10 mM 6-AHA as a function of total SkzL concentration 
([SkzL]o).  Initial rates of Pm generation ((nM Pm/s)/(nM sctPA)) for activation of 100 
nM [Glu]Pg by 3 nM sctPA in the absence (▲) and presence (Δ) of 10 mM 6-AHA as a 
function of total SkzL concentration ([SkzL]o).  Solid lines represent the least-squares fits 
by the quadratic binding equation with parameters given under “Results”, and the dashed 
line represents zero.  Experiments were performed and data analyzed as described under 
“Experimental Procedures”. 
 
 
SkzL Enhances uPA- and sctPA-mediated Plasma Clot Lysis 
 Plasma clot lysis experiments were performed to assess the role of SkzL as an 
effector of uPA- and sctPA-mediated Pg activation in a physiological model system of 
fibrinolysis.  Human plasma and 6 nM human thrombin were reacted with a preincubated 
mixture of either 7 nM uPA or 1.5 nM sctPA and increasing concentrations of SkzL.  The 
results were expressed as time to half-clot lysis as a function of SkzL concentration (72).  
SkzL enhanced clot lysis by uPA and sctPA, decreasing the time to half-clot lysis by ~2-
fold (Fig. 9).  No clot lysis was observed in the absence of uPA or sctPA. 
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 Figure 9. Effect of SkzL on uPA- and sctPA-mediated plasma clot lysis.  Clot lysis 
represented by the time to half-lysis (time to half-lysis) (●) as a function of total SkzL 
concentration ([SkzL]o) for reactions containing uPA (A) or sctPA (B).  Following 
dilution of all proteins in 50 mM HEPES, 125 mM NaCl, pH 7.4, SkzL was preincubated 
with 10 mM CaCl2, 7 nM uPA or 1.5 nM sctPA for 10 min at 37 °C prior to addition of 6 
nM thrombin and 160 µL of plasma (200 µL assay volume).  Clot lysis was measured by 
turbidity as described under “Experimental Procedures”. Analysis of clot lysis by uPA 
and sctPA gave apparent KD values of 1.9 ± 0.9 µM and 2.5 ± 2.5 µM, respectively.   
 
 
Discussion 
 SkzL from S. agalactiae has modest homology to the bacterial Pg activators, 
SAK, SK, and PauB, and is secreted as the monomeric, 47,400-Da form by S. agalactiae 
throughout its growth cycle.  Nineteen proteins were identified in the S. agalactiae 
secretome, including α-enolase and GAPDH, which are known to bind Pg.  In contrast to 
SK, SAK, and PauB, SkzL does not conformationally or proteolytically activate Pg to Pm 
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(results not shown).  SkzL, however, binds Pg and Pm in a LBS-dependent manner, 
resulting in enhanced [Glu]Pg activation by the endogenous human Pg activators, uPA 
and sctPA. To our knowledge, SkzL is the first S. agalactiae-secreted protein that targets 
uPA, sctPA, and Pg to facilitate activation of the human fibrinolytic system. 
 Equilibrium binding studies show that SkzL binds to [Glu]Pg with low affinity, 
likely due to low accessibility of the LBS in the kringle domains of the compact [Glu]Pg 
α-conformation.  Nevertheless, the low affinity interaction of SkzL with [Glu]Pg is 
eliminated by 6-AHA, indicating that LBS interactions are involved. Competitive binding 
studies indicate that wtSkzL binds to unlabeled, native [Lys]Pg and FFR-Pm with near-
equivalent KD values of 80 and 50 nM, respectively.  The large increase in affinity 
compared to [Glu]Pg is likely due to the increased LBS accessibility in the partially 
extended [Lys]Pg/Pm β-conformation.  Binding of SkzL to [Lys]Pg and FFR-Pm is 
blocked by 6-AHA, indicating that binding is entirely mediated by LBS interactions. 
 Due to the use of multiple experimental approaches to quantitate SkzL binding to 
different forms of Pg and Pm, it is important to address some apparent discrepancies 
among the dissociation constants obtained.  [5F]-SkzL binds with 5- and 2-fold enhanced 
affinity for native [Lys]Pg and FFR-Pm, respectively, compared to the affinity of 
unlabeled wtSkzL determined by competitive binding.  The dissociation constants 
determined by competitive binding are independent of effects that fluorescence probe-
labeling may have on binding affinity.  The enhanced binding of [5F]-SkzL may be a 
result of the location of probe incorporation.  [5F]-labeled SkzL has a stoichiometry of 
labeling of 1.0 mol of [5F]/mol of SkzL, which reflects probe incorporation on Cys393 and 
Cys401, only 14 residues from Lys415 (see Fig. 1).  On this basis, higher affinity binding to 
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[5F]-SkzL may reflect a favorable direct interaction of Pg with the probes.  Conversely, 
wtSkzL binds with 2- and 3-fold reduced affinity to active site-labeled [5F]FFR-[Lys]Pg 
and [5F]FFR-Pm, respectively. The small decrease in affinity associated with Pg/Pm 
active site-labeling may result from distortion of the conformation of the catalytic domain 
of Pg/Pm due to the presence of the probe and linking tripeptide inhibitor.  These 
opposing effects of probe labeling on [Glu]Pg binding are compounded in comparison of 
[Glu]Pg binding to [5F]-SkzL and SkzL binding to [5F]FFR-[Glu]Pg, which differ by 3-
5-fold. 
 SkzL binding to active site-labeled, [5F]FFR-[Lys]Pg and [5F]FFR-Pm revealed a 
high affinity interaction (KD ~140-170 nM) represented by a decrease in fluorescence 
intensity and a low affinity interaction (KD ~20 µM) represented by a decrease in 
anisotropy.  The latter values were not well determined because little saturation was 
obtained at the highest SkzL concentrations achievable (20 µM).  Titrations performed 
with vertically polarized excitation and emission at the magic angle resulted in near-
elimination of the anisotropy change and observation of the high affinity interaction (KD 
140-150 nM) only, indicating that the low affinity interaction is associated with a 
decrease in anisotropy.  Considering the 2-3-fold weakening of SkzL binding due to 
probe labeling, these values of 140-150 nM for the labeled proteins are close enough (≤ 
3-fold) to the values of 50 and 80 nM for high affinity SkzL binding to unlabeled FFR-
Pm and native [Lys]Pg to support the conclusion that they represent the same interaction.  
It should be noted that 2-fold differences in dissociation constants are generally not 
considered significant. 
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 Because the low affinity interactions had some of the hallmarks of nonspecific 
binding, the presence of two distinct interactions between SkzL and Pm was confirmed 
through analysis of the effect of SkzL on the rates of pyro-EPR-pNA hydrolysis by Pm.  
These studies demonstrated mediation of the high affinity LBS-dependent interaction by 
Lys415 and the presence of a second LBS-dependent ~9 µM KD interaction, which was 
poorly determined. 
 Deletion of SkzL Lys415 results in undetectable binding of [Glu]Pg, suggesting 
that binding is mediated by Lys415 exclusively.  Binding of both native [Lys]Pg and FFR-
Pm to wtSkzL is weakened 30-fold by Lys415 deletion.  The results indicate that Lys415 
plays a major role in the LBS-dependent binding of all forms of Pg and Pm.  Loss of 
Lys415 decreases the affinity of SkzL for native [Lys]Pg and FFR-Pm to KD values of 2.5 
and 1.5 µM, respectively (Table 1), demonstrating that Lys415 is responsible for the high 
affinity interaction.  The remaining interaction is also eliminated by 6-AHA, indicating 
that there are two sites on SkzL that mediate LBS-dependent binding to labeled 
[Lys]Pg/Pm.  A sequence containing pairs of Lys and nearby Glu residues in SkzL (Fig. 
1; Lys218, Lys219, Glu227, Glu228) is similar to that of the 250-loop of SK, with the 
exception of Arg253 (Lys256, Lys257, Glu262, Glu263) and a motif in SAK (Lys97-Lys-Glu-
Glu100), certain residues of which are implicated in mediating LBS-dependent Pg 
substrate interactions with SK•Pg* and SAK•Pm catalytic complexes (42,73).  The 
similar motif in SkzL may be responsible for the low affinity interaction.  Future 
mutagenesis studies may be used to establish the SkzL residues involved in mediating 
this weak interaction.   
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 Pg can adopt three distinct conformations that affect its potential for activation by 
tPA and uPA.  The compact nature of the α-conformation of [Glu]Pg, stabilized by 
physiological chloride concentrations, makes it a poor substrate for uPA, tPA, and SK, 
compared with the partially extended, chloride-independent β-conformation of [Lys]Pg 
(17,22-25,49,66).  Upon occupation of [Glu]Pg and [Lys]Pg kringles 1, 4 and 5 by 6-
AHA, the transition to the fully extended γ-conformation also results in enhanced 
activation by uPA (21,23-25). 
 Because of the highly LBS-dependent nature of SkzL binding to Pg, it was 
hypothesized that SkzL-Pg binding could mimic the conformational change induced by 
6-AHA binding, resulting in the extension of [Glu]Pg and [Lys]Pg from the α- and β-
conformations, respectively, to the γ-conformation.  Activation of [Lys]Pg by uPA, 
however, was inhibited by SkzL to a rate equivalent to that in the presence of either 10 
mM 6-AHA or saturating SkzL.  In these experiments, the apparent dissociation constants 
for SkzL-[Lys]Pg binding were ~4-fold weaker than the native affinity determined by 
competitive binding.  This discrepancy may be due to the inability to discern both the 
high and low affinity interactions between SkzL and [Lys]Pg, resulting in a weaker 
apparent affinity representative of a mixture of binding interactions between SkzL and 
[Lys]Pg.  Activation of [Lys]Pg by uPA is inhibited by SkzL, suggesting that while SkzL 
binding may alter the conformation of [Lys]Pg from the β- to the γ-conformation, similar 
to 6-AHA, it does not enhance [Lys]Pg activation by uPA. 
 In the presence of 100 mM chloride ion, activation of [Glu]Pg by uPA is very 
slow; however, binding of SkzL enhances the rate of Pm generation ~20-fold to the same 
level as [Lys]Pg in the presence of saturating SkzL or 6-AHA.  Rates of Pm generation in 
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the presence of 6-AHA are identical to those in the presence of saturating SkzL, 
suggesting that occupation of the [Glu]Pg LBS and stabilization of the γ-conformation by 
SkzL is responsible for the observed SkzL-enhanced rate of [Glu]Pg activation.  
Together, the results show that SkzL is a specific effector of [Glu]Pg activation by uPA.  
Moreover, the mechanism of SkzL-enhanced [Glu]Pg activation by uPA is shown for the 
first time to be caused by SkzL-mediated transformation of [Glu]Pg from the activation-
resistant, α-conformation to the more rapidly activated, γ-conformation. 
 This mechanism and a hypothetical interpretation of the results of the binding 
studies for [Lys]Pg and Pm are presented in Fig. 10.  In this scheme, [Glu]Pg in the α-
conformation is in unfavorable equilibrium (Reaction 1) with the β-conformation, which 
is governed by the Cl- concentration (17,23-25). SkzL binds preferentially to the β-
conformation, mediated by Lys415 binding to kringle 4, and accompanied by transition of 
[Glu]Pg to the γ-conformation (Reactions 1 and 2), which is more susceptible to 
activation by uPA (Reaction 3).  The proposal of kringle 4 as the Lys415-binding site is 
based on the preference of kringle 4 for COOH-terminal Lys residues (26,31,74), and 
preferential binding of SkzL to the [Glu]Pg β-conformation is supported by evidence that 
kringle 4 is masked in the α-conformation (26,75-77). LBS-dependent monoclonal 
antibody binding specific for kringle 4 has been hypothesized to induce an activation-
enhancing conformational change (23,26,30) distinct from the α- to β-conformational 
change caused by disruption of the PAN module-kringle 5 interaction (27,78), suggesting 
a role for kringle 4 in modulating the β- to γ-conformational change (23,30,32).  
Reactions 4 and 5 illustrate that binding of SkzL to [Lys]Pg (or Pm) can occur through 
two distinct interactions as follows: high affinity Lys415-kringle 4 binding and a weak 
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interaction between the internal SkzL motif and kringle 5, supported by the demonstrated 
specificity of kringle 5 for alkylamines and internal Lys residues (79,80).  All of the 
putative [Lys]Pg/Pm complexes are consistent with the present results, but the Pg 
kringles to which the two sites on SkzL bind and the compositions of the complexes have 
not been substantiated experimentally and therefore remain hypothetical. 
The enhanced rate of [Glu]Pg activation caused by SkzL is not specific to uPA, as 
kinetic studies demonstrate that SkzL also enhances Pg activation by sctPA.  In contrast 
to the results with uPA, however, increased rates of Pm generation are seen for sctPA 
activation of both [Glu]Pg and [Lys]Pg.  The effect of SkzL on [Glu]Pg activation by 
sctPA may be due to SkzL-mediated conformational changes in [Glu]Pg similar to those 
seen with uPA.  However, the apparent dissociation constant for SkzL-enhanced [Lys]Pg 
activation by sctPA appears to be ~12 µM, ~60-140-fold weaker than the KD value for 
SkzL-[Lys]Pg binding determined by fluorescence.  This suggests that the mechanism of 
enhanced [Lys]Pg activation by sctPA is different, and cannot be explained by SkzL-
[Lys]Pg binding interactions alone.  While further studies are needed to evaluate this 
hypothesis, preliminary results suggest that SkzL interacts with sctPA though the LBS on 
kringle 2 of sctPA, which is not present in uPA.  Binding of wtSkzL and SkzL∆K415 to a 
fluorescent sctPA analog was characterized by KD values of 14 and 15 µM, respectively, 
in an LBS-dependent manner (unpublished results).  This result suggests that weak SkzL 
binding to sctPA is due to an interaction of kringle 2 of sctPA with a site distinct from 
Lys415 on SkzL.  As SkzL binding to [Lys]Pg is largely mediated by Lys415, such an 
interaction with sctPA may result in higher order complex formation, which will require 
further experimentation to evaluate.  
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 Figure 10. Diagram of the proposed mechanism of SkzL-mediated [Glu]Pg 
activation by uPA, and postulated LBS-dependent complexes formed with [Lys]Pg 
and Pm mediated by two sites on SkzL.  SkzL is shown in purple with Lys415 (K) on a 
flexible segment, and the postulated SkzL internal motif that mediates kringle binding is 
represented by the “nose”.  [Glu]Pg in light orange is shown with the NH2-terminal PAN 
module in red, 5 numbered kringle domains, and the COOH-terminal catalytic domain.  
[Glu]Pg in the compact, α-conformation ([Glu]Pg-α) is shown as a spiral structure that is 
maintained by the PAN domain interacting with kringle 5.  [Glu]Pg is in equilibrium 
(Reaction 1) with a low concentration of the partially extended, β-conformation 
([Glu]Pg-β), in which the PAN module has been released by kringle 5.  The proposed 
mechanism of SkzL-enhanced [Glu]Pg activation by uPA is shown in Reactions 1, 2, and 
3.  SkzL binds preferentially to the β-conformation of [Glu]Pg, mediated by Lys415 
binding to the LBS of kringle 4, which converts the SkzL•[Glu]Pg complex to the γ-
conformation (SkzL•[Glu]Pg-γ), thereby accelerating the rate of [Glu]Pg activation to 
[Lys]Pm (active site in green) by uPA (Reaction 3).  Conversion of the initial product, 
[Glu]Pm into [Lys]Pm by the Pm generated is not shown.  [Lys]Pg, lacking the PAN 
module, is represented in the partially extended, β-conformation ([Lys]Pg-β).  
Hypothetical complexes formed by wtSkzL and [Lys]Pg or Pm mediated by its two 
binding sites are; Reaction 4, formation of a ternary, SkzL• [Lys]Pg2 complex in which 
one Pg molecule is bound through the Lys415-kringle 4 interaction in the γ-conformation 
and binding of the other Pg molecule mediated by the SkzL internal motif-kringle 5 
interaction, with Pg in the β-conformation (SkzL•[Lys]Pg-γ•[Lys]Pg-β); and Reaction 5, 
formation of an SkzL•[Lys]Pg complex in the γ-conformation with both the internal 
motif and Lys415 engaged with their respective kringles.  Reaction 6 illustrates the 
complex formed between SkzLΔK415 and [Lys]Pg or Pm mediated by the internal motif 
in SkzL. 
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 The present studies show that SkzL is a novel protein that is modestly 
homologous to SK, secreted from S. agalactiae, and acts as a cofactor of sctPA and uPA 
in accelerating Pg activation.  Recent studies have established that an interaction of cell 
surface-bound GAPDH with Pg contributes to the virulence of GBS invasive infection in 
an in vivo murine model (10).  The present studies reveal SkzL as an additional 
component in the interactions between GBS and the proteins of the human fibrinolytic 
system.  As a secreted protein, SkzL may play a role as a Pg-binding protein different 
from the cell surface-bound Pg-binding proteins, α-enolase and GAPDH, in the context 
of GBS infection, or it could act in cooperation with these proteins through as yet, 
unknown interactions.  SkzL has high affinity for Pg and Pm relative to the plasma Pg 
concentration of 2 µM (67), and binds through a strictly LBS-dependent mechanism 
involving the kringle domains of Pg and Pm.  SkzL is a novel effector of uPA-mediated 
[Glu]Pg activation through a LBS-dependent mechanism similar to 6-AHA (22,29).  The 
studies suggest that the role of SkzL as an effector of Pg activation by uPA is specific for 
the circulating form of Pg in blood, [Glu]Pg.  SkzL also enhances sctPA-mediated 
[Glu]Pg and [Lys]Pg activation through a different mechanism that will be examined in 
further studies.  The finding that SkzL enhances clot lysis by both physiological Pg 
activators in plasma provides strong support for a role of SkzL in the interaction of GBS 
with the human fibrinolytic system.  SkzL has the potential to be a new virulence factor 
in life-threatening S. agalactiae infections of neonates and immune-compromised 
individuals. 
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1The abbreviations used are: GBS, Group B streptococci; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase;  SkzL, skizzle; wtSkzL, recombinant wild-type SkzL; SK, 
streptokinase; SAK, staphylokinase; Pg, plasminogen; [Glu]Pg, native plasminogen; 
[Lys]Pg, plasminogen lacking the amino-terminal 77-residue PAN module; Pm, 
[Lys]plasmin; uPA, high molecular weight urokinase; sctPA, single-chain tissue-type 
plasminogen activator; FFR-CH2Cl, D-Phe-Phe-Arg-CH2Cl; [5F]FFR-[Glu]Pg, [5F]FFR-
[Lys]Pg, and [5F]FFR-Pm, [Glu]Pg, [Lys]Pg, or Pm labeled at the active site with 5-
(iodoacetamido)fluorescein attached to the thiol generated on Nα-[(acetylthio)acetyl]-D-
Phe-Phe-Arg-CH2Cl; DTNB, 5, 5’–dithiobis-(2-nitrobenzoic acid); DTT, dithiothreitol; 
6-AHA, 6-aminohexanoic acid; pNA, para-nitroaniline; VLK-pNA, D-Val-Leu-Lys-p-
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nitroanalide; pyro-EPR-pNA, pyro-Glu-Pro-Arg-pNA; LBS, lysine-binding sites; [5F]-
SkzL, SkzL labeled at Cys393 and Cys401 with 5-(iodoacetamido)fluorescein; SkzL∆K415, 
skizzle lacking the COOH-terminal Lys415 residue; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. 
2Schechter-Berger (81) notation referring to the residues of a substrate (from the NH2-
terminal end) as …P4-P3-P2-P1-P1’-P2’… with the scissile bond at P1-P1’. 
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APPENDIX A 
 
STUDIES REPORTED IN CHAPTER 2 AS SUPPLEMENTAL DATA 
 
Analysis of the three Cys residues of SkzL 
 
Experimental Procedures 
 One difference between SK and SkzL is the presence of three Cys residues, 
Cys120, Cys393, and Cys401.  Site-directed mutagenesis (Stratagene QuikChange) was used 
to create single (C120S, C393S, C401S), double (C120S/C393S, C120S/C401S, 
C393S/C401S), and triple (C120S/C393S/C401S) Cys-to-Ser substitution mutants that 
were purified as described for wild type.  Thiols were quantitated by reaction of SkzL (3-
5 µM) with 450 µM 5, 5’ –dithiobis-(2-nitrobenzoic acid) (DTNB) monitored at 412 nm.  
Thiol concentrations were determined under non-denaturing (100 mM HEPES, 0.3 M 
NaCl, 1 mM EDTA, pH 7.0) and denaturing conditions (6  M guanidine, 100 mM 
HEPES, 0.3 M NaCl, 1 mM EDTA, pH 7.0) using absorption coefficients 14150 M-1cm-1 
and 16434 M-1cm-1, respectively.  For determination of intra-molecular disulfide bonds, 
50-100 µM wild-type SkzL and Cys-to-Ser substitution mutants were reacted with a 5-
fold molar excess of DTT for 10 min at 25 °C followed by chromatography on ~1 ml 
freshly poured Sephadex G-25 spin columns (Bio-Rad), and the concentration of thiols 
was determined as described.   
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Results and Discussion 
 
 Analysis of wild-type SkzL showed one thiol under native conditions and two 
thiols under denaturing conditions (Appendix Table A1), indicating that one Cys is 
buried within the protein and one Cys residue was unaccounted for.  Reduction of SkzL 
revealed the observation of two free thiols under non-denaturing conditions and a total of 
2.6 thiols under denaturing conditions.  This result suggests the presence of a partially 
reduced internal disulfide bond.  Single Ser substitution mutants of Cys393 or Cys401 
contained one thiol under native conditions and 2 thiols under denaturing conditions with 
no effect of DTT, indicating the loss of an internal disulfide bond.  The single Ser mutant 
lacking Cys120 contained one thiol under native and denaturing conditions with the 
observation of a second thiol upon reaction with DTT, indicating that the mutant retained 
the internal disulfide bond. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Appendix Table A1. Quantification of SkzL Cys Residues.  Cys-to-Ser substitution 
mutants were generated and thiols expressed as mol thiol/mol SkzL were quantitated as 
described above in “Experimental Procedures”.  The number of thiols are listed for those 
measured under non-denaturing buffer conditions (native), the number of thiols measured 
under denaturing buffer conditions (denatured), and the number of thiols measured under 
the corresponding buffer condition following reaction with a 5-fold molar excess of 
dithiothreitol (+DTT) to reduce disulfide bonds.  Results represent averaged values for at 
least two independent preparations of each mutant. 
 
SkzL mutation native  
native 
+ DTT 
denatured 
 
denatured 
+ DTT 
 (mol thiol/ mol SkzL) 
(mol thiol/ 
mol SkzL) 
(mol thiol/ 
mol SkzL) 
(mol thiol/ 
mol SkzL) 
wild type 1.08 1.95 1.70 2.61 
C120S 0.83 1.44 0.69 1.25 
C393S 0.91 0.82 1.63 1.38 
C401S 0.99 0.96 1.74 1.57 
C120S/C393S 1.04  0.86  
C120S/C401S 0.95  0.97  
C393S/C401S 0.07  0.797  
C120S/C393S/C401S 0.01  0.01  
 
  
The results indicate that Cys120 is buried within the protein and that Cys393 and 
Cys401 each occur partially as free thiols and partially as an intramolecular disulfide bond.  
The results also indicate that non-physiological disulfide-mediated dimerization can 
occur through Cys393 or Cys401.  It is unclear what role the Cys residues and 
intramolecular disulfide bond play in SkzL function, although there is no evidence for the 
formation of covalent Pg/Pm-SkzL complexes through disulfide exchange (results not 
shown). 
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Secreted Protein Profile Analysis 
 
 
Experimental Procedures 
 To determine the secreted protein profile of S. agalactiae, bacterial supernatant 
samples in the mid-logarithmic and stationary growth phases from three separate 
bacterial growths were normalized to identical optical densities and subjected to 
trichloroacetic acid precipitation.  Samples were separated by SDS-PAGE, subjected to 
in-gel tryptic digestion, and analyzed by LC-MS-MS.  Samples were analyzed using a 
Thermo Finnigan LTQ ion trap instrument following separation on a packed capillary tip 
with Jupiter C18 resin using an in-line solid phase C18 extraction column.  Tandem MS-
MS spectra were compared to the S. agalactiae genome using the SEAQUEST algorithm.  
Data were filtered using the following criteria: cross-correlation value of ≥ 1.0 for singly 
charge ions, ≥ 1.8 for doubly charged ions, and ≥ 2.5 for triply charged ions.  A primary 
score of ≤ 5 and a preliminary score of ≥ 350 were required for positive peptide 
identification.  All proteins identified by less than 2 peptides were eliminated.  False 
positive results were filtered and proteins were reassembled using a parsimony method 
(1).  Protein identities are reported as mean peptide count (± 1 SD).  Only proteins 
identified in all three bacterial growths are reported. 
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Appendix Table A2. Secreted protein profile for Streptococcus agalactiae.  Mass 
spectrometry analysis of secreted proteins from three distinct bacterial samples obtained 
at the mid-logarithmic and stationary growth phases as described above in “Experimental 
Procedures”.  Only proteins identified in all three samples are represented. 
 
  logarithmic phase stationary phase 
accession 
number protein name 
mean 
peptide 
count 
standard 
deviation 
mean 
peptide 
count 
standard 
deviation 
22536202 pcsB protein (46.5 kDa) 26.0 13.1 27.3 11.8 
22536217 GBS surface immunogenic 10.0 4.6 17.7 3.2 
22536801 enolase 5.0 5.3 1.3 0.6 
22536926 elongation factor Tu 4.7 3.1 1.3 2.3 
22536996 NP_687847.1 (Zymogen 
Activator and Adhesion 
Protein (ZAAP)) 
32.3 14.2 22.3 16.3 
22536997 NP_687848.1 17.3 2.9 12.0 1.0 
22537285 SkzL (NP_688136.1) 1.0 0.0 3.0 1.7 
22537355 hyaluronidase 5.7 2.1 6.3 2.1 
22537497 surface antigen-related protein 13.7 6.5 18.0 5.6 
22537823 immunogenic secreted protein 84.0 21.0 85.3 10.6 
 ( N-acetylmuramoyl-L-alanine     
 amidase, family 4)     
22537907 glycerladehyde-3-phosphate 2.3 2.5 1.7 1.5 
 dehydrogenase     
22538178 cAMP factor 9.0 1.7 21.0 11.5 
22538282 LysM domain protein 3.3 1.2 3.0 1.0 
22536474 ABC transporter 1.0 1.0 2.0 1.0 
22536566 unknown, lipoprotein putative 1.0 1.0 1.0 1.0 
22536616 surface protein Rib 1.7 0.6 3.3 1.2 
22537364 NP_688215.1 1.0 0.0 2.3 2.3 
22537480 5'-nucleotidase family protein 2.0 3.5 14.3 2.1 
22536554 sag0371 1.7 0.6 1.0 1.0 
 
 
References 
 
1. Zhang, B., Chambers, M. C., and Tabb, D. L. (2007) J. Proteome Res. 6, 3549-
3557 
75 
 
 APPENDIX B 
 
STUDIES REPORTED IN CHAPTER 2 AS UNPUBLISHED RESULTS  
 
Introduction 
 The work in Chapter 2 (published in the Journal of Biological Chemistry 2010; 
285(27): 21153-21164) focuses on the cloning, expression, and purification of SkzL as a 
monomer. In addition, it addresses the characterization of the Cys residues, protein 
secretion from Streptococcus agalactiae, SkzL binding to Pg and Pm, and function of 
SkzL as an effector of uPA- and tPA-mediated Pg activation. Chapter 2: Appendix B will 
focus on results presented as either data not shown or those not included in Chapter 2. 
 
Experimental Procedures 
 
Conformational Activation of Pg by SkzL Assessed by SDS-PAGE 
 To prevent fluorescent labeling of SkzL, free thiol groups were covalently 
blocked by incubation of SkzL with a 5-fold molar excess of iodoacetamide for 2 h at 
room temperature, followed by extensive dialysis to remove excess iodoacetamide. To 
determine if SkzL was capable of conformational activation of Pg, 10 µM [Lys]Pg was 
incubated with 80 µM ATA-FFR-CH2Cl and 16 µM iodoacetamide-blocked SkzL (or 16 
µM native SK as a positive control) for 2 h at 25 °C. Excess ATA-FFR-CH2Cl was 
removed by Sephadex G-25 spin column-chromatography. The ATA-FFR-CH2Cl-
blocked induced active site was reacted with 0.1 M hydroxylamine, to deacetylate the 
ATA-FFR-CH2Cl inhibitor and 40 µM 5-(iodoacetamido)fluorescein (5-IAF). Excess 
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probe was removed by Sephadex G-25 spin-column chromatography. One reaction 
contained all reaction components and 4 control reactions each lacked one of the 
components (5-IAF, SkzL, hydroxylamine, ATA-FFR-CH2Cl). To visualize the reaction 
products SDS-PAGE was performed under reducing conditions to ensure separation of 
the Pg and SkzL bands (1).  
 
Analytical Ultracentrifugation 
 Sedimentation velocity experiments were performed on a Beckman-Coulter XLE-
1 Analytical Ultracentrifuge at the University of Tennessee, Knoxville with the help of 
Dr. Cynthia Peterson. Interference scans were performed at 50,000 RPM at 25 °C with 
the vacuum set at 0 microns. The partial specific volume of SkzL was determined to be 
0.7277 using the Sednterp program. Data were analyzed using the SedFit program to 
determine sedimentation coefficients, molecular weights, and percent abundances of 
species (2-4).   
 
Chromogenic Substrate Kinetics 
 The potential activation of 100 nM [Lys]Pg by SkzL was measured in the absence 
and presence of 0.5 nM [Lys]Pm. In these assays, hydrolysis of 200 µM ᴅ-Val-Leu-Lys-
p-nitroanalide (VLK-pNA) was measured at 405 nm as a function of time. Assays were 
performed in 50 mM HEPES, 125 mM NaCl, 1 mM EDTA, 1 mg/ml PEG 8,000, pH 7.4 
using PEG 20,000 coated polystyrene cuvettes (5-8).  Raw data were reported as 
absorbance at 405 nm (A405 nm) as a function of time. 
Results and Discussion 
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 Due to sequence homology to SK and conservation of key residues involved in Pg 
activation, it was hypothesized that SkzL would activate Pg through the molecular 
sexuality mechanism of NH2-terminal insertion (9). To evaluate this hypothesis, an SDS-
PAGE experiment was performed to investigate potential conformational activation of Pg 
through incorporation of a fluorescence probe at the induced active site. In this reaction, 
SkzL or SK was reacted with Pg in the presence of ATA-FFR-CH2Cl to covalently 
inhibit the induced active site. Deacetylation of the thiol followed by reaction with a 
fluorophore-iodoacetamide would result in incorporation of a fluorescent probe in the 
inhibited, induced active site. As a positive control, SK resulted in efficient 
conformational activation of Pg and probe incorporation in the induced active. Binding of 
SkzL to Pg did not facilitate probe incorporation, indicating failure of SkzL to generate 
an induced active site upon Pg binding (Appendix Fig. B1) (1).  
 
 
78 
 
 Appendix Figure B1. Fluorescence labeling following conformational activation of 
Pg. SDS-PAGE of fluorescence labeling reactions containing [Lys]Pg (Lane 1) and SkzL 
(Lane 2), to determine the potential for conformational activation. Lanes 3-6 correspond 
to labeling reactions in which one reaction component was omitted (Lane 3, 
hydroxylamine omitted; Lane 4, FFR-CH2Cl added for 20 min to block the active site 
prior to  incubation with ATA-FFR-CH2Cl; Lane 5, SkzL omitted; Lane 6, ATA-FFR-
CH2Cl omitted). The complete reaction for SkzL (Lane 7) and SK as a positive control 
(Lane 8) contain all reaction components as described in “Experimental Procedures”.  
 
 
 This result was confirmed using chromogenic substrate kinetic assays to evaluate 
the potential for Pg activation in the absence and presence of catalytic Pm concentrations. 
Pm generated by Pg activation results in measurable hydrolysis of the chromogenic 
substrate (VLK-pNA) as a function of time. No hydrolysis of VLK-pNA was seen 
following reaction of 100 nM [Lys]Pg with µM SkzL concentrations indicating that SkzL 
does not conformationally or proteolytically activate Pg. As SkzL shares sequence 
homology to SAK, which requires catalytic concentrations of Pm for Pg activation, 
assays were also performed in the presence of 0.5 nM Pm. No increase in the rate of 
79 
 
substrate hydrolysis above the Pm baseline was seen, indicating that SkzL does not 
activate Pg in the absence or presence of catalytic Pm (Appendix Fig. B2).  
 
 
Appendix Figure B2. Measurement of VLK-pNA hydrolysis to detect Pg activation 
by SkzL. Rates of hydrolysis of VLK-pNA by 0.5 nM Pm incubated with 100 nM 
[Lys]Pg in the absence (black line) and presence of 1 µM (pink line) and 5 µM (blue line) 
SkzL. Hydrolysis of VLK-pNA was measured at 405 nm (∆A405 nm) as a function of time 
as described in “Experimental Procedures”.  
 
 
 
 Results of the cysteine-to-serine mutagenesis studies in Chapter 2: Appendix A 
indicated that Cys120 is buried within the protein and that Cys393 and Cys401 each occur 
partially as free thiols and partially as an internal disulfide bond. The results also 
indicated that trace disulfide-mediated dimerization may occur through Cys393 or Cys401. 
As a result of the formation of trace levels of SkzL dimer removed during purification, it 
was hypothesized that SkzL may form a non-covalent dimer in solution. To address this 
hypothesis, analytical ultracentrifugation was performed in collaboration with Dr. 
Cynthia Peterson at the University of Tennessee, Knoxville. Sedimentation velocity 
interference scans were performed with varying SkzL concentrations. A 48 kDa 
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monomer was the predominant species accounting for 85% of the protein with a 15% 
contribution from a 84 kDa species (Appendix Fig. B2). The molecular weights are in 
good agreement with those calculated by mass spectrometry for SkzL monomer and 
dimer (47 kDa and 94 kDa, respectively). Densitometry of SDS-PAGE for this protein 
sample at varying protein concentrations confirmed the presence of 13-17% covalent 
SkzL dimer. This indicates that non-covalent dimerization of SkzL in solution does not 
occur (2-4).   
 
 
Appendix Figure B3. Analytical Ultracentrifugation of purified recombinant SkzL.  
Sedimentation coefficients obtained from sedimentation velocity interference scans of 1 
mg/ml SkzL revealed a 48 kDa species accounting for 85% of the protein and an 84 kDa 
species accounting for 15%. Studies were performed and analyzed as described in 
“Experimental Procedures”.  
 
 
Both Pg and Pm contain several Cys residues which stabilize the tertiary protein 
structure through disulfide bonds. To determine the potential covalent complex formation 
between Pg/Pm and SkzL through SkzL free thiol groups, SDS-PAGE experiments were 
performed and no evidence of covalent complex formation was seen (data not shown).  
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However, proteolytic degradation of SkzL was observed at high Pm concentrations. As 
SkzL is hypothesized to be involved in Pm generation, it was vital to characterize the 
stability of SkzL in the presence of Pm. To that end, SDS-PAGE experiments were 
performed to evaluate SkzL stability as a function of Pm concentration. In these studies, 
10 µM [5F]-SkzL was incubated with increasing Pm concentrations (0.5 nM – 2000 nM) 
for one hour at 25 °C in the dark to preserve fluorescence intensity. Pm proteolytic 
activity was quenched with 70 µM FFR-CH2Cl and protein interactions were disrupted 
by addition of hot SDS buffer. Samples were subjected to SDS-PAGE on a 4-15% 
gradient gel followed by Coomassie blue staining. Images of fluorescent and stained gels 
show dramatic proteolytic degradation of SkzL as a function of Pm concentration 
(Appendix Fig. B3).  
Through 1 h, 10 µM SkzL was determined to be stable at 0.5-10 nM Pm. Similar 
results were seen at 2 hours (data not shown). For studies in this thesis, concentrations of 
Pm generated were limited to those less than 10 nM to ensure SkzL stability.  
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 Appendix Figure B4. SkzL stability as a function of Pm concentration. SDS-PAGE 
of 10 µM [5F]-SkzL reacted for 1 h with increasing Pm concentrations with a Pm 
standard (lane 1). Lanes 2-16 correspond to 0.5, 10, 25, 50, 75, 100, 200, 300, 400, 500, 
1000, 1500, and 2000 nM Pm. Reactions were quenched by addition of 70 µM FFR-
CH2Cl and hot SDS buffer as described in “Experimental Procedures”.  
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CHAPTER III 
 
SKIZZLE IS AN EFFECTOR OF TISSUE-TYPE PLASMINOGEN ACTIVATOR-
MEDIATED PLASMINOGEN ACTIVATION 
 
Abstract 
 Skizzle (SkzL), secreted by Streptococcus agalactiae, binds active site 
fluorescently labeled-single-chain tPA (sctPA) with low affinity (KD ~14 µM) through 
Lys415-independent, lysine-binding site (LBS)-dependent interaction of the putative SkzL 
internal motif with tPA kringle 2. SkzL enhances [Glu]Pg activation by non-cleavable 
sctPA (nctPA) and two-chain tPA (tctPA) ~490-fold and ~400-fold, respectively and 
enhances [Lys]Pg activation by nctPA and tctPA ~48-fold and ~7-fold, respectively. The 
apparent affinities of 6-13 µM determined for the SkzL-dependences on enhanced 
[Glu]Pg and [Lys]Pg activation, appear to represent SkzL-tPA binding.  Deletion of the 
COOH-terminal SkzL Lys415 residue results in a ~2.5-4-fold reduction in the 
enhancement of [Lys]Pg activation by nctPA and tctPA, compared with wtSkzL, 
suggesting that Lys415-dependent SkzL-Pg interactions affect the enhancement amplitude. 
Analyses of the Pg-dependence kinetics suggests a mechanism of SkzL•tPA•Pg•SkzL 
quaternary complex formation, although further work is needed to clarify this 
mechanism. As a result, SkzL is identified as a novel cofactor of Pg activation by tPA. 
Combined with enhanced rates of plasma clot lysis by tPA reported in Chapter 2, these 
results support a Pg activation-specific role for SkzL in the pathogenesis of Streptococcus 
agalactiae infection. 
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Introduction 
 Activation of human plasminogen (Pg) occurs endogenously through proteolysis 
by two activators, urokinase (uPA) and tissue-type plasminogen activator (tPA). 
Proteolytic Pg activation occurs by cleavage of the Arg561-Val562 peptide bond in the Pg 
catalytic domain to form the active serine proteinase plasmin (Pm). Following cleavage 
of Pg by Pm, the NH2-terminal 77-residue PAN (Pg/apple/nematode) module of zymogen 
[Glu]Pg is released to yield [Lys]Pg (1).  Three of the five Pg kringle domains (kringles 
1, 4, and 5) contain lysine binding sites (LBS) that exhibit moderate affinity for L-lysine 
and higher affinity for the lysine analog 6-aminohexanoic acid (6-AHA) (1-7).  
 [Glu]Pg is maintained in the compact α-conformation by interaction of the PAN 
module with kringle 5 (8-12). The α-conformation of [Glu]Pg, however, is in equilibrium 
with a low concentration of a partially extended β-conformation [Glu]Pg, governed by 
chloride ion concentration (3,9,13-15).  Upon binding of benzamidine to kringle 5, 
[Glu]Pg assumes the partially extended β-conformation (9,16-19). Lacking the PAN 
module, [Lys]Pg is in the partially extended β-conformation (9,19).  Upon occupation of 
the LBS, particularly that of kringle 4, by ligands such as 6-AHA, both [Glu]Pg and 
[Lys]Pg assume the fully extended γ-conformation (9,16-21).  Because the extended β- 
and γ-conformations offer better binding accessibility, [Lys]Pg and ligand-bound [Glu]Pg 
are better substrates for activation by uPA and tPA than [Glu]Pg in the α-conformation 
(9,16-19). As a result, LBS ligands such as L-lysine, 6-AHA, and fibrin are considered 
effectors of uPA- and tPA-mediated Pg activation (9,18). 
 Studies reported in Chapter 2 revealed the complex binding interactions between 
skizzle (SkzL) and Pg/Pm. The compact zymogen, [Glu]Pg bound SkzL with weak 
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affinity of ~3-16 µM, mediated by LBS-dependent interaction with the SkzL COOH-
terminal Lys415 residue. Binding of SkzL to [Lys]Pg and Pm occurred with near-equal 
affinity through two distinct binding interactions: a high affinity interaction with KD’s of 
50-80 nM and a low affinity interaction with KD’s of 9-20 µM. The LBS-dependent high 
affinity interaction between SkzL and [Lys]Pg/Pm, mediated by SkzL Lys415, occurs 
through a putative interaction with kringle 4 (19,22,23). The LBS-dependent low affinity 
interaction is proposed to occur through interaction of a SkzL internal motif, analogous to 
the motif in the SK 250-loop, with Pg kringle 5 (24,25).  
 Studies of the effect of SkzL on activation of [Glu]Pg and [Lys]Pg by uPA were 
performed to examine the effect of SkzL binding on Pg conformation (Chapter 2). It was 
concluded that SkzL binding induced the [Glu]Pg α/β- to γ-conformational transition, 
reflected by the enhanced rate of [Glu]Pg activation by uPA to rates equivalent to 
[Glu]Pg or [Lys]Pg activation in the presence of 6-AHA (13,20,21). Together, these 
results identified SkzL as a novel effector of uPA-mediated [Glu]Pg activation, with a 
mechanism of action analogous to 6-AHA.  
 One structural difference between uPA and tPA is the presence of a second 
kringle domain in tPA (kringle 2) containing an LBS with high affinity for effector 
molecules such as lysine, 6-AHA, and fibrin fragments (26,27).  In studies of activation 
of [Glu]Pg by tPA, enhanced activation is seen in the presence of these effectors. The 
kinetics of enhanced activation involves a decrease in Km with varied degrees of kcat 
increases reported (13,28-32). Intact fibrin enhances tPA-mediated Pg activation through 
formation of a ternary complex in which fibrin acts as a template to enhance tPA-Pg 
binding and Pg activation (7,33,34). Ternary complex formation occurs through 
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interaction of Pg kringle 5 and tPA-kringle 2 within the fibrin D region resulting in 
enhanced plasma Pg to Pm proteolysis (7,33).  
 The results in Chapter 2 indicated that SkzL enhanced the time to half-clot lysis 
by single-chain tPA (sctPA) ~2-fold. Kinetics assays also demonstrated that, unlike uPA, 
activation of both [Glu]Pg and [Lys]Pg by sctPA were enhanced by SkzL, in an LBS-
dependent manner. The work in this chapter elaborates on these findings in an effort to 
determine the mechanism of SkzL-mediated enhancement of Pg activation by tPA.  
 Zymogen-like sctPA is proteolytically cleaved by Pm in plasma, to form the more 
active two-chain form (tctPA). sctPA is converted into tctPA in clot lysis assays 
performed with 125I-sctPA (35). The studies in this chapter employed a non-cleavable 
sctPA mutant (nctPA) containing an Arg257Glu substitution mutation rendering it resistant 
to Pm cleavage (36). The present studies reveal that SkzL binds tPA with low affinity, in 
an LBS-dependent manner mediated by a site distinct from SkzL Lys415. Kinetic studies 
with nctPA and tctPA confirm the results of studies with sctPA reported in Chapter 2, 
identifying SkzL as an effector of tPA-mediated Pg activation. While the exact 
mechanism remains unclear, SkzL-mediated enhancement is proposed to occur by 
formation of a SkzL2•tPA•Pg quaternary complex unlike the template mechanism for 
fibrin-bound tPA-mediated Pg activation.  
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Experimental Procedures 
 
Protein Purification and Characterization 
 [Glu]Pg, [Lys]Pg, and Pm (all carbohydrate form 2) were prepared as previously 
described (6,37,38). Human sctPA, tctPA and nctPA (the non-cleavable Arg257Glu sctPA 
mutant, Molecular Innovations) were stored in 0.5 M HEPES, 0.5 M NaCl, pH 7.4 buffer 
to ensure solubility and were limited to one freeze-thaw cycle to maintain stable activity. 
[Glu]Pg, [Lys]Pg and SkzL were purified as described in Chapter 2 and stored in 50 mM 
HEPES, 125 mM NaCl, pH 7.4 at -80 °C following snap-freezing (6,39).  
 
Active Site Labeling of sctPA 
 Inactivation of the human sctPA (54 µM) active site was achieved by reaction 
with 500 µM Nα-[(acetylthio)acetyl]-D-Phe-Phe-Arg-CH2Cl (ATA-FFR-CH2Cl) for 3 h 
at 25 °C followed by chromatography on Sephadex G-25 to remove excess inhibitor. 
Deacetylation with 0.1 M NH2OH and thiol-specific reaction with a 4-fold molar excess 
of tetramethylrhodamine-5-iodoacetamide dihydroiodide (TMR, Invitrogen) for 1 h at 25 
°C were followed by chromatography on Sephadex G-25 and dialysis to remove excess 
probe (38,40-42). [TMR]FFR-sctPA was stored in 0.5 M HEPES, 0.5 M NaCl, pH 7.4 
buffer at -80 °C following snap-freezing. Protein concentration was determined by 
bicinchoninic acid protein assay (Pierce). Probe incorporation was determined to be 1.05 
mol probe/mol tPA by absorbance measurements at 280 nm and 557 nm with an 
absorption coefficient of 90,527 M-1 cm-1 for TMR and an A280 nm/A557 nm ratio of 0.215 in 
6 M guanidine, 100 mM Tris-HCl, 1 mM EDTA, pH 8.5 buffer (43).  
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Fluorescence Equilibrium Binding 
 Fluorescence titrations 100 nM [TMR]FFR-sctPA with wtSkzL or SkzL∆K415 
were performed at 25 °C in 100 mM HEPES, 100 mM NaCl, 1 mM EDTA, 1 mg/ml 
PEG 8,000, 0.02% Tween 80, pH 7.4 buffer containing 10 µM FFR-CH2Cl using 1% 
Tween 80-coated acyclic cuvettes. Fluorescence was measured with an SLM 8100 
fluorometer, with excitation at 550 nm and emission at 566 nm with 8 nm band-passes. 
Following correction for buffer blank and probe dilution (≤ 10%), data were expressed as 
the fractional change in the initial fluorescence, (Fobs-Fo)/Fo = ∆F/Fo.  Titrations were 
analyzed by nonlinear least-squares fitting of the quadratic binding equation:  
 
       Eqn. 1, 
      
where ΔFmax/Fo is the maximum fluorescence change, KD is the dissociation constant, n is 
the stoichiometric factor, which was fixed at 1, [P]o is the total concentration of probe-
labeled protein, and [L]o is the total ligand concentration (38,40-42).
 
 
Plasminogen Activation Kinetics 
 The kinetics of activation of 100 nM [Glu]Pg or [Lys]Pg by 3 nM nctPA or 0.5 
nM tctPA was measured as a function of wtSkzL or SkzL∆K415 concentration (0-20 
µM). Studies of [Lys]Pg and [Glu]Pg activation as a function of wtSkzL concentration 
were performed in chloride containing buffer (100 mM HEPES, 100 mM NaCl, 1 mM 
EDTA, 1 mg/ml PEG 8,000, pH 7.4) or no chloride buffer (100 mM HEPES, 100 mM 
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sodium acetate, 1 mM EDTA, 1 mg/ml PEG 8,000, pH 7.4). The only contribution of 
chloride in experiments performed with buffer lacking chloride ion was from the initial 
tPA storage buffer, which after dilution was ≤ 0.1 µM chloride in the assays. Hydrolysis 
of 200 µM D-Val-Leu-Lys-nitroanalide (VLK-pNA) was measured at 405 nm as a 
function of time. Unless stated otherwise, assays were performed in the above buffer 
containing 100 mM NaCl using PEG 20,000-coated polystyrene cuvettes. In assays 
containing SkzL, tPA and SkzL were preincubated at 25 °C for 10 min prior to addition 
of Pg and VLK-pNA. Progress curves at varying SkzL or Pg concentrations were fit by 
the parabolic rate equation:  
 
                            Eqn. 2,  
 
where t is time, and the a term represents the rate of acceleration of chromogenic 
substrate hydrolysis by Pm formation, the b term is any linear rate of substrate hydrolysis, 
and c is the intercept at t = 0. Raw data were truncated to less than 10% chromogenic 
substrate consumption. To ensure no significant substrate depletion, raw data were 
truncated to include only data linear when plotted as absorbance against time2.  
The effect of fixed SkzL concentrations (0, 4, 10, and 15 µM) on [Lys]Pg 
activation by 3 nM nctPA (6 nM nctPA at 0 µM SkzL) or 0.2 nM tctPA were measured 
as a function of [Lys]Pg concentration (2 nM-2.6 µM). Data were obtained and truncated 
as described above and analyzed initially by global nonlinear least-squares fitting of the 
following rapid equilibrium equation for ternary complex formation for the template 
model for effect of fibrin on Pg activation by tPA (34): 
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                            Eqn. 3 
with, 
  Eqn. 4 
 
                     Eqn. 5 
 
                   Eqn. 6, 
 
where [Pg]o is the total [Lys]Pg concentration, [L]o is the total SkzL concentration, kcat is 
the rate of catalytic turnover for the SkzL-catalyzed reaction, KA is the dissociation 
constant determined for the SkzL-tPA interaction (fixed at 14 µM), KC is the dissociation 
constant determined for the SkzL-[Lys]Pg interaction (fixed at 82 nM), Pgfree is the 
concentration of free Pg given by the quadratic equation (Equation 4), K is the complex 
constant (Equation 5), and kucat/Km is the bimolecular rate constant for the uncatalyzed 
reaction (Equation 6) (34). Parameters obtained from global analysis by least-squares 
fitting of the model, combining Equations 3 - 6, are listed in Table 3.  
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 Alternatively, data were analyzed by mechanism-independent nonlinear least-
squares fitting of the sum of the solution to the quadratic equation (analogous to Equation 
1), with (∆vmax 1/vo) as the maximal change in rate for the high affinity interaction, and a 
hyperbola for the weak interaction,  
 
      Eqn. 7 
 
where KD1 and KD2 are the dissociation constants for the high and low affinity 
interactions, Δvmax 1/vo (obtained from the quadratic equation) and Δvmax 2/vo are the 
corresponding maximum changes in rate, and [L]o is the total ligand concentration.  
Experimental error in the fitted parameters represents ± 2 S.D. 
 The data were also analyzed using a model with an additional quaternary complex 
step, in which a second SkzL molecule binds to the proposed SkzL•Pg•tPA ternary 
complex (Equation 8).  
 
         Eqn. 8 
 
where [Pg]o is the total [Lys]Pg concentration, [tPA]o is the total tPA concentration, 
[Pg•SkzL•tPA] and [Pg•SkzL•tPA•SkzL] represent the concentrations of the intermediate 
complexes, kcat 1 is the rate of catalytic turnover for the ternary complex, kcat 2 is the rate of 
catalytic turnover for the quaternary complex, and kucat/Km is the bimolecular rate 
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constant for the uncatalyzed reaction. The data were analyzed by simultaneous solution 
of the expressions for the equilibrium constants and conservation of mass to obtain 
[Pg]free, [SkzL]free, and [tPA]free and the concentrations of the intermediate complexes. KA 
represents SkzL-tPA binding, KC represents SkzL-Pg binding, KB represents binding of 
Pg to the SkzL•tPA complex, KD represents tPA binding to the SkzL•Pg complex, and KE 
represents formation of the Pg•SkzL•tPA•SkzL quaternary complex. Experimental error 
in the fitted parameters represents ± 2 S.D. 
        
Results 
 
Effect of SkzL on Plasminogen Activation by nctPA and tctPA 
 Chromogenic substrate kinetic assays of Pm generation were performed to 
determine the effect of SkzL on activation of [Lys]Pg and [Glu]Pg by nctPA and tctPA 
(Fig. 1).  The rate of Pm generation from [Lys]Pg activation by nctPA and tctPA was 
enhanced by SkzL ~48-fold and ~7-fold, respectively (Table 1). The rate of Pm 
generation from [Glu]Pg activation by nctPA and tctPA was enhanced by SkzL ~490-fold 
and ~400-fold, respectively (Table 1). No SkzL-mediated enhancement of Pg activation 
by nctPA or tctPA was seen in the presence of 10 mM 6-AHA (data not shown), 
consistent with studies reported for sctPA in Chapter 2, indicating an entirely LBS-
dependent mechanism of SkzL-enhanced Pg activation.  
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 Figure 1. Effect of SkzL on Pg activation by nctPA and tctPA. Initial rates of Pm 
generation ((nM Pm/s)/(nM tPA)) for activation of 100 nM [Lys]Pg (●) and [Glu]Pg (○) 
by 3 nM nctPA (A) and 0.5 nM tctPA (B) as a function of total SkzL concentration 
([SkzL]o). Solid lines represent the least-squares fits by the quadratic rate equation with 
parameters listed in Table 1. Experiments were performed and data analyzed as described 
in “Experimental Procedures”. 
 
Fitting of the SkzL-dependences for [Lys]Pg activation by nctPA and tctPA gave 
apparent KD’s of 6 ± 2 µM and 9 ± 3 µM, respectively (Table 1). Fitting of the SkzL 
dependences for [Glu]Pg activation by nctPA and tctPA gave KD’s of 7 ± 3 µM and 13 ± 
3 µM, respectively, indistinguishable from those for [Lys]Pg (Table 1). Consistent with 
parameters reported in Chapter 2 for Pg activation by sctPA, the apparent affinities of 
SkzL for [Glu]Pg agreed with KD’s of 3-16 µM obtained in SkzL-[Glu]Pg binding 
studies. However, the KD’s for [Lys]Pg of 6-9 µM were ~75-110-fold weaker than the 
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values of 80 nM determined for SkzL-[Lys]Pg in competitive binding studies (Table 1).  
In contrast to the studies reported in Chapter 2 for the effect of SkzL on Pg activation by 
uPA, in which the SkzL-induced α/β- to γ-conformational change resulted in enhanced 
[Glu]Pg activation but decreased [Lys]Pg activation, the results for tPA revealed a SkzL-
mediated enhancement of both [Glu]Pg and [Lys]Pg activation, suggesting a more 
complex mechanism for nctPA and tctPA, than uPA. 
 
Table 1. Parameters for the effect of SkzL on Pg activation by tPA. Dissociation 
constants (KD), maximal rates of Pm generation (∆vmax/vo), and fold Rate Enhancement 
listed from analysis of direct titrations of wtSkzL and SkzL∆K415 with the indicated 
enzyme-substrate pairs.  Rate Enhancement represents the fold increase in Pm generation 
from the rate observed in the absence of ligand to the calculated vmax rate. Experimental 
error in parameters represents ± 2 S.D.  Experiments were performed and the data 
analyzed as described under “Experimental Procedures”. 
Enzyme Substrate Ligand KD ∆vmax/vo 
Rate 
Enhancement 
   (µM) ((nM Pm/s)/(nM tPA)) (fold) 
nctPA [Lys]Pg wtSkzL 6 ± 2 0.0018 ± 0.0001 48 
nctPA [Lys]Pg SkzL∆K415 7 ± 6 0.0005 ± 0.0002 13 
nctPA [Glu]Pg wtSkzL 7 ± 3 0.0015 ± 0.0001 490 
tctPA [Lys]Pg wtSkzL 9 ± 3 0.029 ± 0.004 7 
tctPA [Lys]Pg SkzL∆K415 7 ± 5 0.005 ± 0.001 3 
tctPA [Glu]Pg wtSkzL 13 ± 6 0.028 ± 0.006 400 
 
Binding of SkzL to an Active Site-labeled Fluorescent sctPA Analog 
 Fluorescence equilibrium binding studies were performed to quantitate binding of 
wtSkzL and SkzL∆K415 to an active site tetramethylrhodamine-labeled analog of sctPA 
([TMR]FFR-sctPA), in the absence and presence of 6-AHA to determine LBS-
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dependence (Fig. 2). Analysis of titrations of [TMR]FFR-sctPA with wtSkzL and 
SkzL∆K415 revealed equivalent dissociation constants of 14 ± 4 µM and 15 ± 5 µM, 
respectively, and maximal fluorescence changes (ΔFmax/Fo) of -54 ± 80% and -55 ± 
100%, respectively. Both interactions were greatly decreased by 10 mM 6-AHA, 
indicating LBS-dependent interactions between sctPA-kringle 2 and 
wtSkzL/SkzL∆K415. Deletion of Lys415 failed to alter SkzL binding to [TMR]FFR-sctPA 
compared to wtSkzL, indicating that Lys415 does not mediate binding of SkzL to sctPA. 
 
 
Figure 2. Fluorescence titrations of [TMR]FFR-sctPA with wtSkzL and 
SkzL∆K415. A. Titrations of the fractional change in fluorescence (∆F/Fo) of 100 nM 
[TMR]FFR-sctPA as a function of total wtSkzL concentration ([SkzL]o) in the absence 
(●) and presence (○) of 10 mM 6-AHA. B. Titrations of the fractional change in 
fluorescence (∆F/Fo) of 100 nM [TMR]FFR-sctPA as a function of total SkzL∆K415 
concentration ([SkzL∆K415]o) in the absence (●) and presence (○) of 10 mM 6-AHA. 
Solid lines represent the least-squares fits of the data by the quadratic binding equation 
with the parameters given in “Results”. Experiments were performed and the data 
analyzed as described in “Experimental Procedures”.  
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Effect of SkzL Lys415 on [Lys]Pg Activation by nctPA and tctPA 
Chromogenic substrate kinetic assays were performed to determine the effect of 
SkzL Lys415 on SkzL enhancement of [Lys]Pg activation by nctPA and tctPA (Fig. 3).  
The rate of Pm generation determined for [Lys]Pg activation by nctPA and tctPA was 
enhanced 48-fold and 7-fold, respectively, by wtSkzL (Table 1). The rate of Pm 
generation determined for [Lys]Pg activation by nctPA and tctPA was only enhanced 13-
fold and 3-fold, respectively, by SkzL∆K415 representing a ~2.5-4-fold decrease in 
∆vmax/vo from that seen for wtSkzL (Table 1). Fitting of the SkzL dependences for 
SkzL∆K415 on [Lys]Pg activation by nctPA and tctPA gave identical KD’s of 7 µM for 
SkzL∆K415, indistinguishable from the KD’S of 6-9 µM obtained for wtSkzL (Table 1).  
Both wtSkzL and SkzL∆K415 enhancement effects were eliminated in the presence of 6-
AHA (data not shown), indicating an entirely LBS-dependent mechanism for SkzL 
enhancement of Pg activation by tPA. 
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Figure 3. Effect of SkzL Lys415 on Pg activation by nctPA and tctPA. Initial rates of 
Pm generation ((nM Pm/s)/(nM tPA)) for activation of 100 nM [Lys]Pg by 3 nM nctPA 
(A) or 0.5 nM tctPA (B) as a function of total wtSkzL (●) or SkzL∆K415 (○) 
concentration ([SkzL]o or [SkzL∆K415]o). Solid lines represent the least-squares fits by 
the quadratic rate equation with parameters listed in Table 1. Experiments were 
performed and data analyzed as described in “Experimental Procedures”.  
 
 
Effect of Chloride-regulated Pg Conformation on SkzL Enhancement of Pg Activation by 
tPA 
 
 Results of experiments reported in Chapter 2 indicated that wtSkzL binding to a 
small population of [Glu]Pg in the β-conformation initiated the [Glu]Pg β- to γ-
conformational change. This was illustrated through SkzL-mediated enhancement of 
[Glu]Pg activation by uPA to levels indistinguishable from those of [Glu]Pg in the 
presence of 6-AHA or [Lys]Pg in the presence of saturating concentrations of wtSkzL 
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(15-20 µM) or 6-AHA (10 mM). In an effort to elucidate the role of chloride-regulated 
[Glu]Pg conformation in the mechanism of SkzL-mediated enhancement of Pg activation 
by tPA, chromogenic substrate assays were performed to determine the rates of Pm 
generation for [Lys]Pg and [Glu]Pg activation by nctPA and tctPA in the presence (100 
mM) and absence (≤ 0.1 µM) of chloride ion as a function of wtSkzL concentration (Fig. 
4). In contrast to studies reported in Chapter 2, in which 10 mM 6-AHA was used as a 
tool to confirm transition of Pg to the γ-conformation, the LBS-dependent SkzL-mediated 
enhancement of Pg activation by tPA was eliminated by 10 mM 6-AHA and therefore 6-
AHA could not be used in the same capacity in these studies.  
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Figure 4. Role of Pg conformation in SkzL-mediated enhancement of Pg activation 
by nctPA and tctPA.  Initial rates of Pm generation ((nM Pm/s)/(nM tPA)) for activation 
of 100 nM [Lys]Pg (●) and [Glu]Pg (▲)  by 3 nM nctPA (A) and 0.5 nM tctPA (B) in 
buffer containing 100 mM chloride ion as a function of total wtSkzL concentration 
([SkzL]o).  Rates of activation of 100 nM [Lys]Pg (○) and [Glu]Pg (Δ)  by nctPA (A) and 
tctPA (B) in buffer containing ≤ 0.1 µM chloride ion as a function of total wtSkzL 
concentration ([SkzL]o). Solid lines represent the least-squares fits of the data by the 
quadratic binding equation with the parameters listed in Table 2. Experiments were 
performed and the data analyzed as described in “Experimental Procedures”.  
 
 Fitting of the SkzL dependence for enhancement of [Lys]Pg activation by nctPA 
and tctPA in the presence and absence of chloride ion gave indistinguishable apparent 
affinities of ~4-5 µM (nctPA) and ~5-7 µM (tctPA) (Table 2). Indistinguishable apparent 
maximal rates of Pm generation (∆vmax/vo) were observed for SkzL enhanced [Lys]Pg 
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activation by nctPA and tctPA in the absence and presence of chloride ion (Table 2), 
confirming that [Lys]Pg conformation and activation by tPA were chloride-independent.  
 While the qualitative trend of the SkzL enhancement of [Glu]Pg activation by 
nctPA and tctPA appeared to indicate a chloride-dependence with respect to the effect of 
wtSkzL, no such effect was observed in the parameters obtained from fitting of the SkzL 
dependence (Fig. 4, Table 2). As expected, the SkzL dependence of enhanced [Glu]Pg 
activation by nctPA and tctPA in the absence of chloride ion overlays the enhancement of 
[Lys]Pg activation by nctPA and tctPA in the presence and absence of chloride ion.  
Analysis of the SkzL enhancement of [Glu]Pg activation by nctPA in the presence and 
absence of chloride ion revealed near-equal apparent affinities of 8 ± 3 µM and 4 ± 1 µM, 
respectively (Table 2). A slight increase in the apparent maximum rate of Pm generation 
(∆vmax/vo) was seen for [Glu]Pg activation by nctPA, from 0.0015 ± 0.0001 (nM 
Pm/s)/(nM tPA) in the presence of chloride ion to 0.0020 ± 0.0002 (nM Pm/s)/(nM tPA) 
in the absence of chloride (Table 2). This apparent decrease may be a result of the limited 
saturation achieved at the highest wtSkzL concentration attainable in the assay, and it is 
thought that higher, fully saturating wtSkzL concentrations would cause the data sets to 
converge at the same apparent ∆vmax/vo value.  
 The parameters obtained from analysis of the SkzL enhancement of [Glu]Pg 
activation by tctPA in the presence and absence of chloride ion revealed similar apparent 
affinities of 11 ± 6 µM and 7 ± 2 µM, respectively, equivalent within the experimental 
error (Table 2). The slight decrease seen in ∆vmax/vo for [Glu]Pg activation by nctPA in 
the presence of chloride ion was not seen for [Glu]Pg activation by tctPA, with rates of 
0.028 ± 0.006 (nM Pm/s)/(nM tPA) in the presence of chloride and 0.028 ± 0.003 (nM 
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Pm/s)/(nM tPA) in the absence of chloride (Table 2). This confirms the hypothesis that 
higher, fully saturating wtSkzL concentrations would cause the two data sets for [Glu]Pg 
activation by nctPA (± chloride ion) to converge at the same ∆vmax, app/vo value, 
eliminating the apparent effect of chloride-regulated Pg conformation in the mechanism 
of SkzL enhancement of Pg activation by nctPA.  
 
Table 2. Parameters for the role of Pg conformation on the effect of wtSkzL on Pg 
activation by nctPA and tctPA. Apparent dissociation constants (KD) and apparent 
maximal rates of Pm generation (∆vmax, app/vo) are listed from analysis of direct titrations 
of wtSkzL with the indicated enzyme-substrate pairs. Experiments were performed in the 
presence of low and high total chloride ion concentration ([chloride ion]o). Experimental 
error in parameters represents ± 2 S.D.  Experiments were performed and the data 
analyzed as described under “Experimental Procedures”. 
Enzyme Substrate [Chloride ion]o KD ∆vmax, app/vo 
   (µM) ((nM Pm/s)/(nM tPA)) 
nctPA [Lys]Pg 100 mM 5 ± 2 0.0018 ± 0.0001 
nctPA [Lys]Pg ≤ 0.1 µM 4 ± 1 0.0017 ± 0.0002 
nctPA [Glu]Pg 100 mM 8 ± 3 0.0015 ± 0.0001 
nctPA [Glu]Pg ≤ 0.1 µM 4 ± 1 0.0020 ± 0.0002 
tctPA [Lys]Pg 100 mM 7 ± 3 0.030 ± 0.004 
tctPA [Lys]Pg ≤ 0.1 µM 5 ± 2 0.026 ± 0.002 
tctPA [Glu]Pg 100 mM 11 ± 6 0.028 ± 0.006 
tctPA [Glu]Pg ≤ 0.1 µM 7 ± 2 0.028 ± 0.003 
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Effect of wtSkzL on [Lys]Pg Activation by tPA as a Function of Pg and SkzL 
Concentrations   
 
To determine the mechanism of SkzL enhancement of Pg activation by tPA, 
chromogenic substrate kinetic assays were performed of [Lys]Pg activation by nctPA and 
tctPA as a function of both [Lys]Pg and wtSkzL concentration. The rates of Pm generated 
from [Lys]Pg activation by nctPA were determined in the presence of 0, 4, 10, and 15 
µM wtSkzL as a function of [Lys]Pg concentration (Fig. 5A and C). Identical titrations 
were performed with tctPA (Fig. 5B and D). For both nctPA and tctPA, the uncatalyzed 
rate of Pg activation in the absence of wtSkzL was linear and slow through the highest 
achievable [Lys]Pg concentration of 2.6 µM. This suggested a Km of ≥ 2.6 µM for the 
tPA-[Lys]Pg uncatalyzed reaction and that the uncatalyzed reaction was bimolecular 
under the conditions used. For Pg activation by both nctPA and tctPA, the rates of Pm 
generation in the presence of 10 and 15 µM wtSkzL were indistinguishable, indicating 
that SkzL saturation had been achieved (Fig. 5).   
Paralleling the linear rates of Pm generation observed for the uncatalyzed reaction 
as a function of Pg concentration, linear rates with comparable slopes were observed for 
the SkzL-catalyzed reaction. Taking into consideration the dissociation constant of 80 nM 
determined for SkzL-[Lys]Pg binding, in titrations containing 4-15 µM SkzL, the vast 
majority (~ 95%) of [Lys]Pg in the reaction should be SkzL-bound. As a result, for 
titrations containing 4-15 µM SkzL, the increased rate of Pm generation as a function of 
[Lys]Pg concentration should be minimal and non-linear, representing activation of 
SkzL-bound Pg, and not free Pg (Fig. 5).   
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Figure 5. Pg and wtSkzL concentration-dependences on [Lys]Pg activation by 
nctPA and tctPA. A and C. Initial rates of Pm generation ((nM Pm/s)/(nM tPA) (10-3)) 
for [Lys]Pg activation by nctPA in the presence of 0 (●), 4 (○), 10 (▲), and 15 µM (Δ)  
wtSkzL as a function of [Lys]Pg concentration ([[Lys]Pg]o), with C highlighting the low 
[Lys]Pg concentration range.  B and D. Initial rates of Pm generation ((nM Pm/s)/(nM 
tPA)) for [Lys]Pg activation by tctPA in the presence of 0 (●), 4 (○), 10 (▲), and 15 µM 
(Δ) wtSkzL as a function of [Lys]Pg concentration ([[Lys]Pg]o), with D highlighting the 
low [Lys]Pg concentration range. Experiments were performed and data analyzed as 
described in “Experimental Procedures”. 
 
 Analysis of the Pg-dependence data was attempted using numerous variations of 
models of ternary complex formation without success. A model of rapid equilibrium 
ternary complex formation derived from the model for the effect of fibrin on Pg 
activation by tPA (34) offered a good fit to the data (Fig. 6A and B).  
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 Figure 6. Mechanism of Pg activation by tPA in the absence and presence of SkzL. 
A. Activation of [Lys]Pg by tPA in the absence of SkzL with kucat/Km representing the 
bimolecular rate constant of the uncatalyzed reaction. B. Proposed mechanism for SkzL 
enhanced Pg activation by tPA, where the dissociation constant for SkzL-tPA binding 
(KA), the dissociation constant for SkzL-[Lys]Pg binding (KC), the Michaelis constant or 
affinity for the SkzL•tPA complex binding [Lys]Pg (KB), the complex constant (K), 
which by detailed balance is equal to (KAKB)/KC, and the catalytic turnover of the SkzL 
enhanced reaction (kcat). 
 
 Analysis of the data (Fig. 5) for the effect of SkzL on the Pg-dependence for Pg 
activation by tPA according to the mechanism illustrated in Fig. 6, including both the 
catalyzed and uncatalyzed reactions, gave kinetic parameters for each step in the reaction.  
The parameters for KA and KC were fixed at the known dissociation constants of 14 µM 
and 82 nM, determined for SkzL-tPA and SkzL-[Lys]Pg binding, respectively. The rate 
of catalytic turnover determined for the catalyzed (kcat) and uncatalyzed (kucat/Km) 
reactions of [Lys]Pg activation by nctPA were 2.6 ± 0.4 x 10-6 and 3.9 ± 0.4 x 10-7 nM-1s-
1, respectively (Table 3). The rates determined for kcat and kucat/Km for [Lys]Pg activation 
by tctPA were 5.2 ± 1.3 x 10-5 and 4.0 ± 0.2 x 10-5 nM-1s-1, respectively (Table 3). The 
Michaelis constants or affinities of the nctPA- or tctPA-SkzL complex binding [Lys]Pg 
(KB) were 0.11 ± 0.03 nM and 0.20 ± 0.09 nM, respectively (Table 3). The uncatalyzed 
activation of Pg by both nctPA and tctPA was represented by the bimolecular rate 
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constant (kucat/Km). The fitted complex constant (K), however, for the SkzL•Pg complex 
binding of nctPA or tctPA was 11 ± 3 and 12 ± 6 µM, respectively. Under the assumption 
of rapid equilibrium kinetics, K is equivalent to KD in the proposed mechanism (Fig. 6). 
Detailed balance, in which KD = (KAKB)/KC, yielded calculated apparent affinities of 18 
nM and 33 nM for nctPA and tctPA binding to the SkzL•[Lys]Pg complex, respectively. 
The discrepancy between the K and KD parameters represents a difference of nearly 3 
orders of magnitude, and indicates a faulty global analysis using the model of ternary 
complex formation. Other models of ternary complex formation failed to appropriately 
represent the data.  
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Table 3. Parameters for the effect of [Lys]Pg and wtSkzL concentration-
dependences on [Lys]Pg activation by nctPA and tctPA.  The Michaelis constant for 
the SkzL-catalyzed reaction (KB), complex constant (K), and catalytic turnover for the 
catalyzed and uncatalyzed reaction (kcat, kucat/Km) are listed from global analysis of 
[Lys]Pg concentration-dependence on [Lys]Pg activation by tPA in the presence of SkzL 
concentrations 4, 10, or 15 µM. Dissociation constants for interactions of SkzL with tPA 
(KA) and [Lys]Pg (KC) were fixed at the values determined by equilibrium binding. The 
value for KD was calculated from detailed balance (Fig. 6), where KD = (KAKB)/KC. 
Experimental error in parameters represents ± 2 SD.  Experiments were performed and 
the data analyzed as described in “Experimental Procedures”. 
Enzyme KA KB KC KD K kcat kucat/Km 
 (µM) (nM) (nM) (nM) (µM) (s-1) (nM-1s-1) 
nctPA 14 0.11 ± 0.03 82 18 11 ± 3 2.6 ± 0.4 x 10-6  3.9 ± 0.4 x 10-7
tctPA 14 0.20 ± 0.09 82 33 12 ± 6 5.2 ± 1.3 x 10-5 4.0 ± 0.2 x 10-5
 
 To gain further insight into the mechanism, a mechanism-independent analysis of 
the bimodal data was performed for each data set at single SkzL concentrations 
separately (Figure 5). With the dissociation constant for the weak affinity interaction 
fixed at 5 µM, the dissociation constant for the high affinity interaction as a function of 
[Lys]Pg concentration varied with SkzL concentration for both nctPA and tctPA. For 
nctPA, KD values of 4.5 ± 2, 13 ± 4, and 42 ± 10 nM were determined for the [Lys]Pg 
concentration dependences in the presence of 4, 10, and 15 µM SkzL, respectively (Table 
4). Similarly, for tctPA, KD values of 7.5 ± 6, 14 ± 8, and 34 ± 18 nM were obtained for 
the [Lys]Pg concentration-dependences in the presence of 4, 10, and 15 µM SkzL, 
respectively. The high affinity interaction represents the affinity of tPA for the substrate, 
SkzL-bound [Lys]Pg (KD). This shows a ~60-570-fold increase in affinity for binding of 
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tPA to [Lys]Pg, when [Lys]Pg is in complex with SkzL, compared with ≥ 2.6 µM in the 
absence of SkzL.  
 
Table 4. Parameters obtained from bimodal data analysis for the effect of wtSkzL 
concentration on the [Lys]Pg concentration-dependence of [Lys]Pg activation by 
nctPA and tctPA. The dissociation constant (KD) is listed from bimodal analysis of 
[Lys]Pg concentration-dependences at single SkzL concentrations ([SkzL]o)  for nctPA 
and tctPA (Enzyme). Dissociation constants for the weak interaction were fixed at 5 µM, 
consistent with previously established parameters. Data were analyzed as described in 
“Experimental Procedures”.  
Enzyme [SkzL]o KD 
 (µM) (nM) 
nctPA 4 4.5 ± 2 
nctPA 10 13 ± 4 
nctPA 15 42 ± 10 
tctPA 4 7.5 ± 6 
tctpA 10 14 ± 8 
tctPA 15 34 ± 18 
 
  
A second global analysis was performed for the Pg dependence data (Fig. 5), 
including data for activation of 100 nM [Lys]Pg as a function of SkzL concentration.  To 
account for the apparent increase in kcat with increasing fixed SkzL concentration, this 
analysis used a modified version of the ternary complex model (Fig. 6), in which a 
second SkzL molecule binds the SkzL•tPA•Pg ternary complex, with resulting Pm 
generation represented by kcat 2 (Fig. 7).  
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 Figure 7. Mechanism of Pg activation by tPA in the absence and presence of SkzL, 
including quaternary complex formation.  A. Activation of [Lys]Pg by tPA in the 
absence of SkzL with kucat/Km for the uncatalyzed reaction. B. Proposed mechanism for 
SkzL enhanced Pg activation by tPA, where the dissociation constant for SkzL-tPA 
binding (KA), the dissociation constant for SkzL-[Lys]Pg binding (KC), the Michaelis 
constant or affinity of [Lys]Pg for the SkzL•tPA complex (KB), KD is the Michaelis 
constant for SkzL•Pg activation by tPA, which by detailed balance is equal to (KAKB)/KC, 
catalytic turnover by the SkzL•tPA•Pg ternary complex,  (kcat 1). KE represents binding of 
a second SkzL molecule to the SkzL•tPA•Pg ternary complex, and kcat 2 is the catalytic 
turnover driven by the quaternary SkzL•tPA•Pg•SkzL complex.  
  
 
Analysis of the data with the model of quaternary complex formation gave a good 
fit to the data and determined parameters for both the catalyzed and uncatalyzed reactions 
(Fig. 8). KA and KC were fixed at the known dissociation constants of 14,000 nM and 82 
nM for SkzL-tPA and SkzL-[Lys]Pg binding, respectively (Table 5). The parameters of 
KB for binding of Pg to SkzL-bound tPA were fit by 23 ± 8 nM and 530 ± 470 nM for 
nctPA and tctPA, respectively. The value determined for kcat 1 rapidly approached zero 
and was therefore fixed at zero.  Values of 6600 ± 1800 nM and 760 ± 660 nM were 
determined for the KE parameter for nctPA and tctPA, respectively, corresponding to 
binding of SkzL to the SkzL•tPA•Pg ternary complex. The rates of catalytic turnover for 
the nctPA and tctPA reactions enhanced by formation of the SkzL•tPA•Pg•SkzL 
quaternary complex (kcat 2) were 2.1± 0.2 x 10-3 s-1 and 32 ± 3.2 x 10-3 s-1.  The 
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bimolecular rate constants of the uncatalyzed reaction (kucat/Km) determined for nctPA 
and tctPA were 1.3 ± 0.1 x 10-6 nM-1s-1 and 7.7 ± 0.3 x 10-6 nM-1s-1, respectively.  
 
 
Figure 8. Evidence for productive quaternary complex formation in SkzL 
enhancement of [Lys]Pg activation by tPA. A and C. Initial rates of Pm generation 
((nM Pm/s)/(nM tPA) (10-3)) for [Lys]Pg activation by nctPA in the presence of 0 (●), 4 
(○), 10 (▲), and 15 µM (Δ)  wtSkzL as a function of [Lys]Pg concentration ([[Lys]Pg]o), 
with C showing 100 nM [Lys]Pg activation by nctPA as a function of SkzL concentration 
([SkzL]o).  B and D. Initial rates of Pm generation ((nM Pm/s)/(nM tPA)) for [Lys]Pg 
activation by tctPA in the presence of 0 (●), 4 (○), 10 (▲), and 15 µM (Δ) wtSkzL as a 
function of [Lys]Pg concentration ([[Lys]Pg]o), with D showing 100 nM [Lys]Pg 
activation by tctPA as a function of SkzL concentration ([SkzL]o). Solid lines represent 
non-linear least squares fitting with the parameters listed in Table 5. Experiments were 
performed and data analyzed as described in “Experimental Procedures”. 
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Table 5. Parameters for the effect of quaternary complex formation on [Lys]Pg 
activation by nctPA and tctPA.  The Michaelis constant for the SkzL-catalyzed reaction 
(KB), and bimolecular rate constant for the uncatalyzed reaction (kucat/Km) are listed from 
global analysis of [Lys]Pg concentration-dependence on [Lys]Pg activation by tPA in the 
presence of SkzL concentrations 4, 10, or 15 µM using the model of quaternary complex 
formation. Dissociation constants for interactions of SkzL with tPA (KA) and [Lys]Pg 
(KC) were fixed at the values determined by equilibrium binding. KD was calculated from 
detailed balance. The value for KE represents binding of the second SkzL molecule to the 
ternary complex, with kcat 2 representing catalytic turnover for the quaternary complex. 
Experimental error in parameters represents ± 2 SD.  Experiments were performed and 
the data analyzed as described in “Experimental Procedures”. 
 
Enzyme KA KB KC KD KE kcat 2 kucat/Km 
 (µM) (nM) (nM) (μM) (nM) (s-1) (nM-1s-1) 
nctPA 14 23 ± 8 82 3.9 6580 ± 1800 2.1 ± 0.2 x 10-3  1.3 ± 0.1 x 10-6
tctPA 14 530 ± 470 82 90.4 760 ± 660 32 ± 3.2 x 10-3 7.7 ± 0.3 x 10-6
 
 
Discussion 
 Results presented in Chapter 2 support the proposed mechanism for SkzL binding 
to Pg/Pm; mediated by Lys415, SkzL binds a small population of β-conformation [Glu]Pg 
through interaction with kringle 4, causing a transition to the γ-conformation. The 
interaction of SkzL with [Lys]Pg and Pm proved more complex, with binding studies 
revealing the presence of distinct high and low affinity interactions between wtSkzL and 
[Lys]Pg/Pm. The LBS-dependent high affinity interaction of SkzL with [Lys]Pg/Pm, 
mediated by SkzL Lys415, was proposed to occur through interaction with Pg/Pm kringle 
4, triggering the β- to γ-conformational transition (19,22,23). The LBS-dependent low 
affinity interaction between wtSkzL and [Lys]Pg/Pm was proposed to occur through 
interaction of a putative SkzL internal motif with [Lys]Pg/Pm kringle 5 (24,25). Kinetic 
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studies in Chapter 2 revealed a SkzL enhancement of [Glu]Pg and [Lys]Pg activation by 
sctPA, however the mechanism of action remained unclear.  
 Kinetic experiments in the present studies confirmed the SkzL-mediated 
enhancement of [Glu]Pg and [Lys]Pg activation seen for sctPA with cleavage-resistant 
nctPA and the more enzymatically active, tctPA. The SkzL enhancement of [Glu]Pg and 
[Lys]Pg activation by both nctPA and tctPA was eliminated by 10 mM 6-AHA. 
Mirroring SkzL-Pg binding, this result indicated that the mechanism of SkzL 
enhancement of Pg activation by tPA is entirely LBS-dependent. The apparent 
dissociation constant determined for SkzL enhancement of [Glu]Pg activation by nctPA 
and tctPA was near-identical to the dissociation constant determined for SkzL-[Glu]Pg 
binding interactions. However, the apparent dissociation constant determined for SkzL 
enhancement of [Lys]Pg activation was ~75-110-fold weaker than the dissociation 
constant of 80 nM determined for SkzL-[Lys]Pg binding. As a result, the mechanism for 
SkzL enhancement of [Lys]Pg, and possibly [Glu]Pg, activation by tPA could not be 
explained by SkzL-[Lys]Pg binding interactions alone.   
 Equilibrium binding studies showed that LBS-dependent, weak binding of SkzL 
to active site-labeled [TMR]FFR-sctPA was not affected by deletion of Lys415. This result 
indicated that the LBS-mediated interaction between SkzL and sctPA-kringle 2 occurred 
through a site distinct from Lys415, most likely through the putative SkzL internal motif 
proposed to mediate the low affinity interaction with Pg kringle 5. 
 Kinetic studies were performed to determine the effect of SkzL Lys415 deletion on 
SkzL enhancement of [Lys]Pg activation by nctPA and tctPA. The apparent affinities 
observed for the wtSkzL- and SkzL∆K415-dependences were indistinguishable for 
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[Lys]Pg activation by both nctPA and tctPA. This result suggested that the observed 
affinity did not represent SkzL-[Lys]Pg binding, which is decreased ~30-fold by Lys415 
deletion (Chapter 2). Combined with the results of the SkzL-sctPA binding studies, which 
reported a Lys415-independent interaction, the Lys415-independent apparent affinity may 
reflect SkzL-tPA binding. The ~2-fold decrease in apparent affinity (KD ~7 µM) obtained 
in the kinetic analysis compared with the dissociation constant determined by 
fluorescence equilibrium binding studies of [TMR]FFR-sctPA with SkzL (KD ~14 µM), 
may reflect a small effect of the active site incorporated inhibitor and/or probe on the 
conformation of sctPA.   
 In kinetic studies of [Lys]Pg activation by nctPA and tctPA, deletion of Lys415 
resulted in a ~2.5-4-fold decrease in ∆vmax/vo for SkzL∆K415 from that seen for wtSkzL. 
As SkzL-sctPA binding was shown to be Lys415-independent and SkzL-[Lys]Pg binding 
is largely mediated by Lys415, the reduction in ∆vmax/vo upon deletion of Lys415 suggested 
that the increase in ∆vmax/vo observed in [Lys]Pg activation by tPA as a function of SkzL 
concentration was regulated by interaction of SkzL Lys415 with [Lys]Pg.  
 Kinetics experiments were performed in the presence and absence of chloride ion 
to determine the role of chloride-regulated [Glu]Pg conformation in the mechanism of 
SkzL enhancement of Pg activation by tPA. A slight ~25 % decrease in the calculated 
∆vmax, app/vo value was observed for [Glu]Pg activation by nctPA in the presence of 
chloride ion compared with [Glu]Pg activation by nctPA in the absence of chloride. This 
decrease in ∆vmax, app/vo was not observed for [Glu]Pg activation by tctPA. Because 
Lys415-mediated Pg binding has been shown to induce the [Glu]Pg β- to γ-conformational 
change, it was hypothesized that the maximum rate of Pm generation for the SkzL 
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dependence would be identical and chloride-independent. It is thought that at fully 
saturating SkzL concentrations, greater than those achievable in these studies, the SkzL-
saturated data sets would converge to the same ∆vmax, app/vo value, eliminating the 
apparent effect of chloride. These results suggest that in the presence of SkzL, the rates of 
tPA-catalyzed [Glu]Pg and [Lys]Pg activation are independent of Pg conformational 
changes.  
 To derive the mechanism of SkzL enhancement of Pg activation by tPA, kinetic 
studies of [Lys]Pg activation by nctPA and tctPA as a function of both [Lys]Pg and 
wtSkzL concentration were performed. A previous study of the stimulatory effect of 
fibrin on Pg activation by tPA generated a template model to describe the ternary 
complex mechanism of fibrin-mediated enhancement of Pg activation (34). In the present 
studies, this model, including both the uncatalyzed and SkzL-catalyzed reactions, offered 
a good fit to the data but was occasionally inconsistent with respect to fit reproducibility. 
However, the model of ternary complex formation offered only moderately reasonable 
kinetic parameters and large deviations of the complex constant (K). 
 Linear rates of Pm generation were observed for the uncatalyzed reaction as a 
function of Pg concentration. Similarly, linear rates with comparable slope were observed 
for the reaction in the presence of SkzL. However, the high affinity of the SkzL-Pg 
interaction would ensure that in reactions containing ≥ 4 µM SkzL, at least 95% of Pg 
would be SkzL-bound. Activation of SkzL-bound Pg would result in increased rates of 
Pm generation that were non-linear as a function of Pg concentration. The unpredicted 
and unexplained linear increase in Pm generation observed at saturating SkzL 
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concentrations may be a result of the complex high and low affinity binding interactions 
of SkzL-[Lys]Pg.  
 The major flaw in the global analysis is in the complex constant parameter (K); 
for SkzL-catalyzed activation of Pg by nctPA and tctPA K was 11 ± 3 and 12 ± 6 µM, 
respectively. Under the assumption of rapid equilibrium kinetics, K should be equivalent 
to KD. Detailed balance of the mechanism, in which KD = (KAKB)/KC, offered apparent 
affinities of 18 nM and 33 nM for nctPA and tctPA binding to the SkzL•[Lys]Pg 
complex, respectively. This discrepancy between K and KD represents a difference of 
nearly 3 orders of magnitude, and indicates a significant flaw in the global analysis using 
the ternary complex formation model. 
 Data analysis with the model of ternary complex formation, illustrated in Figs. 6 
and 7, offered a good fit to the data but the flawed kinetic parameters obtained suggested 
that the model employed does not fully represent the proposed mechanism for SkzL 
enhancement of [Lys]Pg activation by tPA. As a result, a mechanism-independent 
analysis of the SkzL-containing [Lys]Pg dependence curves, separated by SkzL 
concentration, was performed.  For [Lys]Pg activation by nctPA and tctPA, KD values of 
4.5-7.5, 13-14, and 34-42 nM were determined for the [Lys]Pg concentration 
dependences in the presence of 4, 10, and 15 µM SkzL, respectively. This increase in KD 
indicates a decrease in apparent affinity with increasing SkzL concentration in the 
[Lys]Pg concentration dependence. The KD values of 4.5 ± 2 (nctPA) and 7.5 ± 6 nM 
(tctPA) observed for the [Lys]Pg concentration dependence likely represent the high 
affinity interaction of tPA and SkzL-bound [Lys]Pg. Compared with the estimated Km 
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value of ≥ 2.6 μM for the uncatalyzed reaction, these KD values represent a ~350-570-
fold increased affinity of tPA for SkzL-bound [Lys]Pg compared with unbound [Lys]Pg.  
 Data analysis with the model of quaternary complex formation, illustrated in Figs. 
7 and 8, is very preliminary but offers a good fit to the data with acceptable kinetic 
parameters. There is inconsistency in the kinetic parameters determined, comparing 
nctPA and tctPA, suggesting an imperfect analysis. This analysis offers evidence for 
formation of a quaternary SkzL•tPA•[Lys]Pg•SkzL complex that enhances Pm generation 
in [Lys]Pg activation by both nctPA and tctPA.  
 Limited conclusions can be drawn from this analysis due to the lack of kinetic 
parameters determined for the uncatalyzed reaction. With limited attainable [Lys]Pg 
concentrations, we were unable to estimate a value for Km in the uncatalyzed reaction. As 
a result, catalytic turnover rate for the uncatalyzed reaction, kucat/Km, must be expressed as 
a bimolecular rate constant in units of nM-1s-1. This leaves us unable to draw comparisons 
with the rate of catalytic turnover determined for the reaction enhanced by quaternary 
complex formation. However, this analysis does suggest that Pm generation is enhanced 
only by the quaternary complex, not the ternary complex (Figure 9).  
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 Figure 9. Proposed mechanism for SkzL-catalyzed enhanced Pg activation by tPA. 
SkzL is shown in purple with Lys415 (K) on a flexible segment, the proposed SkzL 
internal motif is represented by the “nose”, [Lys]Pg in light orange is shown with five 
numbered kringle domains and the COOH-terminal catalytic domain, and tPA in blue is 
shown with two kringle domains and the COOH-terminal catalytic domain, with the 
active site in green. Low affinity (KD ~ 14 µM) SkzL•tPA complex formation through the 
putative SkzL internal motif (nose)-tPA-kringle 2 interaction (Reaction 1) and SkzL•Pg 
complex formation through the proposed SkzL Lys415-[Lys]Pg kringle 4 interaction (KD 
80 nM) (Reaction 2) . Reactions 3 and 4 result in formation of a non-productive ternary 
complex. With increasing SkzL concentrations (~5-20 µM), a second SkzL molecule 
binds the ternary complex (Reaction 5), mediated by the putative SkzL internal motif-
kringle 5 interaction.  Reaction 6 represents enhanced Pm generation (active site in 
green), compared with the uncatalyzed reaction not shown. 
 
 
 We therefore can infer that Lys415-independent binding of SkzL to [Lys]Pg 
contributes strongly to enhanced [Lys]Pg activation through formation of the quaternary 
complex. This would suggest that the weak affinities observed for activation of [Lys]Pg 
by tPA as a function of SkzL concentration in Figure 1 can not be solely contributed to 
SkzL-tPA binding, but also to the weak SkzL-[Lys]Pg interaction resulting in quaternary 
complex formation. These analyses are preliminary and further study is needed to clarify 
this mechanism of higher order complex formation in SkzL enhanced [Lys]Pg activation 
by tPA.  
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The present studies identify SkzL as a novel cofactor of Pg activation by tPA. In 
addition to SkzL increasing the rate of [Glu]Pg activation by tPA, SkzL enhances clot 
lysis by tPA in plasma (Chapter 2). Together, these results provide strong support for a 
role of SkzL as a Streptococcus agalactiae secreted Pg-binding protein with established 
enhancement of the human fibrinolytic system. This interaction may lead to identification 
of SkzL as a virulence factor in Streptococcus agalactiae pathogenesis, a pathogen with 
increasing morbidity and mortality, particularly in the neonatal population.  
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CHAPTER IV 
 
SIGNIFICANCE AND FUTURE DIRECTIONS 
 
Identification of Skizzle as a Plasminogen and Plasmin Binding Protein 
 The work in this thesis identifies skizzle (SkzL) as a novel protein secreted by 
Streptococcus agalactiae, the only known species of streptococci that does not express 
the secreted bacterial plasminogen (Pg) activator streptokinase (SK). The studies show 
that SkzL binds Pg and Pm and enhances Pg activation and plasma clot lysis by the two 
endogenous Pg activators, uPA and tPA. Streptococcus agalactiae expresses two 
membrane-bound proteins, glyceraldehyde-3-phosphate dehydrogenase and enolase, with 
established Pg binding interactions. The current studies identify SkzL as the first 
Streptococcus agalactiae-secreted protein that targets the human fibrinolytic system. 
 SkzL binds [Glu]Pg with weak affinity through LBS-dependent putative 
interaction with Pg kringle 4. The SkzL Lys415-dependent binding is hypothesized to 
occur preferentially through interaction with the low concentration of [Glu]Pg in the 
partially extended β-conformation in unfavorable equilibrium with activation resistant, α-
conformation [Glu]Pg. Proposed occupation of kringle 4 results in a conformational 
transition to [Glu]Pg-γ, observed via enhanced activation of SkzL-bound [Glu]Pg by 
uPA.  Binding of SkzL to [Lys]Pg-β and [Lys]Pm-β occurs through two LBS-dependent 
interactions; high affinity interaction of Lys415 with kringle 4, and low affinity interaction 
of a putative SkzL internal motif with kringle 5. Proposed occupation of kringle 4, in 
parallel with [Glu]Pg, results in conformational transition to [Lys]Pg-γ. Specific kringle 
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interactions remain hypothetical and will require further investigation with Pg variants to 
confirm. While we hypothesize the putative SkzL internal motif to be analogous to the 
250-loop of SK, responsible for interaction with Pg kringle 5, further mutagenesis studies 
will be necessary to determine the residues responsible for the low affinity interaction of 
SkzL with Pg/Pm (1).   
  
Significance of SkzL Enhancement of Pg Activation 
 These studies provide evidence of two mechanisms by which SkzL enhances Pm 
formation, specific for uPA and tPA. SkzL enhances activation of both [Glu]Pg and 
[Lys]Pg by LBS-containing tPA, in contrast with [Glu]Pg-specific enhancement of Pg 
activation by uPA. The kringle domain of uPA, unlike tPA, contains no LBS, leaving 
uPA incapable of binding SkzL (2). Enhanced Pg activation by uPA is therefore specific 
for [Glu]Pg through a mechanism in which SkzL-[Glu]Pg binding induces a transition to 
[Glu]Pg in the γ-conformation, which like [Lys]Pg is more readily activated by uPA.  
 SkzL binds tPA with relatively weak affinity through LBS-dependent interaction 
of the putative SkzL internal motif and tPA kringle 2. Together with the high affinity 
interaction of SkzL Lys415 and Pg kringle 4, we hypothesize that SkzL forms a non-
productive SkzL•tPA•Pg ternary complex. At higher SkzL concentrations, low affinity 
Lys415-independent binding of a second SkzL molecule to the SkzL•tPA•Pg ternary 
complex occurs.  
 The mechanism of fibrin-mediated enhancement of Pg activation by tPA involves 
ternary complex formation.  Formation of this fibrin•tPA•Pg ternary complex affects the 
Michaelis-Menten kinetic parameters observed for Pg activation by tPA. Compared with 
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the uncatalyzed reaction, fibrin•tPA•Pg ternary complex formation results in a decrease 
in Km and a slight increase in kcat, although there is variation in the amplitude of increase 
or decrease in the published parameters (Table 1).   
 Of particular interest to the current studies are the published parameters for 
activation of [Lys]Pg by tctPA, which reveal Km values of 19 µM without fibrin (effector) 
and 0.02 µM with fibrin (effector), representing a 950-fold decrease in Km. The Km value 
of 19 µM observed in the absence of effector is consistent with the value of ≥ 2.6 µM 
estimated in the current studies. The presence of fibrin (effector) decreased the Km value 
to 20 nM, compared with 4.5-7.5 nM in the present studies, yielding an overall fold 
decrease in Km observed for fibrin (950-fold) compared with SkzL (~350-750-fold), 
estimated by mechanism-independent analysis.  
 
Table 1. Michaelis-Menten kinetic parameters for effect of fibrin on [Glu]Pg and 
[Lys]Pg activation by tPA. Illustration of the distribution in the published parameters 
for the effect of fibrin on Km and kcat determined for activation of [Glu]Pg and [Lys]Pg by 
tPA obtained from various sources (mtPA represents melanoma-derived tPA).  
tPA Pg Km 
Km  
+ effector 
(Km + effector)/ 
Km 
kcat  
kcat  
+ effector 
(kcat + effector)/ 
 kcat 
Ref. 
  (µM) (µM) (fold) (s-1) (s-1) (fold)  
sctPA [Glu]Pg 4.9 0.46 11 0.0013 0.084 65 (3) 
tctPA [Glu]Pg 7.6 0.18 42 0.008 0.12 15 (3) 
mtPA [Glu]Pg 3.0 0.1 30 0.0005 0.008 16 (4) 
mtPA [Glu]Pg 83 0.18 460 0.07 0.28 4 (5) 
tctPA [Glu]Pg 65 0.16 410 0.06 0.1 2 (6) 
tctPA [Lys]Pg 19 0.02 950 0.2 0.2 1 (6) 
 
 Additional preliminary analysis of the data suggests that a second SkzL molecule 
binds the SkzL•tPA•Pg ternary complex and that the quaternary, not ternary complex 
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results in enhanced [Lys]Pg activation by tPA. This indicates a mechanism of action 
distinct from the ternary complex model employed by fibrin. Both the weak second 
SkzL-[Lys]Pg interaction and weak SkzL-tPA interaction are Lys415-independent. As a 
result, further study including mutagenesis to elucidate the residues involved in binding is 
required to clarify further this mechanism.  
  
Proposed Skizzle ternary complex formation  
 Streptococcus agalactiae is the only known streptococcal species that does not 
express the potent conformational Pg activator, SK. Comparison of sequence alignment 
and secondary structure prediction illustrated in Chapter 2; Fig. 1 suggests both sequence 
and structural similarity between SkzL and SK resulting in predicted functional 
similarity. One major difference between SK and SkzL is the presence of three Cys 
residues within SkzL, which may have an impact on protein folding and function. 
Partially LBS-dependent SK-Pg binding occurs through both LBS-dependent kringle-
Lys414 interaction and LBS-independent interaction of the SK three-domain structure with 
the Pg catalytic domain, as shown by the crystal structure (7). In constrast, binding of 
SkzL to Pg is entirely LBS-dependent, supporting a hypothesis of altered protein folding 
possibly due to presence of SkzL Cys residues, specifically internally located residue 
Cys120. Altered SkzL folding and subsequently altered Pg binding may be the reason for 
the failure of SkzL to directly activate Pg. We hypothesize that SkzL•tPA•Pg ternary 
complex formation occurs in a manner similar to SK-Pg binding in the mechanism of Pg 
activation by SK, which also involves ternary complex formation (Fig. 1). In both 
complexes, LBS-dependent interactions occur between the COOH-terminal Lys residue 
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of the ligand (SkzL or SK) and Pg, followed by LBS-dependent interaction of the internal 
motif (250-loop for SK) with the respective second substrate protein through the kringle 
domain closest to the catalytic domain (Pg or tPA). Mutagenesis studies are needed to 
determine the residues of SkzL responsible for LBS-dependent interaction of the 
proposed internal motif with both Pg and tPA.  
 
 
Figure 1. Comparison of SK- and SkzL-enhanced Pg activation. A. Representation of 
the three domain structure of SK with Lys414 (K) on a flexible linker and the 250-loop in 
the β-domain responsible for Pg binding in the substrate mode represented by the “nose”. 
Conformational Pg activation by SK involves binding of SK to Pg (Pg 1), partially 
mediated by LBS-dependent Lys414 binding and partially through wrapping of SK around 
the Pg catalytic domain. The resulting conformationally activated SK•Pg 1 complex 
binds a second Pg molecule (Pg 2) in the substrate mode through interaction of the 250-
loop in the SK β-domain with the LBS of Pg kringle 5, which undergoes proteolysis to 
Pm (not shown). B. While the tertiary structure of SkzL is unknown, proposed 
SkzL•tPA•Pg ternary complex formation occurs through LBS-dependent interaction of 
SkzL Lys415 (K) with Pg kringle 4 and LBS-dependent interaction of the putative SkzL 
internal motif (nose) with tPA kringle 2. 
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Hijacking the Fibrinolytic System to Evade Fibrinolytic Regulation 
 Inhibition of the fibrinolytic system is critical to maintaining the balance between 
wound healing and vascular repair and aberrant thrombus formation. The balance of this 
system is regulated, in part, through inhibition of Pm and tPA by the serine proteinase 
inhibitors (serpins) α2-antiplasmin (α2-AP) and plasminogen activator inhibitor-1 (PAI-
1), respectively (2,8-11). Both SK-bound and fibrin-bound Pm are protected from 
inactivation by α2-AP, allowing for efficient, localized fibrin proteolysis (8,9). Similarly, 
fibrin-bound tPA is protected from inactivation by PAI-1 (8-10).  As a result, fibrin-
mediated resistance to inhibition by α2-AP and PAI-1 ensures that fibrin•tPA•Pg ternary 
complex formation and resulting fibrin-mediated amplification of Pm generation are 
locally restricted to the fibrin-stabilized thrombus.  
 Based on the structural similarity to SK, and the established SkzL LBS-dependent 
kringle interactions with both Pg and tPA, it is hypothesized that SkzL binding may 
render Pm and tPA resistant to inhibition by α2-AP and PAI-1, respectively.  Putative 
resistance of SkzL-bound tPA to PAI-1 inhibition would allow for fluid phase activation 
of Pg by tPA, not restricted to the thrombus, as in the case of fibrin. Putative resistance of 
SkzL-bound Pm to α2-AP inhibition could result in circulating active Pm poised for rapid 
degradation of cross-linked fibrin. While tPA functions predominantly in the vasculature 
for fibrinolysis, uPA facilitates extracellular proteolysis (12). Activation of native 
[Glu]Pg by uPA occurs at very low level in the absence of fibrin or other LBS-ligands, 
therefore the dramatic enhancement of SkzL-bound [Glu]Pg activation by uPA may 
indicate a major role of SkzL in invasive S. agalactiae infection. If generated by uPA in 
the extracellular milieu, α2-AP-resistent SkzL-bound Pm could facilitate proteolysis of 
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fibronectin and other extracellular matrix proteins allowing for higher permeability 
between cell layers, increasing the propensity for invasive infection (2). Animal studies 
are needed to determine if SkzL is a virulence factor in S. agalactiae infection and its 
related disease processes. 
 While purely speculative, the proposed resistance of SkzL-bound Pg and tPA to 
inhibition by their respective inhibitors may result in unregulated amplification of Pm 
generation and unregulated Pm proteolytic function in circulating plasma within the 
vascular system. This unregulated activity would disrupt the delicate balance of the 
fibrinolytic system between ensuring proper vascular repair and prevention of aberrant 
thrombus formation. Unregulated fibrinolysis could result in hemorrhage following 
improper wound healing. This imbalance could also leave the closed vasculature system 
open to assault from infectious agents resulting in bacteremia and septicemia, major 
disease processes in S. agalactiae infection (13,14).   
 
Role of Skizzle in Streptococcus agalactiae Pathogenesis 
 Streptococcus agalactiae, specifically, serotype V, is emerging as an invasive 
pathogen with particular morbidity and mortality in neonates (13-17). The mechanisms of 
pathogenesis involved in the virulence of this pathogen within this patient population are 
poorly understood. Similar to immune-compromised patients, neonates possess inherently 
underdeveloped or weakened immune systems. It is unclear whether the enhanced 
virulence in both neonates and pregnant women is purely opportunistic with respect to 
decreased innate host defense, or if a more complex mechanism of pathogenesis 
involving host fibrinolysis is involved.  
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  One possible rationalization for increased invasive S. agalactiae infection in 
neonates, may lie in the inherent differences in the maturity and function of the 
fibrinolytic system compared with the normal adult population.  While all components of 
the fibrinolytic system are present before birth, the structural composition and relative 
abundances of many key factors are different from adults (18,19).  The neonate possesses 
slightly altered forms of some fibrinolytic proteins. For example, both fibrinogen and Pg 
in the neonate, known as fetal fibrinogen and fetal Pg, contain increased phosphorus and 
sialic acid content and increased carbohydrate modification, respectively (18-20). 
Whether fetal fibrinogen is structurally or functionally different from the adult form 
remains unclear (19). Although early studies suggested decreased activation of fetal Pg 
by uPA and tPA due to the increase in carbohydrate modification, recent detailed 
examinations concluded that activation of fetal Pg in the absence or presence of fibrin by 
uPA and tPA is comparable to activation of adult Pg (20-22).  
 The major difference in the fibrinolytic system of the neonate compared with 
adults is the relative abundance of key fibrinolytic proteins. Compared with levels 
determined 6 months after birth (6 months) and for adults (levels not shown), neonates 
(day 1) have decreased levels of Pg (day 1, 1.95 U/mL; 6 months, 3.01 U/mL) and α2-AP 
(day 1, 0.85 U/mL; 6 months, 1.1 U/mL) and increased tPA levels (day 1, 9.6 ng/mL; 6 
months, 2.8 ng/mL) (19,23).  Many of the clotting factors occur at low levels in neonates 
(day 1) compared with levels determined 6 months after birth (6 months) and for adults 
(levels not shown), specifically but not limited to factor II (day 1, 0.48 U/mL; 6 months, 
0.88 U/mL), factor V (day 1, 0.72 U/mL; 6 months, 0.91 U/mL), factor IX (day 1, 0.53 
U/mL; 6 months, 0.86 U/mL), and factor X (day 1, 0.4 U/mL; 6 months, 0.78 U/mL). 
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This results in delayed and decreased thrombin formation (19). While there is no 
evidence for increased bleeding risk in healthy neonates, should the already decreased 
levels of key clotting factors decrease due to illness, sick neonates are at increased risk 
for fibrinolysis and hemorrhage (19). Together with the decrease in plasma Pg 
concentration and increase in plasma tPA concentration, this would likely suggest a 
system poised for enhanced fibrinolytic activity. Enhancement of Pg activation by S. 
agalactiae-secreted SkzL, particularly the proposed inhibitor-resistant enhancement, 
could shift this already delicate balance to an overly fibrinolytic state. Animal studies are 
needed to determine if SkzL is a virulence factor in S. agalactiae infection, particularly in 
neonates.  
 Subversion of the host fibrinolytic system is a mechanism of pathogenesis 
employed by most streptococci, in part through expression of cell-surface Pg binding 
proteins. In this mechanism, the streptococci hijack the fibrinolytic system causing 
enhanced Pm generation, which can degrade fibrin, laminin, fibronectin and other 
extracellular matrix proteins to disseminate spread of the bacteria through soft tissue 
(2,12). Activation of Pg localized on the bacterial surface through Pg binding proteins 
such as Pg-binding Group A Streptococcal M-like protein (PAM, Group A, C, G 
streptococci), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Group A, B, C 
streptococci), and α-enolase (Group A, B streptococci) can result in coating of the cell 
surface with readily activated Pg or active Pm (12,24-29). Active Pm can degrade 
extracellular matrix proteins as discussed above, allowing streptococci to transmigrate 
through cell layers (30). Transmigration may occur via extracellular matrix degradation 
or via bacterial internalization into host cells (30). Streptococcus agalactiae has been 
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shown to transmigrate through both endothelial and epithelial barriers as well as through 
the microvascular endothelium of the blood brain barrier, critical for meningitis caused 
by S. agalactiae in neonates (30). 
 Streptococcus agalactiae is known to interact with the host fibrinolytic system 
through bacterial surface expression of α-enolase and GAPDH (24,27,28,31). A recent 
study indicated that Pg activation on the surface of S. agalactiae occurs through GAPDH-
bound Pg. GAPDH-mediated Pg binding enhanced S. agalactiae virulence and promoted 
systemic bacterial invasion in a murine model (26).  While SkzL was identified in the 
secreted protein profile of S. agalactiae in the present studies, it is unclear if post-
secretion SkzL also exists bound to the bacterial surface through unknown binding 
interactions. SkzL possesses affinity for Pg and has been shown to induce a 
conformational change in the native zymogen [Glu]Pg to the extended, more readily 
activated, γ-conformation, in parallel with the function of known streptococcal surface Pg 
binding proteins, such as PAM. This would suggest that SkzL is a Pg cofactor secreted by 
S. agalactiae that may or may not bind to the bacterial surface post-secretion.  
 Nevertheless, these studies indicate that secreted SkzL acts as a novel fluid phase 
cofactor for enhanced Pg activation by both uPA and tPA (Figure 2). Based on the 
predominant functions of tPA and uPA in vascular fibrinolysis and extracellular 
proteolysis, respectively, the conformational change induced upon SkzL-Pg binding and 
enhanced [Glu]Pg activation by both enzymes provides strong evidence for a bifunctional 
role of SkzL in S. agalactiae pathogenesis. Enhancement of tPA-mediated Pg activation 
in the vessel could result in degradation of thrombi critical for vessel repair, rendering the 
damaged vessel permeable to bacterial transmigration (Fig. 2A). In contrast, enhancement 
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of uPA-mediated Pg activation, functioning in extracellular proteolysis, could result in 
increased extracellular matrix (ECM) degradation and bacterial transmigration through 
soft tissue (Fig. 2B). As a result of the enhanced tPA- and uPA-mediated Pg activation by 
SkzL, we hypothesize that SkzL is a secreted virulence factor in S. agalactiae 
pathogenesis.   
 
 
Figure 2. Comparison of surface-bound Pg receptor-mediated and secreted SkzL-
mediated enhanced Pg activation. Bacterial surface receptors, such as α-enolase and 
GAPDH (brown), bind Pg through LBS-dependent kringle interactions. Surface-bound 
Pg is readily activated by both uPA and tPA. A. Pg (light orange) activation by tPA 
(blue), predominantly occurring in the vascular system, is enhanced by the 
conformational change induced upon surface-bound receptor Pg binding and by 
SkzL•tPA•Pg ternary/quaternary complex formation. Increased Pm generation results in 
enhanced fibrin proteolysis and degradation of thrombi involved in vessel wall repair, 
leaving the vessel vulnerable to bacterial transmigration. B. Pg activation by uPA (green), 
predominantly functioning in extracellular proteolysis, is enhanced by the conformational 
change induced upon both surface-bound receptor Pg binding and SkzL binding. 
Increased Pm generation results in enhanced extracellular matrix (ECM) proteolysis, 
bacterial transmigration, and bacterial dissemination into soft tissue. 
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 The known interaction of S. agalactiae surface proteins, α-enolase and GAPDH, 
with Pg in fibrinolysis provided a solid rationale for the investigation of SkzL and its 
potential interaction with the human fibrinolytic system. The interaction of SkzL with Pg, 
resulting in enhanced Pg activation by both uPA and tPA, provides an additional novel 
interaction of S. agalactiae with the human fibrinolytic system and a new branch in the 
potential mechanism for S. agalactiae pathogenesis. 
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